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General Introduction
Congenital heart disease (CHD) has an estimated incidence of about 5−6 per 
1000 live births.1 Variation in reported incidence of CHD mainly depends on 
the ability to diagnose trivial lesions. Incidence is not subjected to diff erences 
between countries or time periods.1 In the Netherlands an estimated number 
of 1.500 children is born with CHD each year. The total estimated number of 
patients with CHD in the Netherlands is 50.000. About half of the patients with 
CHD is in the paediatric age group.2
The aetiology of CHD may be; 1) chromosomal (8 − 10%), 2) monogenetic 
(3 − 5%), and 3) multi-factorial (85%).3 Numeric chromosomal abnormalities, 
such as trisomy 13, 18, 21, and Turner’s syndrome are frequently associated 
with CHD.4-9 Most life-born patients with trisomy 13 or 18 die within the fi rst 
year of life, the majority with trisomy 21 or Turner’s syndrome on the other 
hand survive to adulthood.10-12 Monogenic genetic disorders occur as a direct 
consequence of a single gene being defective. Monogenic disorders may result 
in a combination of congenital abnormalities among which cardiovascular 
abnormalities (eg. Marfan syndrome, Ehlers-Danlos syndrome), but also in 
isolated cardiovascular disease (eg. long QT syndrome).13 Monogenic disorders 
are inherited in a simple patt ern according to Mendel’s Laws (Mendelian 
disorders). In multi-factorial models the cause of the CHD is more complex 
and assumed to be a combination of genetic factors (polygenic) and non-
genetic factors such as environmental factors (eg. maternal diabetes, maternal 
rubella infection) and teratogenic substances (eg. alcohol, anticonvulsive 
drugs, lithium).13
Many types of CHD require surgical or catheter-based interventions. 
In the 1960’s before the widespread availability of cardiac surgery with 
cardiopulmonary bypass, about 50% of children in need of therapy died within 
the fi rst year of life and less than 15% reached adulthood.2 Major developments 
in the fi elds of diagnostics, anaesthesia, intensive care and cardiac surgery 
radically changed prognosis of patients with CHD. Peri-operative mortality 
declined and currently 85 − 95% of infants are expected to reach adulthood.2,14 
As such the number of adult patients with CHD in the Netherlands is growing 
with approximately 5% per year.15 
Data on long-term outcome still are lacking in some areas of CHD. 
Nevertheless it has become clear that complete cure is only seldomly achieved. 
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The perception of “cure” aft er surgery for CHD is fostered by surgical 
descriptions of “total correction”, but in most cases is incorrect.16 The long-
term outcome of corrected or palliated congenital heart disease is determined 
by residua (pre-interventional abnormalities, intentionally left  unaff ected by 
intervention), sequelae (unintended but foreseen results of intervention), and 
complications aft er intervention.17 Following interventions for CHD almost all 
patients have residual abnormalities of some sort. This stresses the importance 
for professionals in the fi eld to emphasise upon patients and parents that 
“corrective surgery” for CHD oft en is not curative. 
In contrast to patients with acquired heart disease who at onset of disease 
may notice a distinct change in clinical condition or symptoms, patients 
with CHD may not detect the subtle continuous changes in their clinical 
condition.18-21 By the time symptoms or exercise limitations become distinct 
with chronic cardiac overload, substantial or even irreversible ventricular 
remodelling and dysfunction may have occurred.14,22-24 Therefore close serial 
follow-up of functional cardiovascular condition should be eff ectuated from 
early childhood on to monitor the eff ects of the hemodynamic load from either 
the original CHD or post-interventional residua, sequelae and complications. 
This requires development of adequate diagnostic tools and criteria to monitor 
patient’s cardiac condition and guide the process of decision making regarding 
(re)interventions to preserve cardiac condition.25 The requirement for follow-
up of CHD during adolescence and adult life is likely to grow with increasing 
complexity of CHD treated and the need for reinvestigation and reintervention 
with time.16
One of the most frequent congenital heart lesions is tetralogy of Fallot. As 
with other CHD pace of deterioration of functional cardiovascular condition in 
surgically corrected tetralogy of Fallot with residual pulmonary regurgitation 
is unknown and as such can not be predicted. Especially data on patients 
corrected at young age, using transatrial transpulmonary techniques oft en is 
limited to a relatively short period following surgical correction. The studies 
described in this thesis specifi cally focussed on patients corrected according to 
contemporary surgical techniques at relatively young age.
Up to 76% of patients with Turner’s syndrome have structural cardiovascular 
malformations.6,8 With the majority of patients reaching adulthood, Turner’s 
syndrome is one of the most important numeric chromosomal abnormalities 
within the fi eld of cardiology. Aortic dilation makes up for a quarter to half of 
Chapter 1
12
the structural cardiovascular malformations in Turner’s syndrome.6-8 Aetiology 
of aortic disease in Turner’s syndrome still is unknown. Furthermore during 
childhood virtually all patients with Turner’s syndrome in the Western world 
are given high dosed growth hormone treatment for short stature.26 However 
the potential long-term cardiovascular side-eff ects associated with this type of 
treatment remain unclear.
1  Tetralogy of Fallot
1.1 Background
Tetralogy of Fallot (TOF) is the most common cyanotic CHD. TOF constitutes 
3.5% to 4.5% of all CHD.1 The fi rst complete description of TOF is credited 
to the French physician Etiennne Fallot who published his fi ndings in 1888.27 
Males and females are almost equally aff ected. Most cases are spontaneous, 
although familial occurrences have been described.28 With no other aff ected 
fi rst-degree relatives, the recurrence risk in siblings is about 3%. TOF patients 
have a chance of approximately 10% to have a child with TOF, regardless of 
whether the father or mother is aff ected. If the aff ected parent has an aff ected 
sibling this risk increases to above 40% 28. The precise aetiology still is unknown. 
In up to about 20% of TOF patients a microdeletion of the q11 region of the 
chromosome 22 (22q11 deletion) is found.29 The 22q11 deletion is well known 
to be associated with Di George syndrome and velocardiofacial syndrome. The 
association of TOF with 22q11 deletion may point to the relationship between 
abnormal migration of cells from the neural crest and the anatomical features 
found.30
1.2  Anatomic characteristics of tetralogy of Fallot
TOF is characterised by a specifi c combination of four anatomical abnormalities. 
The central feature in TOF is an anterior-cephalad deviation of the septal 
insertion of the outlet (infundibular) septum relative to the septomarginal 
trabeculation.31 The deviation of the muscular outlet septum combined with 
hypertrophy of septoparietal trabeculations results in a narrowed muscular 
orifi ce of the subpulmonary infundibulum which is found in approximately 
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75% of patients. This subpulmonary stenosis oft en is associated with a stenosis 
at the level of the pulmonary valve. In the remaining patients an isolated 
obstruction is found at the pulmonary valve level (10%), or patients have 
pulmonary valve atresia (15%). The deviation of the muscular outlet septum 
also accounts for both the ventricular septal defect (misalignment VSD) and 
the more rightward position of the aortic root.31 Right ventricular hypertrophy, 
the fourth anatomical anomaly in TOF, is to be considered a hemodynamic 
consequence of the other anatomical lesions. As a consequence of the RV 
outfl ow tract obstruction, hypoplasia of the trunk of the pulmonary, the 2 
mean branches and the more distal arterial braches may be seen. 
This specifi c anatomical description of the malformations may suggest a 
clearly defi ned group of patients, but precise anatomy and hence hemodynamic 
consequences vary considerably. A more correct vision would be to regard 
Fallot’s tetralogy as part of a spectrum of cardiac anomalies. 
1.3 Clinical features and diagnosis of tetralogy of Fallot
The clinical features in patients with TOF refl ect the amount of pulmonary 
blood fl ow, which in turn depends on severity of the right ventricular (RV) 
outfl ow tract obstruction or pulmonary stenosis, and the relative resistance 
of the systemic and pulmonary circulation. Only those infants with severe 
pulmonary stenosis at birth will immediately present with cyanosis due to 
predominant right to left  shunting through the VSD. Pulmonary blood fl ow 
in this subgroup may be dependent on the ductus arteriosus. Closure of the 
ductus arteriosis within the fi rst days of life may result in a circulatory collaps. 
However, most patients are acyanotic at birth. With increasing infundibular 
hypertrophy the transition from acyanotic to cyanotic disease oft en occurs 
with in the fi rst year of life. A last group of infants with only mild pulmonary 
stenosis may be asymptomatic and acyanotic. They may even present with 
signs of congestive heart failure from a large left  to right shunt.
Prolonged cyanosis will result in clubbing of the fi ngers and toes, extreme 
cyanosis (blue skin surface) and gray sclerae with engorged blood vessels. 
Furthermore complications from right to left  shunting (abscesses and 
thromboembolic strokes of the brain) and from polycythemia (high thrombosis 
risk) may occur. Without surgical intervention most patients with TOF die 
during childhood: the survival rate is 66% at 1 year of age, 40% at 3 years, 11% 
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at 20 years, 6% at 30 years and 3% at 40 years.32 Therefore intra-cardiac surgical 
repair is not only recommended to relieve symptoms but also to improve 
survival.
1.4  Surgery in tetralogy of Fallot
1.4.1 Surgical correction 
Nowadays the natural history of TOF is virtually only seen in less developed 
countries where paediatric cardiac surgery along with general medical care 
is less developed. The fi rst successful intra-cardiac repair using human cross-
circulation was described by Lillehei in 1955.33 The fi rst successful repair using 
a pump oxygenator was performed one year later by Kirklin et al.34 Corrective 
surgery includes closure of the VSD and relieve of the RVOT stenosis. Before 
the availability of intra-cardiac repair for TOF palliative shunting procedures 
were performed. Palliative shunt procedures aimed to increase pulmonary 
blood-fl ow, thereby reducing severity of cyanosis and improving exercise 
capacity. Diff erent types of shunting procedures were developed including 
subclavian artery-pulmonary shunts ((modifi ed) Blalock-Taussig shunt) and 
aorto-pulmonary shunts (Pott s shunt, Waterston shunt and Central shunt).35 
However, palliative shunts have some well known long-term complications 
such as distortion of the pulmonary arterial branches and disproportional large 
shunt volumes causing pulmonary hypertension and LV volume overload.32
Currently many centres prefer a one-stage complete surgical correction 
performed at young age, a procedure that can be performed with low peri-
operative mortality rates.36-38 Palliative surgery or balloon pulmonary 
valvuloplasty is reserved for severely ill infants and patients for who complete 
repair is unsuitable, such as patients with underdeveloped pulmonary 
arteries. Correction at young age has the advantage of: 1) shortening of the 
period of possible neurological damage due to hypoxemia, 2) reduction of 
the risk for cerebral abscesses and emboli, 3) avoidance of longstanding RV 
pressure overload with the resultant myocardial hypertrophy and fi brosis, and 
4) optimization of pulmonary artery growth. There is general agreement that 
there is no advantage of a delay of correction beyond the age of 1 year.36,39 
Nevertheless, controversy on optimal age for total repair of TOF still exists as 
several authors found post-operative outcome was worse in patients operated 
before the age of 3 months.36,39,40 Among patients from the earliest era of 
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surgical correction of tetralogy of Fallot 5 years survival was 95%, 10 years 
survival was 92% and 25 years survival was 87%.41 Older age at surgery was 
found to be a powerful predictor of poorer late survival.41,42
In recent years a trend towards the use of transatrial transpulmonary 
approaches at the cost of transventricular approaches is seen. The transatrial 
transpulmonary approach, fi rst described in 1963 by Hudspeth et al., has the 
theoretical advantage of elimination or reduction of right ventriculotomies.43 
Late complications like RV dilation and dysfunction, as well as ventricular 
arrhythmia are thought to in part derive from the site of the ventriculotomy. 
Multiple studies report superiority of the transatrial approach over the 
transventricular approach with regard to RV function, RV dimensions and 
ventricular arrhythmia risk during follow-up.36,44,45 However, so far the 
comparison of both techniques in literature oft en is hampered by several data 
limitations. In many centres the transatrial transpulmonary technique was the 
successor of the transventricular technique and therefore data may refl ect a 
diff erent surgical era.36,38 Simultaneous changes in other surgical preferences, 
such as age at repair, may have occurred.36,46 In direct relation to the previous 
limitations follow-up duration in many studies is shorter with the transatrial 
transpulmonary technique. Furthermore institutions may choose one technique 
over the other based on patients characteristics, which though legitimate in 
itself, results in two less comparable patient populations.37 
The optimal result aft er surgical correction would include absence of a 
gradient between the RV and the pulmonary trunk to normalise RV pressures, 
and a competent pulmonary valve. As with other CHD the term “corrective” is 
somewhat misleading as residual lesions are almost obligatory.35 Nevertheless 
survival of surgically corrected TOF is good, though it remains somewhat 
below that in the general population.41,42
1.4.2 Residual defects
Residual lesions are frequent following correction of TOF. A residual VSD, 
most oft en caused by partial patch release or presence of multiple VSD’s, is 
found in 10 − 20% of patients and requires re-operating in case of a large shunt 
volume (by defi nition a Qp/Qs-ratio > 1.5).32,35 Residual gradients of the RV 
outfl ow tract are also found in approximately 20% of patients. Residual RVOT 
obstruction is a known important risk factor for early and late RV failure 
and therefore should carefully be avoided during surgery. In case of a post-
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operative RV pressure > 50% of LV pressure reoperation is indicated.35 The trade 
off  for total desobstruction of the RV outfl ow tract at repair, mostly achieved 
by more extensive surgery, is disturbance of normal RVOT and pulmonary 
valve function. Therefore the most frequently encountered residual defect in 
repaired TOF is pulmonary regurgitation (PR).
Isolated pulmonary regurgitation has been shown to clinically be well-
tolerated for decades by most patients.47 However, during early adulthood - 
middle age, patients start to manifest symptoms of right sided heart failure 
and may present with sudden cardiac death.47,48 Since symptoms from RV 
failure may appear only when advanced myocardial damage has occurred, 
the more subtle eff ects of PR may easily be missed.25,49 The long-term negative 
eff ects of PR on RV dimensions, RV and LV function, exercise performance 
and arrhythmia have been well documented.25,50,51 With the growing number 
of long-term survivors of initial corrective surgery the clinical management 
of TOF patient with residual PR is of growing importance. Though long-
term deleterious eff ects of PR on right sided dimensions and global systolic 
function have extensively been addressed in literature, litt le is known on rate 
of progression of both processes over time and on the factors involved. 
1.4.3  Treatment of PR
The most widely accepted treatment for PR is pulmonary valve replacement. 
The fi rst reports on pulmonary valve replacement date from the early 1980’s.25 
A fi rst pulmonary valve replacement can be performed with a peri-operative 
mortality rate of 0 − 4%52-57 and excellent mid-term survival.52,54-57 Clinical status 
and RV volumes almost unanimously are shown to recover in response to 
pulmonary valve replacement,23,55,56,58,59 but results on recovery of RV function 
are confl icting.25,53,58 Optimal timing of pulmonary valve replacement appears 
crucial to prevent irreversible right ventricular (RV) damage.23,55 
Prostheses used for pulmonary valve replacement have a limited lifespan 
and therefore the procedure should not be timed to soon. Freedom of repeated 
valve replacement has been reported in 58% to 86% of Fallot patients aft er 10 
years of follow-up.52,57 However lifespan of prostheses relates to age of the 
patient, with longer durability in adults than in children.48
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2  Turner’s syndrome
2.1  Background
Turner’s syndrome is characterized by the absence of all or part of the normal 
second sex chromosome, which leads to a constellation of visible (dysmorphic) 
and non-visible physical fi ndings in aff ected women.60 Turner’s syndrome was 
fi rst described in 1768 by the anatomist Giovanni Morgagni who reported 
post-mortem fi ndings of a woman with short stature, renal malformations and 
gonadal dysgenesis. In 1902 Funke described a girl with gonadal dysgenesis, 
short stature, absent puberty, congenital lympedema and a webbed neck.61 
The defi nitive description of the clinical features characteristic of Turner’s 
syndrome was given by Ullrich in 1930. However the syndrome is named 
aft er Henry Turner, an American endocrinologist who in 1938 described 7 
women with the characteristic phenotypic features of the syndrome.62 Turner’s 
syndrome occurs in 1 out of 2.000 to 3.000 live born girls.60,63 Approximately 
half of the patients have X-chromosomal monosomy (45, X), 5 to 10% have a 
duplication of the long arm of one X-chromosome (duplication, 46, X, i(Xq)), 
the remaining have mosaicism for 45,X, with one or more additional cell 
lineages.60 Turner’s syndrome is associated with a 3-fold increase in overall 
mortality. Life expectancy of women with Turner’s syndrome is reduced by 
up to 13 years.61 Cardiovascular disease is the most common cause of death in 
adult women with Turner’s syndrome.61 Complications from other disease like 
diabetes also contribute importantly to mortality.60 
2.2  Clinical features and diagnosis
There is a wide variation of clinical features seen in girls and women aff ected 
by Turner’s syndrome. The phenotype in Turner’s syndrome correlates with 
the exact cytogenetic appearance, with the most severe phenotype seen with 
45,X.61 Approximately ⅕ to ⅓ of aff ected girls are diagnosed as newborns 
because of puff y hands and feet or redundant nuchal skin. Approximately ⅓ is 
diagnosed in mid-childhood due to short stature while others show failure to 
enter puberty during adolescence. Diagnosis may be delayed until adulthood 
in approximately 10% of patients, almost exclusively those who enter puberty 
spontaneously and subsequently present with amenorrhea, infertility or 
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recurrent pregnancy loss. The clinical factors with the greatest impact on the 
lives of girls with Turner’s syndrome are: 1) short stature, 2) ovarian failure 
and 3) congenital cardiovascular abnormalities.26 These will be discussed in 
the following paragraphs. 
2.2.1  Short stature
Short stature is the most common readily recognizable sign of Turner’s 
syndrome found in at least 95% of all patients.64 In north-western Europe 
mean adult height in women with the Turner’s syndrome is about 147 cm, 
which is approximately 20 cm below the normal mean in women.26 The cause 
of growth failure in Turner’s syndrome is currently unknown, but is thought to 
be a primary bone defect. Candidate genes for short stature have been localized 
on the distal part of the short arm of the X and Y chromosomes, the so-called 
pseudoautosomal regions. A strong candidate gene for short stature found 
within these regions is the short stature homeobox-containing gene (SHOX 
gene) or pseudoautosomal homeobox containing osteogenic gene (PHOG). 
Point mutations of the SHOX/PHOG have been shown to be associated with 
short stature as well as some of the skeletal abnormalities found in Turner’s 
syndrome.61
Supra-physiologically dosed growth hormone treatment has been shown to 
accelerate height velocity in Turner’s syndrome65,66 and result in normalization 
of fi nal height in most girls with Turner syndrome.65 However, studies that 
included a randomized control group are scarce and effi  cacy of growth 
hormone treatment could not be established in all studies.60 Nevertheless 
in many countries growth hormone therapy currently is well accepted for 
treatment of short stature in Turner’s syndrome.26
As important as effi  cacy of growth hormone (GH) treatment to increase adult 
height, is the safety of this treatment. Short-term safety of recombinant human 
growth hormone treatment in Turner’s syndrome appears to be acceptable.26,60 
Increased blood pressure and insulin resistance have been reported during 
treatment, but resolved aft er discontinuation of therapy. Long-term eff ects of 
recombinant human growth hormone on for example the lifetime risk of type 
2 diabetes, but also on cardiovascular status so far are unknown.60
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2.2.3  Gonadal dysgenesis
Gonadal dysgenesis is a cardinal feature in Turner’s syndrome as already 
emphasized by Henry Turner. Gonadal failure occurs in over 90% of patients.64 
A comparable percentage will require hormone replacement therapy to 
initiate puberty and complete growth.60 Dependent on karyotype up to 40% 
of patients may undergo spontaneous pubertal development, and 2 − 5% 
may have spontaneous menses and the potential to achieve pregnancy.61,64 
Spontaneous fertility is most likely with mosaicism for a normal 46,XX cell 
lineage or a 47,XXX cell lineage of very distal Xp deletions.60 Both the short 
(distal to Xp11) and long arm (Xq13-25 and Xq26-28) of the X chromosome 
contain “critical regions” vital for normal ovarian development.60,61 Other 
genes, like the ZFX (zink fi nger) gene and the DFFRX (Drosophila fat facets 
related X), have also been identifi ed as possible candidate genes for normal 
ovarian development .61 Mechanism like aneuploidy and sex chromosome 
imbalance with impaired meiosis may contribute to a reduced number of germ 
cells and reduced survival of these cells.60,61
When induction of pubertal development is needed it is recommended to try 
and mimic normal pubertal development taking in account individual factors 
such as physiological issues and family history of age at onset of puberty.26,60,64 
Oestrogen substitution therapy during childhood includes a risk of premature 
epiphyseal closure. Therefore oestrogen therapy should be carefully timed 
as to minimize any negative eff ect on growth while inducing puberty at an 
approximately normal age.60,64 Long-term oestrogen replacement therapy is 
important to prevent osteoporosis and reduce the risk for atherosclerosis.61 
Progestagen should be added aft er the fi rst 12 − 24 months of oestrogen 
treatment to prevent endometrial hyperplasia and carcinoma.60,61,64
Most Turner patients are infertile, but various assisted reproductive 
techniques are now available. All pregnancies in patients with Turner’s 
syndrome should be monitored by a multidisciplinary team, both in the 
preparation phase and during follow-up of the pregnancy.64 The interest from 
cardiologic point of view in part results from the increasing number of reports 
on aortic dissection (also see paragraph 2.2.4.2) in the Turner syndrome during 
pregnancy.8,67 All women are advised to undergo a full cardiologic assessment 
before pregnancy, including echocardiography or magnetic resonance imaging 
of the aortic root, the cardiac valves and left  ventricular function. 
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2.2.4  Cardiovascular disease in Turner’s syndrome
2.2.4.1  Structural cardiovascular malformations 
Structural cardiovascular malformations, or congenital heart disease occur in 
up to ¾ of patients with Turner’s syndrome.6,8 Coarctation of the aorta and 
bicuspid aortic valve are common and represent respectively 25 − 30% and 
25 – 35% of cardiovascular malformations in the Turner syndrome.6-8 Besides 
structural cardiovascular malformations hypertension is frequently found 
in Turner’s syndrome.61,68 Already during childhood patients show higher 
pressure compared to a reference population, with hypertension found in up 
to 25% of girls.69,70 Furthermore an abnormal circadian blood pressure rhythm 
with blunted nocturnal reduction in blood pressure was found in over 50% of 
girls with Turner syndrome which increases the risk of end-organ hypertensive 
damage.69 The majority of Turner patients with hypertension have no obvious 
secondary cause of hypertension, despite the young age of onset.61
Bicuspid aortic valve usually is found as an isolated abnormality but may 
occur in association with other anomalies, particularly coarctation of the aorta. 
The cause of the abnormal aortic valve in Turner’s syndrome is unknown. 
A bicuspid aortic valve may develop progressive valvular dysfunction both 
in terms of stenosis and insuffi  ciency. Coarctation is especially common in 
Turner patients with webbing of the neck. This association together with the 
high incidence of coarctations found in aborted foetuses with 45,X and severe 
lymfedema, led to the theory that aortic coarctation in Turner’s syndrome may 
be caused by abnormal lymphatic fl ow and compression of the descending 
aorta.61,71 
2.2.4.2  Aortic dilation and dissection
For years aortic dilation was regarded a less common cardiovascular 
malformation in Turner’s syndrome, with a reported prevalence up to 6.5%.8 
However, in recent studies using magnetic resonance imaging (MRI), aortic 
dilation was found in 25 − 50% of patients with Turner’s syndrome and 
cardiovascular malformations.6,7,72 Dilation and dissection most frequently (50 
– 70% of cases), but not exclusively, occur in the ascending aorta.6,8 Dilation of 
the ascending aorta was found in 20 − 40% of patients.6,73,74
Aetiology of aortic dilation in Turner’s syndrome is unknown. Aortic 
dilation and dissection may occur at any age.8,73 As in the normal population 
it has been well established in Turner’s syndrome that coarctation of the aorta, 
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bicuspid aortic valve and hypertension are associated with a increased risk for 
aortic dilation and dissection.8,75 However in 5 to 10% of women with Turner’s 
syndrome and aortic root dilatation no associated risk factor for dilation is 
found.73 Post-mortal fi ndings in 71% of 25 Turner cases with histological data 
available, showed arterial cystic media degeneration similar to that seen in 
Marfan syndrome.61 Increased incidence of complications aft er surgery for 
coarctation has been reported in Turner’s syndrome as a result of apparent 
friability of the aortic wall.8 A recent study in Turner’s syndrome showed 
increased carotid-femoral pulse wave velocity, increased carotid intima-media 
thickness, and a larger carotid augmentation index.74 All these reports support 
the hypothesis that connective tissue abnormalities might play a role in aortic 
disease in Turner’s syndrome. 
 
2.3  Cardiovascular eff ects of growth hormone 
In Turner’s syndrome growth hormone is given for the restricted (but still 
fairly long) period of time during which a gain in patient’s fi nal height can 
be accomplished. Especially when started at young age and given at supra-
physiological dosages results on fi nal height are good.26,65 However, concerns 
have risen on the possible long-term cardiovascular side eff ects of supra-
physiological GH-therapy in Turner’s syndrome based on knowledge of 
cardiovascular side eff ects in other situations of growth hormone excess.
2.3.1  Eff ects on the heart
Growth hormone stimulates growth of the cardiomyocyte.76,77 The eff ects 
of growth hormone on cardiac size and function appear to occur in stages. 
Administration of growth hormone to healthy controls rapidly induces 
changes in LV geometry and function.76,78 Short term growth hormone induced 
myocardial hypertrophy has been shown to be reversible.76 In response to GH 
the cardiomyocyte initially increases its size and cross-sectional area, refl ecting 
parallel apposition of sarcomeres.77 As such short term growth hormone excess 
results in concentric ventricular remodelling, which according to the law of 
Laplace results in decreased wall stress. During initial acromegaly and with 
short term growth hormone excess diastolic function remains unchanged, 
while heart rate and left  ventricular contractility increase.76-80
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In animal models of myocardial ischemia short-term GH/IGF-I excess 
reduced the extent of cell necrosis and apoptosis.77 Initial GH/IGF-I induced 
myocardial hypertrophy in heart failure occurred proportional for the 
cardiomyocytes and the non-myocyte portion, thus without disproportional 
fi brosis.77 Moreover short-term GH has been shown be able to restore reduced 
myocardial capillary density to normal levels. Finally short-term GH/IGF-I 
excess is thought to activate a myocardial energy-saving program, including 
reduced oxygen demand and improved calcium handling, which results in 
improved LV mechanical performance.77,81 As such, short-term GH excess 
induces a physiological type of myocardial hypertrophy. 
Pathological myocardial hypertrophy is characterized by cardiomyocyte 
lengthening or serial deposition of sarcomeres, which results in eccentric 
remodelling. With pathological hypertrophy decreased myocyte density is 
found due to necrosis and apoptosis of myocytes combined with increased 
myocardial fi brosis. Pathological myocardial hypertrophy, typically found with 
chronic heart failure, is also found with long-term untreated acromegaly. Over 
time patients with active acromegaly develop signs of LV diastolic dysfunction 
even in the absence of myocardial hypertrophy.82,83 Diastolic dysfunction in 
acromegaly relates to disease activity and can be detected before evident 
systolic dysfunction.81,83,84 Progressive pathological myocardial hypertrophy 
in acromegaly results in impaired LV performance, low cardiac output failure, 
impaired LV stress response and reduced exercise tolerance.80 As such end-
stage acromegaly may be regarded a congestive heart failure syndrome in 
which disease duration and activity independently predict mortality.81
The pathological type of hypertrophy seen with long-term acromegalic 
cardiomyopathy is a cause of concern in all (high dosed) GH treated patients 
populations, including patients with Turner’s syndrome. During growth 
hormone treatment results have been reassuring with no signs of hypertrophy 
found in Turner’s syndrome,70,85 Noonan syndrome,86,87 growth hormone 
defi ciency,88 or children with idiopathic short stature,89,90 However data 
on possible long-term side-eff ects of growth hormone treatment are scarce, 
with almost no data available on cardiac status following discontinuation of 
treatment.91
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2.3.2  Eff ects on the large arteries
The biophysical properties of the arterial wall depend on the presence and 
proportion of smooth muscle cells and major components of the extra-cellular 
matrix (collage and elastin).92,93 The arterial media contains a mixture of 
collagen and elastin fi bres typical for the respective vessel. The aorta contains 
about 60% elastin fi bres and 40% collagen fi bres.92 Elastin fi bres are highly 
extensible, have a remarkable longevity, but fracture at low stress and show no 
appreciable synthesis in the adult aorta. Collagen fi bres on the other hand act 
as a stiff  reinforcing component, are only relatively inextensible, but can resist 
much higher levels of stress. The mixture of components with diff erent elastic 
properties results in a non-linear pressure-diameter (volume) relation of the 
aortic wall.94,95 This non-linear provides elastic stability and prevents the aorta 
of dilating or rupturing.92 Changes in content and composition of the extra-
cellular matrix will infl uence the mechanical properties of the arteries. 
A variety of factors and diseases infl uence aortic stiff ness. Aortic 
distensibility in normal subjects negatively correlates with age, progression 
of atherosclerosis, abnormal lipid profi le, and with post-menopausal state in 
women.96-98 The degenerative changes of the aortic wall in Marfan syndrome, 
a heritable connective tissue disorder, result in increased aortic stiff ness, as 
indicated by fi ndings of decreased aortic distensibility and increased pulse 
wave velocity compared to healthy controls.99 In Marfan syndrome both aortic 
diameter and distensibility are independent predictors of progressive aortic 
dilation.100
With aging plasma levels of anabolic hormones, among which GH and 
insulin-like growth factor-1, decrease. Growth hormone therapy has been 
shown to be able to reverse age-related catabolic changes.96 Patients with growth 
hormone defi ciency show wall thickening of large arteries and a tendency 
toward decreased compliance. In response to growth hormone substitution 
therapy patients with growth hormone defi ciency showed a decrease in 
arterial wall thickness and an increase in arterial wall compliance.101,102 In rats 
growth hormone was found to infl uence collagen metabolism and change the 
mixture of fi brous elements in the aortic wall which led to increased aortic wall 
distensibility in young animals.103 
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3  Imaging in congenital heart disease 
3.1  Cardiac magnetic resonance imaging; general considerations
Imaging plays an increasingly important role in the diagnostic and the 
therapeutic management of CHD.104 With various forms of CHD, among which 
TOF, the RV is subject to abnormal pressure and/or volume load and has been 
shown to be a major determinant of clinical outcome.105 Accurate assessment 
of RV anatomy, volume and ejection fraction in CHD, both before and aft er 
reparative surgery requires one or more of the following imaging modalities: 
echocardiography, contrast X-ray angiography, radionuclide studies, computed 
tomography, and magnetic resonance imaging (MRI).106
Transthoracic echocardiography still is the workhorse of non-invasive 
imaging in CHD as it is non-invasive, low-cost, without ionising radiation and 
can be performed virtually anywhere.51,104,107 However, echocardiography may 
be hampered by its limited imaging window, particularly in (adult) patients 
aft er previous surgery. For a long time conventional X-ray angiography has 
been used in addition to echocardiography if necessary for the evaluation of 
extra-cardiac vascular structures, both arterial and venous. Transoesophageal 
echocardiography shows bett er sensitivity and specifi city for the evaluation 
of CHD compared to transthoracic echocardiography, but is semi-invasive 
and not well suited for evaluation of the anterior positioned RV.108 Currently 
MRI is considered an extremely useful tool to study CHD as it combines the 
main advantages of echocardiography and conventional X-ray angiography. 
Like (transthoracic) echocardiography MRI provides accurate non-invasive 
information on morphology and function of the heart, while allowing for the 
evaluation of extra-cardiac vascular structures at the same time. 
Many of the advantages of MRI over echocardiography and X-ray 
angiography also hold for computed tomography. However, MRI does not use 
ionising radiation and iodine-based contrast agents, which have a three times 
higher risk for contrast mediated reactions compared to gadolinium based 
MRI contrast agents.107 Exposure to ionising radiation increases the risk of 
later malignancy in children, which is especially important in patients in need 
of repeated or serial examinations such as patients with CHD.109
Like other imaging techniques MRI has limitations and contra-indications. 
The most important practical limitations of MRI are the limited availability 
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and high cost. Cardiac MRI requires dedicated hardware and soft ware, 
and specifi cally trained technologists and physicians. Acquisition of a full 
cardiac MRI examination requires relatively much time (30 − 60 minutes) 
but is tolerated well by most patients.51,107 Children should be old enough to 
follow breath-hold instructions (approximately 7 − 10 years) to be scanned 
without (general) anaesthesia 51,107. Most contraindications besides severe 
claustrophobia, arise from the eff ects of the magnetic fi eld on magnetic or 
metallic prosthesis and implants (Table 1). Up to date listings of prosthesis 
and implants to verify possible contra-indications for MRI are published 
periodically and can be found on the internet (www.MRIsafety.com). Metal 
clips, suture wire in the sternum and vascular-coronary endoprosthesis (stents) 
do not represent a contra-indication for MRI. MRI is not contra-indicated with 
most valvular mechanical prosthesis, except with the oldest types. Pacing or 
defi brillator wires are a contra-indication for MRI as electromagnetic currents 
may induce internal heating of the wires.110,111 Furthermore the magnetic fi eld 
may interfere with the electronic components of pacemakers and internal 
cardiac defi brillators and cause malfunction, although with newer devices 
and wires there only appears to be a relative contra-indication.110,112,113 Multi-
slice computed tomography has emerged as an alternative modality for the 
population with an implantable metallic device, but requires slow heart rates 
which is a relative limitation in paediatric patients.107 
Table 1. Contra-indications for magnetic resonance imaging
Pacemaker, implanted defi brillator or neurostimulator
Intracranial iron clips
Metallic intraocular foreign body
Metallic projectile fragment near a vital structure
Cochlear implant or hearing aid
Starr-Edwards mitral valve prosthesis
Claustrophobia
Critical patient with a Swan-Ganz catheter
Pregnancy (teratogenic eff ect not demonstrated)
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3.2  Assessment of ventricular size 
In CHD accurate (serial) assessment of biventricular size is important to 
evaluate the impact of cardiac loading on cardiac condition. For the assessment 
of ventricular size many imaging modalities such as 2D-chocardiography and 
biplane contrast ventriculography use mathematical assumptions for chamber 
shape. Such assumptions may be applicable to the conical shaped LV, but not 
to the geometrically more complex RV. Especially with RV dilation predefi ned 
geometrical models may no longer apply and errors may occur or increase. 
Biplane contrast ventriculography, which used to be the gold standard for RV 
evaluation, now has largely been replaced by newer “non-geometric” imaging 
techniques like cardiac magnetic resonance imaging, three-dimensional 
echocardiography and multi-slice CT.104
The problem of geometric assumptions with echocardiography is being 
overcome with recently developed 3D-techniques. Validation studies using 
3D-echocardiography have shown promising results for RV volumetric 
measurements, with good correlations found with MRI measures.114-116 
Independent of the imaging technique used for volumetric ventricular 
assessments appropriate detection of the endocardial border is required. Using 
echocardiography this has been shown diffi  cult for the heavy trabeculized 
RV. As a resultant a systematic underestimation of RV volume with both 2D- 
and 3D-echocardiography was found.116,117 Further diffi  culties with 2D- (and 
3D) transthoracic echocardiography may occur when the RV is positioned 
substernal, which is especially seen with hemodynamic overloading and 
congenital malformations.118
Compared to 2D-echocardiography nuclear imaging techniques off er RV 
volume assessment not dependent on RV geometric assumptions. However 
the technique does require views that exclude counts form other chambers, 
which can usually be obtained for the left  ventricle but not always for the right 
ventricle.119 Furthermore radionuclide angiography requires bolus-injections, 
a regular cardiac rhythm, has limited resolution compared to other imaging 
modalities, and uses ionising radiation (though at relative low doses).104 
Radionuclide angiography does provide a reliable quantitative measurement 
of RV ejection fraction and wall motion.106,120
Common to all tomographic imaging techniques is that they generate 
a contiguous set of image sections encompassing the ventricular cavity 
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to provide a three dimensional data-set from which ventricular volumes 
can be calculated without the need for geometric assumptions. Volumetric 
measurements obtained with computed tomography provide accurate 
stroke volumes and ejection fractions for the right ventricle, and highly 
reproducible RV volumes.121-123 However computed tomography requires the 
use of intravenous contrast to provide suffi  cient diff erentiation between the 
ventricular lumen and the myocardium. Currently gradient-echo tomographic 
MRI has been established as the standard of reference for quantitative 
assessment of RV volume, mass, and function.124,125 In contrast to computed 
tomography and echocardiography high contrast is obtained between the 
blood and the myocardium without the use of contrast agents. Tomographic 
cine MRI can be performed reliably and reproducibly for repeated ventricular 
measurements.126,127 
3.3  Assessment of ventricular function
3.3.1  Ventricular function in general
Functional performance of the heart depends on both intrinsic and extrinsic 
factors. The most important intrinsic factor is the contractile state of the 
myocardium. Contractile state at the level of the myocyte depends on the 
interaction between actin and myosin, which in turn depends on cross-bridge 
formation regulated by cellular calcium homeostasis and calcium sensitivity of 
the myofi laments.128-130 At the level of the ventricle contractile state is defi ned 
by the amount of pressure generated by the ventricle at a fi xed volume (also 
see paragraph 3.3.2).
Extrinsic determinants of ventricular function include heart rate, preload, 
aft erload and ventricular interaction. According to the formula of cardiac 
output (CO = heart rate * stroke volume) changes in heart rate may infl uence 
cardiac performance. During exercise ventricular end-diastolic volume remains 
approximately constant while end-systolic volume decreases, which results in 
a larger ventricular stroke volume.131,132 Therefore the increase in heart rate 
with exercise together with the increase in stroke volume results in increased 
cardiac output. 
Preload refers to the load imposed on the myocardium prior to contraction. 
Higher load is refl ected by longer myocyte length or at the ventricular level by 
a larger end-diastolic volume. To a certain extent stroke volume as a measure 
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of cardiac pump performance is linearly related to end-diastolic volume, which 
is known as the Frank-Starling mechanism.133 The Frank-Starling mechanism 
was partly explained by improved overlap and interaction of the myofi laments 
(force-length relationship) and partly by stretch-induced increase in calcium-
sensitivity (length dependent activation).134,135
Aft erload refers to the load that has to be overcome by the ventricle to 
be able to eject and is refl ected by the build up of ventricular pressure until 
the semilunar valve opens. Aft erload depends on several factors including 
total peripheral resistance, ventricular wall thickness and ventricular size. In 
Laplace’s law for wall stress (Wall stress = Pressure*radius /2*wall thickness) 
ventricular size is refl ected by radius (r). According the Laplace’s law, ventricular 
dilation increases aft erload while ventricular hypertrophy decreases aft erload. 
Aft erload is best refl ected by arterial imput impedance, which, however, is hard 
to determine and therefore has limited clinical use.136 For practical purposes 
aft erload is frequently approximated by diastolic pressure in the great arteries 
and/or by end-systolic ventricular pressure. 
Ventricular function is generally used to refer to function of the heart during 
the cardiac cycle. However during this cycle we can distinguish between a phase 
of ventricular contraction and ejection, and a phase of ventricular relaxation 
and fi lling. During both phases abnormalities in normal function may occur, 
but not necessarily at the same time. It is, therefore more appropriate to address 
both entities separately during discussions on ventricular (dys)function. 
3.3.2  Systolic function 
For the assessment of systolic function several groups of parameters can be 
distinguished; 1) isovolumic indices, 2) pressure-volume relation derived 
indices, and 3) ejection phase indices. The most commonly used isovolumetric 
index of systolic performance is the maximal rise in ventricular pressure (dP/
dtmax). The dP/dtmax is highly sensitive to acute inotropic changes, but has marked 
inter-individual variation and strong preload dependency.137,138 To deal with 
the preload dependency Litt le et al. introduced the dP/dtmax – end-diastolic 
volume relation.137 According to the pressure volume relation, ventricular 
contractile state has been defi ned as the amount of pressure generated by 
the ventricle at a fi xed volume. The linear relationship between end-systolic 
pressure and ventricular volume is bett er known as the end-systolic pressure-
volume relationship (ESPVR).139 The slope of the ESPVR is sensitive to changes 
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in inotropic state while relatively insensitivity to changes in preload and 
aft erload and is used to measure ventricular contractility.139-141 The ESPVR is 
derived from pressure-volume loops (PV-loops). A second parameter derived 
from PV-loops is stroke work, which refers to the total amount of external 
work performed by the ventricle and refl ects the amount of energy used to 
propel blood during ventricular contraction. Glower et al. found stroke work 
and end-diastolic volume (a representative of preload) are linearly related 
which lead to the term preload recruitable stroke work relation (PRSW).142 The 
PRSW is preload-independent and insensitive to changes in aft erload within 
the physiological range.137,143 
The common disadvantage of the so far discussed indices of systolic 
ventricular function is that they require an invasive procedure to be assessed. 
Therefore the clinical applicability in research projects and for repeated 
measurements is limited, especially in children. The parameters categorized 
as ejection phase indices on the contrary can be derived non-invasively. Stroke 
volume and ejection fraction can be derived using gradient-echo tomographic 
MRI, the standard of reference for quantitative assessment of (right) ventricular 
volume, mass, and function.124 Compared to 2D-echocardiography the required 
sample size with MRI is substantially (80 to 90%) smaller to detect changes 
in ventricular ejection fraction or size.144,145 Reproducibility values for the RV 
are generally lower compared to the LV and as such the sample sizes for RV 
studies should in general be somewhat larger than those for LV studies.127 
Breathhold cardiac MRI has been proven accurate and highly reproducible 
for ventricular function and size.124,127,144,146 The major draw-back of stroke 
volume is its load-dependency. The preload-dependency of stroke volume can 
be reduced by using ejection fraction (EF). Ejection fraction can defi ned as the 
amount of fl ow ejected during systole (or stroke volume) relative to the total 
amount of blood present at the start of the ejection phase (or end-diastolic 
volume, considered a good representative of preload). Ejection fraction in turn 
is hampered by it’s aft erload-dependency with an inverse linear relationship 
between ejection fraction and aft erload. Nevertheless ejection fraction has 
been shown to sensitively detect depression of myocardial contractility. Worse 
ejection fraction has been associated with poorer clinical status.49 Like ejection 
fraction velocity of circumferential fi ber shortening (VCF), another ejection 
phase index of systolic function, is hampered by aft erload-dependency. 
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3.3.2  Diastolic function
Cardiovascular disease may lead to the clinical heart failure syndrome. For the 
clinical management of patients at risk for development of heart failure early 
diagnosis of ventricular dysfunction is essential. Many patients present with 
symptoms of heart failure including exertional dyspnoea, fl uid retention, and 
pulmonary oedema. Previous epidemiologic studies indicated nearly half of 
patients with heart failure have normal systolic function.147 It has been shown 
that diastolic ventricular dysfunction in various cardiovascular diseases may 
precede systolic ventricular dysfunction.148 As such adequate recognition 
of diastolic dysfunction may contribute to early detection of ventricular 
dysfunction. 
Diastole is the period available for ventricular fi lling defi ned as the 
period following closure of the semilunar valve extending to the point of 
atrioventricular valve closure. Diastole can be divided into four phases: 1) 
isovolumic relaxation, 2) rapid early fi lling, 3) diastasis and 4) (late) atrial 
contribution to ventricular fi lling. Isovolumic relaxation stretches from 
closure of the semilunar valve to opening of the atrioventricular valve. 
Isovolumic relaxation depends on active excitation-contraction decoupling 
by the active release of actin-myosin crossbridges that were formed during 
systole. The process depends on the number of crossbridges formed during 
systole (increases with increased ventricular load) and the time available 
for uncoupling of crossbridges (depends on heart rate). Indices used for this 
purpose are peak pressure decline rate (dP/dtMin) and the time constant of 
pressure decay (tau = time needed for pressure to drop to about 37% of starting 
pressure), which require invasive pressure recordings.149 Isolumic relaxation 
time can be assessed non-invasively using Doppler echocardiography by 
measuring the interval between pulmonary (or aortic) valve closure and the 
start of tricuspid (or mitral) fl ow. 
Ventricular fi lling is composed of the remaining three phases: the rapid 
early fi lling phase, the diastasis and the late atrial contribution to ventricular 
fi lling. Rapid fi lling occurs directly aft er AV-valve opening. The driving force 
behind early infl ow is a pressure gradient over the AV-valve present due 
to relaxation of the ventricle causing ventricular pressure to decline, which 
in turn causes an atrioventricular pressure gradient to arise. The velocity 
of this infl ow (peak early fi lling rate) will be proportional to the driving 
force (atrioventricular pressure gradient). This pressure gradient in turn is 
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dependent on the ventricle’s abilities for relaxation and is inversely related 
to the time constant of pressure decay (tau). Like the phase of isovolumic 
relaxation the phase of early fi lling depends on the active process of actin-
myosin cross-bridge decoupling. As the ventricle enlarges during fi lling 
passive properties of the ventricle ultimately will prevent a further increase 
in ventricular volume. During this early fi lling phase ventricular pressure 
gradually increases which will cause the atrioventricular pressure gradient to 
decrease leading to a point of equalisation of pressures. This point in time, 
known as diastasis is characterised by zero ventricular infl ow. In late diastole 
a second atrioventricular pressure gradient is created by atrial contraction. As 
such atrial contraction (atrial systole) acts as the driving force for late (atrial) 
diastole fi lling. Counteraction to the driving force in late diastolic is given 
by the passive mechanical properties of the ventricular myocardium (like 
compliance, distensibility, stress and elasticity), the overlaying pericardium, 
and ventricular interaction. The RV and LV interact especially during diastole 
when pressures are low. The position of the interventricular septum depends 
on the transseptal pressure diff erence. As such an increase of RV volume and/
or pressure decreases LV fi lling. 
Ventricular fi lling can be characterized non-invasively by Doppler 
echocardiography, radionuclide techniques, or MRI techniques. Irrespective 
of the technique used, all assess diastolic function by measuring indices 
of volume transient during ventricular fi lling.149 Figure 1 shows a typical 
example of an AV-valve infl ow patt ern as assessed by velocity encoded cine 
MRI. Comparable curves can be obtained with radionuclide techniques and 
Doppler echocardiography (however with fl ow velocity on the Y-axis). As 
illustrated by Figure 1 indices that characterize the patt ern of ventricular 
fi lling can be derived from such curves. The typical diastolic fi lling parameters 
measured from VEC MRI determined time-volume change curves are depicted 
in Table 2.
In the normal heart two thirds of stroke volume enter the ventricle during 
early diastole and about a fi ft h to a quarter of stroke volume enters during late 
diastole (A-peak). Therefore in healthy subjects the E/A-ratio will be expected 
to be larger than 1.0 (Figure 2). Abnormalities in the ventricular fi lling patt ern 
may occur with cardiovascular disease and relate to degree of impairment 
of ventricular diastolic function. Relaxation related ventricular dysfunction 
interferes with the normal build up of the driving pressure gradient responsible 
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for early ventricular fi lling. The fi lling patt ern of relaxation related diastolic 
dysfunction therefore is characterised by a smaller relative contribution of early 
ventricular fi lling (E-peak), prolongation of E-peak deceleration time, a larger 
relative contribution of atrial fi lling to total ventricular fi lling and a declined E/
A-ratio (Table 2 and Figure 2). In patients with restrictive ventricular diastolic 
dysfunction the patt ern is characterised by restriction of RV fi lling to the early 
phase with a relatively small contribution of atrial contraction to ventricular 
fi lling (Table 2 and Figure 2). 
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Figure 1: Phase velocity encoded mitral valve fi lling patt ern
AFF = atrial fi lling fraction, Dt = deceleration time, FF = early fi lling fraction, 
PaFR = peak atrial fi lling rate, PeFR = peak early fi lling rate
Patients with repaired tetralogy of Fallot in the majority of cases have some 
degree of pulmonary regurgitation. At least part of these patients show free 
communication between the right ventricle and the pulmonary artery with 
instant fi lling of the RV from the pulmonary artery when ventricular relaxation 
starts. An isovolumic diastolic time period can not be detected in these patients 
and therefore not be studied. RV diastolic fi lling in most cases can be studied 
using Doppler echocardiographic infl ow-patt ern across the tricuspid valve. 
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However, in patients with PR fi lling of the RV occurs through both the tricuspid 
and pulmonary valve. In this sett ing Doppler echocardiography cannot 
adequately quantify total RV diastolic fi lling. In contrast to echocardiography 
phase velocity encoded (VEC) or fl ow-sensitised MRI off ers volumetric fl ow 
quantifi cation. Volumetric quantifi cation allows for inclusion of both tricuspid 
and pulmonary fl ow into the analysis of RV fi lling by accumulation of curves 
(Figure 3). At rest VEC MRI has successfully been validated for the assessment 
of RV diastolic function in patients with PR.150 
Right ventricular diastolic filling paern:
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Filling characteristics:
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Figure 2. Diastolic ventricular fi lling in the normal heart and with cardiovascular 
disease.
A = peak atrial fi lling, DT = deceleration time, E = peak early fi lling
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Table 2. Indices of ventricular diastolic fi lling derived from VEC-MRI time-
volume curves: changes from normal in relation to type of diastolic dysfunction 
Index Description Relaxation Restriction
PeFR (ml/s) Peak early fi lling rate; fi rst peak defl ection 
from baseline during ventricular fi lling
− +
TtPeFR (ms) Time from end-systole to PeFR + 0
FF (%) Early fi lling fraction; ventricular volume 
increase during fi rst ⅓ of diastole/stroke 
volume *100%
− +
Dt (ms) Deceleration time; time from PeFR to the 
exploration point of deceleration of fl ow to 
the baseline
+ 0/+
PaFR (ml/s) Peak atrial fi lling rate; peak defl ection from 
baseline during atrial systole
+ −
AFF (%) Atrial fi lling fraction; ventricular volume 
increase aft er atrial contraction / stroke 
volume *100%
+ −
E/A-ratio Ratio of PeFR over PaFR − +
− = decrease, + = increase, 0 = constant
3A RV time – volume change curve: rest and stress
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Figure 3. Diastolic fi lling in tetralogy of Fallot with pulmonary regurgitation
3A. Dt = deceleration time, PaFR = peak atrial fi lling rate, TtPa = time to PaFR, PeFR = peak 
early fi lling rate, TtPe = time to PeFR
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3B RV time − volume curve: rest and stress 
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3B. AFF = atrial fi lling fraction, FF = early fi lling fraction
3.4  Arterial wall stiff ness
One of the main functions of the aorta is maintenance of steady blood 
fl ow through the capillary bed by the transformation of pulsatile fl ow into 
continuous fl ow. For this purpose the central aorta and major arteries distend 
during systole and store up to 60% of the LV stroke volume. By recoil of the 
central arteries during cardiac diastole, blood is pushed towards the periphery. 
Effi  cacy of this function is determined by the biophysical wall properties, or 
stiff ness, of the central arteries. Biophysical wall properties largely dependent 
on presence and proportion of smooth muscle cells and major components 
of the extra-cellular matrix (collage and elastin), or in short on arterial wall 
composition.92,93 
The aortic biophysical wall properties seem to play a signifi cant role in the 
pathogenesis of a variety of cardiovascular diseases such as atherosclerosis, 
hypertension, aneurysm formation, stroke, myocardial infarction, renal failure 
and Marfan’s syndrome.92 In these disease states arterial wall stiff ness is 
increased.93,151 Early detection of abnormal arterial wall function could provide 
a tool for early detection of cardiovascular disease. Methods for detection than 
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should be routinely available, non-invasive and safe, and allow for accurate 
and reproducible measurements. 
Various imaging techniques proved to be suitable for this purpose, the 
most important ones being ultrasound and MRI. As with other applications 
ultrasound benefi ts from its readily availability and low cost. Its use however 
is limited to the larger and more accessible arteries. Hence, the technique is 
used mainly on the brachial, femoral and carotid arteries and the abdominal 
aorta. The main site of application for MRI, a technique with an unlimited 
acoustic window, is the (thoracic) aorta. To quantify arterial stiff ness a host 
of indices have been introduced of which none has been proven superior 
and all have their problems during measurement and interpretation.93 Direct 
measurement of arterial stiff ness by imaging relates to measurement of change 
in arterial diameter and pressure at the same site.92 As a resultant non-invasive 
techniques applied on the aorta (and other central arteries) are limited by the 
fact that blood pressures are determined indirectly at the site of a peripheral 
artery.92 In measurements of pressure and diameter, stiff ness can be expresses 
as: Distensibility, Compliance, Elastic modulus (Peterson) and Elastic modulus 
(Young) and Stiff ness index (Table 3). 
Table 3. Indices of arterial wall stiff ness; defi nitions and formulas 
Index Defi nition Formula
Arterial 
distensibility
Relative diameter or area change for a pressure 
increment 
ΔD/ΔP * D 
(mmHg−1)
Arterial 
compliance
Absolute diameter or area change for a given 
pressure step at a fi xed vessel length
ΔD/ΔP 
(cm²/mmHg)
Elastic modulus The pressure step required for 
(theoretical)100% stretch from resting diameter 
at fi xed vessel length 
ΔP*D/ ΔD
(mmHg)
Young’s modulus Elastic modulus per unit area; the pressure 
step per square centimetre required for 100% 
stretch from resting length 
ΔP*D/ (ΔD*h)
(mmHg/cm)
Stiff ness index Ratio of logarithm (systolic/ diastolic pressure) 
to (relative change in diameter)
Ln (Ps/Pd)/
[(Ds-Dd)/Dd]
(nondimensional)
P = pressure, D = diameter, h = wall thickness, s = systolic, d = diastolic
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Both ECG-gated spin echo and ECG-triggered cine-gradient-echo sequences 
have been validated to determine regional aortic distensibility and compliance 
with magnetic resonance imaging.92 The main draw back of an ECG gated 
spin echo sequence is the diffi  culty of proper selection of the end-diastolic 
and end-systolic time-frames. Using ECG-triggered cine-gradient-echo 
sequences images are acquired throughout the cardiac cycle, which allows 
for accurate selection of the diastolic and systolic time-frames when scanned 
at an appropriate temporal resolution (approximately 25 ms).92 The main 
disadvantage of gradient-echo sequences compared to spin echo sequences 
is the limited contrast between vessel wall and lumen. The limited contrast 
with gradient echo sequences can be overcome by using an appropriate spatial 
resolution (< 1mm) and a small fl ip angle (20 − 30 degrees).92
The velocity at which the pulse wave travels along the arteries largely 
depends on the biophysical wall properties of the vessel. Therefore, another 
measure of arterial wall stiff ness is pulse wave velocity defi ned as the distance 
between two points divided by the time needed for the pulse wave to propagate 
between these points. Pulse wave velocity is related to arterial compliance 
according to the equation C = 1/PWV²*p 151 and to arterial distensibility 
according to the equation PWV = √(1/p*D) (C = compliance, D = distensibility, 
PWV = pulse wave velocity, and p= blood mass density).92 
Transthoracic Doppler ultrasound is limited by technical factors such as 
transducer placement and beam angle, but most important for the assessment 
of PWV in the aorta is the limited access to the central arteries.93 Therefore, 
conveniently accessible (carotid and femoral artery) points of measurement 
have to be chosen and compromises have to be made for determination of 
arterial distance over which the pulse wave travels.92,151 MRI is an alternative 
method for measuring PWV that allows accurate path length determination 
(along the centreline of the aorta) between two points of measurement.92 To 
allow for good accuracy scanning should be performed at high temporal 
(approximately 25 ms) and spatial (1 – 2 mm) resolution.92 
In summary phase velocity encoded MRI (cine-gradient-echo sequences) 
has been validated as an accurate tool for determination of both regional aortic 
distensibility and PWV.92 The use of MRI-determined measurements related 
to the biophysical arterial wall properties has been put forward for (early) 
detection of aortic wall dysfunction and quantifi cation of (small) intervention 
related eff ects on wall function, such as drug related eff ects.
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4  Heart failure and the neuro-endocrine system
4.1  Heart failure; general considerations
Normal homeostasis is maintained by a complex system with the heart as the 
central component, the muscular pump necessary for propulsion of blood. 
Other contributors to normal homeostasis are the nervous tissue, endocrine 
organs, the endothelium, the kidneys, blood constituents, and skeletal muscles. 
Disruption of normal myocardial geometric integrity results in changed intra-
cardiac pressures, wall stress and wall tension. This ultimately leads to loss of 
the normal fl ow patt ern through the heart and a relative reduction in cardiac 
output.152 To be diagnosed with heart failure according to the diagnostic criteria 
of the European society of cardiology (ESC) patients should have a clinical 
syndrome characterized by symptoms (breathlessness and fatigue), signs 
of salt and water retention, and cardiac dysfunction on cardiac imaging.153 
Both diagnostic guidelines of the ESC and the ACC/AHA state heart failure 
is a clinical diagnosis mainly based on carefully taken history and physical 
examination.153,154
In response to a reduction in cardiac output homeostatic mechanisms, 
focussed on restoring circulating volume by salt and water retention, 
vasoconstriction and increasing heart rate, are activated. In LV disease states 
it is commonly accepted that chronic insult to the myocardium and the 
resultant changes in geometry and structure, also known as remodelling, are 
accompanied by neurohormonal activation.155,156 The resultant is a vicious cycle 
characterized by excessive neurohormonal stimulation that is responsible not 
only for the chronic expression of adverse hemodynamic abnormalities but also 
contributes to further myocardial and vascular remodelling, the hallmark of 
progressive HF.155-157 This “neurohormonal concept” has been used during the 
design of recent treatment guidelines for heart failure.153,154 Pharmacological 
manipulation of neurohormonal pathways is now the cornerstone of heart 
failure therapy with improved morbidity and mortality found with various 
drugs.158-164
The shared hallmarks of cardiac injury and heart failure seen with both 
congenital heart disease and conventional heart failure cohorts, calls to classify 
congenital heart disease as a heart failure state.165 It is becoming increasingly 
clear that activation of neurohormonal pathways may also occur in congenital 
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heart disease.165 Surprisingly few data is available on the relation between 
RV remodelling as a result of chronic PR and the level of neurohormonal 
activation. Therefore the prognostic signifi cance of neurohormonal activation 
and the effi  cacy of interventions in neurohormonal pathways should be further 
elucidated. 
4.2  Catecholamines
Catecholamines (norepinephrine and epinephrine) are secreted by the 
adrenal glands in response to sympathetic nervous system activation. The 
sympathetic nervous system is activated by decreased vascular perfusion 
pressure registered by the baroreceptors. The so-called “baroreceptor refl ex” 
consists of; 1) an increase in heart rate (positive chronotropy) and ventricular 
contractility (positive inotropy), 2) vasoconstriction in the skin, splanchnic 
viscera and kidneys with shunting of blood away towards the heart and brain, 
3) vasodilation of the aff erent vasculature of the skeletal muscles. With chronic 
stimulation the sympathetic nervous input is taken over by peripheral and 
central chemo-refl exes and metabo-ergoreceptor refl exes.166
This response is only suitable for the acute compensation of insuffi  cient 
circulating volume. Chronic sympathetic stimulation results in increased cardiac 
work with increased myocardial oxygen requirements, while a higher baseline 
vascular resistance (aft erload) adds to the myocardial work requirements.167 
Circulating plasma level of norepinephrine closely correlates with degree of 
ventricular dysfunction and with prognosis of heart failure.168,169 Long term 
catecholamine stimulation may lead to down-regulation of the β1-receptor, 
which ultimately reduces the myocardial ability to improve contractility to 
stimulation.170-172
Clinical trials suggest that long-term carefully dose-adjusted β-blocker 
therapy improve symptoms, ventricular ejection fraction, exercise time, quality 
of life, and possibly even long-term survival.173-175 The negative inotropic and 
chronotropic eff ects of β-blockers initially worsen heart failure symptoms 
and some patients can not even tolerate the lowest dose.176 For Carvedilol (a 
combined β-blocker, α-blocker, and antioxidant) comparable or even bett er 
benefi cial results were found with heart failure.161,177,178 
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4.3  Renin-angiotensin-aldosterone system (RAAS)
The renin-angiotensin-aldosterone system (RAAS) is composed of a cascade 
of hormones initially triggered by the release of renin from the kidney 
(juxtaglomerular apparatus). RAAS contributes to maintaining vascular tone, 
optimal salt and water homeostasis, and forward cardiac output in human 
beings. The RAAS is stimulated by diminished renal fl ow. Renin cleaves 
angiotensinogen (a protein precursor produced in the liver) to form biologically 
inactive angiotensin I (AI). Angiotensin-I is converted to angiotensin II (AII) 
by angiotensin-converting enzyme (ACE). Finally, aldosterone is synthesized 
in the zona glomerulosa of the adrenal gland. Two subtypes of receptors, 
angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptors, mediate the 
major physiologic actions of angiotensin II. Amongst others AT1-receptors 
mediate; vasoconstriction, aldosterone stimulation, increased renal sodium 
reabsorption, vascular smooth muscle growth, endothelial dysfunction and 
activation of infl ammatory cytokines. AT2-receptors mediate; vasodilation, 
antiproliferation (cardiomyocyte and vascular smooth muscle cells) , decreased 
renal sodium reabsorption, decreased myocyte hypertrophy, decreased cardiac 
fi brosis. Plasma renin and aldosterone are increased with heart failure. 
Inhibition of the renin-angiotensin-aldosterone system can take place 
at multiple sites in the cascade by: angiotensin-converting enzyme (ACE) 
inhibitors, by angiotensin receptor blockers (ARBs), or by aldosterone 
antagonists. Angiotensin-converting enzyme (ACE) inhibitors given in 
addition to conventional therapy in patients with severe congestive heart 
failure improved symptoms and reduced mortality particularly due to 
reduced progression of heart failure among treated patients.162,164 ARB’s 
improved morbidity and survival in symptomatic heart failure when used as 
an alternative for ACE-inhibitors in case of intolerance, or in addition to ACE-
inhibitors in patients that remained symptomatic.179-181
According to recent European heart failure guidelines ACE-inhibitors and/
or ARB’s are indicated in all patients with LV systolic dysfunction in NYHA 
class II-IV.153 For patients in NYHA class I ARB’s are only indicated if ACE-
inhibitors are not tolerated. Aldosterone antagonists should be added in NYHA 
class I-II patients with LV dysfunction aft er a recent myocardial infarction, and 
in all NYHA class III-IV patients to improve survival and morbidity.153
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4.4  Natriuretic peptides
Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) play 
an important role in the regulation of extracellular fl uid volume and blood 
pressure homeostasis. ANP and its N-terminal prohormone (NT-proANP) are 
primarily produced by the right atrium. Brain natriuretic peptide (BNP) and 
N-terminal prohormone (NT-proBNP) are primarily secreted by the ventricular 
myocardium. Levels increase in response to increased wall stress with volume 
or pressure overload and to neuro-endocrine stimuli such as angiotensin II 
and endothelin.182,183 NT-proANP and NT-proBNP, the physiological inactive 
fragments of the natriuretic prohormones have a longer plasma half-life 
and bett er in vitro stability compared to the biological active parts.183,184 In 
patients with LV dysfunction NT-proBNP has at least identical and possibly 
bett er diagnostic value compared to BNP.182,183 ANP and BNP have natriuretic, 
diuretic, vasodilative, and renin-inhibiting eff ects.182,183 Natriuretic peptides 
may be regarded the natural antagonists of the renin-angiotensin system. 
Markedly elevated levels of ANP and BNP, have emerged as a useful 
diagnostic marker in heart failure.153 In congestive heart failure higher levels 
of NT-proBNP have been associated with future risk of CHF decompensation, 
CHF hospitalization and mortality, independent of other factors such as LV 
ejection fraction, peak oxygen consumption and NHYA class. The European 
Society of Cardiology considers normal values for natriuretic peptides to be 
specifi cally helpful for the exclusion of the diagnosis in patients clinically 
suspected of heart failure.153
4.5  Infl ammatory mediators 
Suffi  ciently high concentrations of infl ammatory mediators can mimic certain 
aspects of heart failure, including progressive LV dysfunction, LV remodelling 
and cardiomyopathy.185-187 The cardiomyocyte produces TNF-alpha in response 
to stress or injury.187 Known eff ects of TNF in heart failure are negative 
myocardial inotropy, decreased β-adrenergic responsiveness, hypertrophy 
of the myocyte, ventricular dilation and dysfunction, increased apoptosis, 
extracullular matrix alterations, endothelial dysfunction and activation of fetal 
gene expression.187 Elevated levels of TNF-alpha were found in patients with 
(advanced) heart failure.185 In heart failure progressive increases of TNF-alpha 
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related to deteriorating NYHA class status.185 Preliminary reports suggested 
TNF-alpha inhibition had benefi cial eff ects, but several clinical trials were 
discontinued because of lack of effi  cacy or even higher rates of mortality in 
treated groups.186
Interleukin-6 is produced by many cell types among which endothelial cells. 
Typical stimuli for IL-6 secretion are IL-1, TNF, hypoxia and bacterial LPS.186,188 
IL-6 levels are elevated in the sett ing of heart failure and negatively relate to 
functional status.188-190 IL-6 and related cytokines play a role in both myocyte 
hypertrophy and apoptosis, which suggest an important role in maintaining 
an equilibrium and in prevention of progression of compensated hypertrophy 
towards heart failure.188
The increase in pro-infl ammatory cytokines is independent of the etiology of 
congestive heart failure.186 Increased levels of pro-infl ammatory cytokines are 
not accompanied by increased levels of anti-infl ammatory cytokines, resulting 
in an imbalance of the cytokine network.186 Failure of one target therapeutic 
approaches underlines the complexity of the cytokine network in relation to 
cardiac function. Future research probably should be directed against several 
factors involved in immuno-pathogenesis of heart failure to try and restore the 
imbalance between pro-infl ammatory and anti-infl ammatory markers.
4.6  Endothelin
Endothelin-1 (ET-1), the predominant isoform of the endothelin peptides, 
is produced by the endothelium and a variety of other cells including 
cardiomyocytes.191 Synthesis is regulated by physicochemical factors such as 
pulsatile stretch, shear stress, and pH. A more complex regulation by vaso-
constrictors, growth factors, cytokines, adhesion molecules, NO, prostacyclin, 
ANP and estrogens also exists. 
In the clinical sett ing only plasma ET-1 concentrations can be measured. 
ET-1 acts through Gi-protein coupled receptors. ETA receptors mediate vaso-
constriction and cell proliferation, ETB receptors are important for clearance 
of ET-1, endothelial cell survival, the release of nitric oxide and prostacyclin, 
and the inhibition of endothelin-converting enzyme. Levels of ET-1 are 
increased in patients with heart failure, correlated with the severity of heart 
failure, and were predictive of survival.192,193 Because of the opposing actions 
of ETA and ETB receptors therapeutic implications must be carefully assessed. 
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Nevertheless various studies have shown (a)specifi c ET-receptor antagonists 
improve cardiovascular function and structure.191,194
4.6  High sensitive CRP
C-Reactive Protein (CRP) is produced in the liver during episodes of acute 
infl ammation or infection. Serum levels of C-reactive protein are elevated in 
patients with heart failure.195,196 Data on the prognostic value of CRP in chronic 
heart failure are inconsistent.195 CRP levels oft en remain within the normal 
range (≤ 10 mg/L). Standard clinical assays lack sensitivity within this low 
range (3 − 8 mg/L), which prohibits eff ective risk prediction. High sensitive 
CPR (hsCRP) potentially enhances the prognostic and therapeutic capabilities 
and has now become available in inexpensive commercial kits.
CRP is a marker of infl ammation in coronary artery disease.197 Plasma 
levels of hsCRP were one of the strongest independent predictors of future 
cardiovascular events in apparently healthy men and women.197 In chronic 
heart failure increased levels of CRP have been found and levels positively 
correlated with severity of disease (NYHA class, quality of life, worse 
hemodynamics).195,196 Higher levels of serum CRP in dilated cardiomyopathy 
related to an increased mortality risk.198 CRP predicted adverse clinical 
outcome in heart failure, independent of etiology and independent of the 
value of BNP.196 Clinical data on hsCPR in relation to heart failure are limited. 
Its relation to interventions and prognosis have to be further determined.
5  Aims and outline of this thesis
5.1  Study aims in corrected tetralogy of Fallot 
There is broad evidence that chronic residual PR in corrected TOF results 
in RV dilation, biventricular dysfunction, clinical deterioration and exercise 
intolerance, with an increased risk for ventricular arrhythmia and sudden 
cardiac death.48,50,199-201 Over the last decades several trends were seen in 
the fi eld of corrective surgery for TOF aimed at reducing late morbidity 
and mortality. These trends include surgery performed at young age and by 
transatrial transpulmonary approaches.
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In patients corrected according to these current strategies there is a lack 
of long-term follow-up studies that applied appropriate diagnostic tools. 
Many studies included a mixture of patients from diff erent surgical era, with 
optimal and suboptimal surgical results, such as a residual VSD or important 
pulmonary stenosis. This hampers interpretation of results and precludes 
assessment of long-term clinical condition aft er contemporary repair of 
TOF with (inevitable) PR, and of factors associated with decline in clinical 
condition in patients. In patients with TOF, surgically corrected at young age 
by a transatrial-transpulmonary approach, without residual VSD or important 
pulmonary stenosis, chapter 2 therefore aimed to:
assess clinical condition at mid- to long-term follow-up, including 
assessment of biventricular volumes and function at rest by cardiac MRI 
identify factors associated with RV dilation, RV dysfunction and with 
decreased exercise tolerance 
As with other cardiac disease states the assessment of diastolic function may 
play a role in (early) detection of ventricular dysfunction.148,149 Diff erent types 
of RV diastolic dysfunction have been reported in repaired TOF among which 
restriction to RV fi lling.150,202-205 Reports have been equivocal on how restriction 
to RV fi lling aff ects late functional condition in repaired TOF.150,203,204 Data on 
RV fi lling patt ern changes with stress may provide additional information but 
so far has not been acquired. Therefore, in chapter 3 we aimed to:
assess RV diastolic function in terms of RV fi lling patt ern, at rest and 
during pharmacological stress;
evaluate the eff ect of restrictive RV physiology, indicated by end-diastolic 
forward fl ow in the main pulmonary artery, on clinical condition. 
Pulmonary valve replacement currently is the only widely accepted 
treatment option for PR. Criteria to guide timing of pulmonary valve 
replacement in TOF are mainly based on progression of RV dilation and presence 
of symptoms.23,25,206,207 In heart failure literature it is commonly accepted 
that a chronic insult to the LV myocardium results in changes of ventricular 
geometry and structure accompanied by neurohormonal activation 155-157. 
This neurohormonal concept has guided recent treatment guidelines for heart 
−
−
−
−
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failure.153,154 Functional decline and especially loss of contractile reserve 
have also been shown of great prognostic value in LV disease states.208-212 
Surprisingly few data is available on RV remodelling as a result of chronic PR 
and its relation to neurohormonal activation or ventricular functional reserve. 
Considering LV heart failure guidelines this information is required. Therefore, 
in chapter 4 we aimed to:
assess the level of neurohormonal activity, biventricular contractile reserve 
and maximal exercise capacity, in relation to the amount of residual PR 
and biventricular function at rest
Sudden cardiac death is a major cause of late mortality in repaired TOF which 
oft en is att ributed to ventricular arrhythmia. Risk stratifi cation for sudden 
cardiac death in corrected TOF successfully focused on indicators of electrical 
inhomogeneity in the surface ECG to predict ventricular arrhythmia.50,213,214 
Exercise is considered a predisposing factor for ventricular arrhythmia in 
congenital heart disease and guidelines for exercise restrictions have been 
published.215 ECG markers for arrhythmia risk in TOF were all established at 
rest, while ECG changes with exercise were suggested to be relevant indicators 
of cardiac disease. In chapter 5 we therefore aimed to: 
assess pro-arrhythmogenic electrocardiographic changes in the surface 
ECG during maximal physical exercise
evaluate the relation of electrocardiographic changes during exercise to 
severity of residual PR, degree of RV dilation and hypertrophy, severity 
of systolic dysfunction, and maximal exercise capacity 
5.2  Study aims in Turner’s syndrome
Structural cardiovascular malformations were demonstrated in ½ to ¾ of 
patients with Turner’s syndrome.6,7,60,73 Up to 50% of these patients show 
aortic dilation.6,7,72 Aortic dilation may be complicated by aortic dissection, 
rupture and death. Risk factors for aortic dilation and dissection include aortic 
dilation, the bicuspid aortic valve and arterial hypertension, which all are 
relatively common fi ndings in Turner’s syndrome.8,73,216-218 Pregnancy has been 
suggested to carry an increased risk for aortic dissection, and an increasing 
−
−
−
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number of Turner patients is included in oocyte donation fertility programs.8,67 
The so far unknown aetiology behind aortic disease in Turner’s syndrome 
should be unravelled. Abnormalities in aortic wall composition may be behind 
aortic dilation and dissection, especially with disease in young subjects.8,217 
Phase velocity contrast MRI is an accurate, reproducible, non-invasive tool to 
determine aortic biophysical wall properties that indirectly refl ect aortic wall 
composition.92,93 Applying these MRI techniques in chapter 6 we aimed to 
assess:
aortic dimensions and distensibility in young adults with Turner’s 
syndrome treated with growth hormone during childhood in comparison 
to fi ndings in healthy age, gender and body surface area matched 
controls
the eff ect of growth hormone dose on aortic dimensions and distensibility 
Supra-physiological dosed growth hormone therapy nowadays is well-
established in Turner’s syndrome.26,65 If left  untreated the growth hormone 
excess in acromegaly has been shown to results in dynamic changes of cardiac 
structure and function, that eventually result in “acromegalic cardiomyopathy” 
considered to be a heart failure syndrome.77,81 This knowledge has raised 
concerns on possible cardiovascular side eff ects in all diseases that require 
growth hormone treatment during childhood, including Turner’s syndrome. 
These concerns have been addressed during childhood with active growth 
hormone treatment and results were reassuring.70,85-90 However data on 
cardiovascular status following discontinuation of treatment in Turner’s 
syndrome (and other diseases) are lacking. Midterm aft er discontinuation of 
growth hormone treatment, we therefore: 
assessed biventricular size and function in young adults with Turner’s 
syndrome and compared results to fi ndings in healthy age, gender and 
body surface area matched controls
evaluated the eff ect of growth hormone dose on biventricular size and 
function 
−
−
−
−
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5.3  Outline of this thesis:
In the fi rst chapter an overview of literature is given on the topics discussed in 
this thesis, followed by the main study aims and the outline of this thesis.
Chapters 2 to 5 describe fi ndings from an observational cross-sectional 
study of a cohort of patients with surgically corrected tetralogy of Fallot. 
Patients underwent surgical correction between 1980 and 1997 in either the 
Erasmus MC – Sophia Children’s Hospital or the UMC Utrecht – Wilhelmina 
Children’s Hospital. Selection criteria aimed to select patients with optimal 
post-operative results acquired with currently generally accepted surgical 
techniques performed at a relative young age. 
In chapter 2 the clinical condition of patients with repaired TOF subjected to 
chronic residual PR was assessed at mid- to long-term follow-up. Tomographic 
cine MRI was used to quantify the degree of biventricular dilation and systolic 
dysfunction. Maximal bicycle exercise tests applying breath-by-breath 
measurement were used to quantify patient’s functional capacity. Multiple 
linear regression analysis was employed on pre-operative, peri-operative and 
post-operative fi ndings to identify predicators of decline in clinical condition. 
In chapters 3 and 4 low dose (7.5 µg/kg/min) dobutamine stress MRI was 
used to evaluate cardiac response to stress in patients with corrected TOF and 
chronic residual PR. Chapter 3 describes right ventricular diastolic function 
by means of RV fi lling patt ern. Phase velocity encoded magnetic resonance 
imaging was applied to derive combined RV time-volume-change curves that 
represent the total RV fi lling information (combined tricuspid and pulmonary 
valve fl ow information). From these curves indices of RV fi lling were obtained. 
Changes in RV fi lling patt ern between rest and stress were evaluated. Special 
att ention was given to diff erences between patients with and without end-
diastolic forward fl ow in the main pulmonary artery. 
Applying the same tomographic MRI techniques used in chapter 2, chapter 
4 quantifi ed the systolic biventricular response to stress. Furthermore plasma 
levels of neurohormonal markers previously proven to be associated with 
cardiac function were assessed. As such exercise capacity, cardiac functional 
stress reserve and level of neurohormonal activation could be related to 
determinants of clinical condition. 
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In chapter 5 changes in the surface ECG of Fallot patients are assessed and 
compared to fi ndings in healthy controls. The changes that occurred with 
maximal physical exercise were related to determinants of clinical condition.
Chapters 6 and 7 of this thesis describe the fi ndings on functional cardio-
vascular status from an observational MRI study among a cohort of young 
adult women with Turner’s syndrome. All patients were treated with 
growth hormone during childhood and were former participants of a Dutch, 
randomized growth hormone dose response study. Patient data was compared 
to fi ndings in healthy gender, age and body surface area matched controls. 
Chapter 6 focused on aortic distensibility and dimensions in Turner‘s 
syndrome and their relation to the received growth hormone dose during 
childhood. Distensibility is a non-invasive measure of arterial wall stiff ness 
known to be abnormal in patients with connective tissue disease and therefore 
abnormal aortic wall composition. Aortic dimensions and distensibility were 
assessed at four predefi ned levels along the thoracic aorta and the upper part 
of the abdominal aorta. 
Chapter 7 assessed biventricular size and function in patients with Turner’s 
syndrome to evaluate the possible long-term cardiac side-eff ects of supra-
physiologically dosed growth hormone treatment during childhood.
In chapter 8 of this thesis the results from the studies described in chapters 
2 to 7 are summarized and future research perspectives are discussed. This is 
followed by a short summary in Dutch.
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Abstract
Objectives: To assess the clinical condition at mid-to-late follow-up in tetralogy 
of Fallot corrected by a transatrial-transpulmonary approach at young age, 
and to identify risk factors associated with RV dilation/dysfunction and with 
decreased exercise tolerance.
Methods: Fallot patients underwent cardiac MRI, maximal bicycle ergometry, 
ECG, Holter-monitoring and spirometry. Multivariate linear regression 
analyses was employed to determine independent predictors for selected 
clinical parameters.
Results: Fift y-nine patients (mean ± SD age) at repair 0.9 ± 0.5 years, interval 
since repair 14 ± 5 years) were included. The median pulmonary regurgitant (PR) 
fraction was 32% (0 − 57%). Compared to published data on healthy controls, 
Fallot patients had signifi cantly larger RVEDV and RVESV, smaller RVEF, and 
smaller LVEF. VO2max was 97 ± 17 % and workload max 89 ± 13 % of predicted. 
Median QRS-duration was 110 ms (82 − 161 ms). No important ventricular 
arrhythmias were found. Compared to patients without a transannular patch, 
patients with a patch had more PR, a larger RV, worse RVEF and LVEF but 
comparable exercise capacity.
Multivariate regression analysis identifi ed the following independent 
determinants for larger RV-volumes: longer interval since repair, longer QRS-
duration, higher PR-percentage. For smaller RVEF: abnormal RVOT wall 
motion, longer interval since repair, longer QRS-duration. For smaller VO2max: 
smaller RVEF and longer QRS-duration.
Conclusions: At mid- to-late follow-up clinical condition in tetralogy of 
Fallot corrected according to contemporary surgical approaches appears well 
preserved. However, even these patients show RV dilation and dysfunction 
associated with impaired functional capacity. Abnormalities relate to RVOT 
motion abnormalities, longer interval since repair, longer QRS-duration and 
more severe PR.
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Introduction
Over the last decades peri-operative mortality of correction for tetralogy of 
Fallot (TOF) decreased for all ages, including infants.1,2 Repair at a young age 
shortens the period the patient is subjected to systemic hypoxemia and to 
right ventricular (RV) pressure overload. These considerations have lead to a 
trend of primary correction performed at young age, aimed at optimal relief 
of RV outfl ow obstruction and closure of the VSD.1,2 In addition, the concept 
of transatrial-transpulmonary repair for TOF gained popularity.3 This concept 
aims at reducing the side eff ects associated with a ventriculotomy, such as 
RV myocardial and coronary artery damage. Outcome of TOF repair has 
extensively been described. Pulmonary regurgitation (PR) is a crucial factor in 
long-term outcome.4 There is a lack of studies reporting on long-term follow-
up, acquired with appropriate tools, in TOF patients repaired according to 
recent surgical strategies. Furthermore, most studies have included a mixture 
of patients with optimal and suboptimal surgical results, such as residual VSD 
or important pulmonary stenosis. This precludes assessment of optimal long-
term eff ects of repair of TOF, and of factors associated with decline in clinical 
state aft er optimal repair, that is, clinical condition in patients with (inevitable) 
PR, but without additional problems. Therefore, the present study aimed 1) to 
assess clinical condition at mid- to long-term follow-up, including assessment 
of biventricular volumes and function by cardiac magnetic resonance imaging 
(CMR), 2) to identify factors associated with RV dilation, RV dysfunction and 
with decreased exercise tolerance, in TOF patients, operated at young age 
by the transatrial-transpulmonary approach and without residual VSD or 
important pulmonary stenosis.
Patients and Methods
A cross-sectional study of patients aft er surgical repair of TOF was performed. 
The local medical ethics committ ee approved our study protocol. Informed 
consent was obtained from patients or parents if patients were not of the legal 
age to provide consent. Patients were included for data collection between 
September 2002 and November 2004. The following inclusion criteria were 
used: 1) complete repair of tetralogy of Fallot without associated cardiac lesions, 
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including double outlet right ventricle (except patent ductus arteriosus), 2) 
age at repair ≤ 2 years, 3) transatrial-transpulmonary approach to repair, 4) 
duration of follow-up since repair ≥ 5 years. Patients with one or more of the 
following criteria were excluded: residual VSD, residual pulmonary stenosis 
(echo Doppler mean gradient > 30 mm Hg), repair with a homograft , mental 
retardation, known extracardiac pathology. Criteria were reviewed using 
patient’s medical records. Pre-operative hemodynamic data was obtained from 
diagnostic heart catheterization reports. 
Magnetic resonance imaging protocol
A 1.5 Tesla Signa CVi scanner was used with soft ware releases V8 and V9.1 
(General Electric, Milwaukee, USA). A cine volumetric data-set was acquired 
in short axis direction using a 2D fast imaging employing steady-state 
acquisition sequence (SSFP). Imaging parameters were: fl ip angle = 45°, TE set 
at min full, TR= 3.4 – 3.6 ms, 8 − 9 mm slice thickness, 0 − 1 mm inter-slice gap, 
12 views/segment, readout bandwidth = 111Khz, a square FOV (30 − 34 cm), 
and a scanning matrix of 160 * 128. Twenty-four phases per cardiac cycle were 
reconstructed retrospectively.
Pulmonary valve fl ow measurements were performed perpendicular to 
fl ow using a standard 2D retrospectively gated fl ow-sensitised sequence. 
Thirty cardiac phases were reconstructed retrospectively. Imaging parameters 
were: 2D FSPGR, TR = 6 − 7 ms, TE = 3 ms, fl ip angle = 20o, readout bandwidth 
= 90 Khz, 6 mm slice thickness, 6 views/segment, a rectangular FOV (75% in 
phase encoding direction) and a scanning matrix of 256 *128.
Magnetic resonance image analysis
CMR studies were analysed on an Advanced Windows workstation (General 
Electric, Milwaukee, USA). Flow images were quantitatively analysed using 
the Flow analysis soft ware package V2.0 (Medis Medical Imaging Systems, 
Leiden, The Netherlands). Residual pulmonary stenosis was calculated 
using the simplifi ed Bernoulli equation (ΔP = 4*Vmax²). Volumetric data was 
quantitatively analysed using the Mass analysis soft ware package V3.1 (Medis 
Medical Imaging Systems, Leiden, The Netherlands), with parameters assessed 
according to analysis techniques widely reported in literature.5 Volumetric CMR 
Clinical condition aft er transatrial-transpulmonary repair of Fallot
67
parameters were indexed for BSA unless specifi ed otherwise. Values outside 
the mean ± 2SD range in healthy controls were defi ned to be abnormal. On the 
cines an experienced observer assessed wall motion in the RVOT. Abnormal 
wall motion was defi ned as absent or outward movement of part of the RVOT 
wall during systole. To calculate the pulmonary regurgitant fraction, amount 
of PR was normalised for the systolic stroke volume across the pulmonary 
valve (PR-percentage = Backward fl ow/Systolic forward fl ow *100%). Critical 
upper limits for RV end-diastolic volume, 200 ml/m² in children and 170 ml/m² 
in adults, associated with absent return of RV-volume to normal size following 
pulmonary valve replacement have been reported and were applied on our 
population.6,7
Bicycle ergometry 
Patients performed a symptom limited bicycle exercise test on a Jaëger Oxycom 
Champion System (Viasys Healthcare, Hoechberg, Germany), allowing breath-
by-breath-ergometry. Workload was increased with 10 − 20 Watt s per minute. 
Patients were encouraged to perform to exhaustion. Tests were regarded 
maximal with a respiratory quotient (RQ) ≥ 1.05 in children and ≥ 1.10 in adults 
at peak exercise. Exercise capacity was compared to that of normal individuals, 
corrected for age, sex, and weight.8 Values > 85% of predicted were considered 
normal.
Spirometry
Preceding the exercise test patients performed a standard maximal forced vital 
capacity manoeuvre using a dry rolling seal spirometer (Jaëger, Würzburg, 
Germany). From the obtained loops the following parameters were derived: 
forced vital capacity (FVC), forced expiratory volume in the fi rst second (FEV1), 
ratio FEV1/FVC, and maximum expiratory fl ow at 25% of FVC (MEF25). Results 
were compared to those from normal individuals corrected for age, gender 
and body composition and expressed as percentages of predicted values. 
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ECG
A standardised 12-lead ECG was obtained to assess QRS (ms), QTc (ms), and 
JTc (ms) duration. A 24-hours Holter monitoring was performed on a day with 
usual activities. 
Statistical analysis
CMR results of patients were compared to a reference population from literature 
using the two-sample t-test.9 Data were log10-transformed when appropriate to 
obtain approximately normal distribution. Results are expressed as mean ± SD 
for normally distributed data, otherwise as the median and range. Bivariate 
correlation coeffi  cients were calculated using Spearman’s method. Multivariate 
linear regression analyses (backward stepwise regression method) was 
employed to determine major independent predictors for outcome variables. 
Only variables signifi cant in univariate analysis were included in these 
multivariate analyses. Percentages were compared using the χ²-test. Analysis 
was performed using the SPSS-PC statistical soft ware package version 11.5 
(SPSS, Chicago, Il, USA). A p-value ≤ 0.05 was considered to indicate statistical 
signifi cance.
Results
Patient characteristics
Records of 169 eligible patients alive in 2002 and operated between 1980 to 
1997 before the age of 2 years by a transatrial-transpulmonary approach at the 
Erasmus MC Rott erdam or the University MC Utrecht were checked. Reasons 
for exclusion were; residual VSD (n = 3), residual RVOT stenosis (> 30 mm Hg) 
(n = 11), repair with a homograft  (n = 15), mental retardation (n = 16), extracardiac 
pathology (n = 7), lost to follow-up (n = 32). Eighty-fi ve patients fulfi lled all 
inclusion criteria and received an invitation for this study. Sixty-three (74%) 
patients agreed to participate. Four of our youngest participants (aged 5.9 − 
6.5 years) did not complete the entire protocol and were excluded from all 
results. The characteristics of the remaining 59 patient are shown in Table 1. 
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Patients that refused to participate, and those lost to follow-up, did not diff er 
from participants in mean age at repair, interval since repair, incidence of 
staged repairs or gender distribution. Patients did not use cardiac medication, 
51(86%) were in NYHA class I (86%) and 8(14%) in class II. 
In 42 (71%) patients a transannular patch (TAP) repair was performed. In the 
remaining 17 (29%) patients desobstruction of the RVOT was achieved using 
a combination of the following techniques: infundibulectomy, valvulotomy, 
commissurotomy or partial valvectomy. Pre-repair, patients with a TAP had a 
lower arterial oxygen saturation (86 ± 9 versus 92 ± 9 %, p < 0.05) and a higher 
RV/aortic peak pressure ratio (1.0 ± 0.1 versus 0.9 ± 0.1, p < 0.05) compared to 
patients without a TAP. TAP repairs were performed at younger age (median 
age at repair 0.6 (0.2 − 2.0) years versus 1.1 (range 0.3 − 2.0), p < 0.05). Interval 
since repair was comparable between patients with a TAP and those without 
(15 ± 5 years versus 13 ± 4 years, p = 0.14).
Table 1. Patient characteristics 
Patient Total n = 59 (100%)
Gender (M/F) 41/18
Age at repair (years) 0.8 (0.2 − 2.0)
Age at study (years) 15 (6 − 23)
Interval since repair (years) 14 (6 − 23)
BSA (m²) 1.5 ± 0.4
Previous Blalock-Taussing shunt 3 (5%)
Preoperative measures RV/Aorta peak pressure ratio 1.0 ± 0.1
RV peak pressure (mmHg) 88 ± 9
Oxygen saturation (%) 87 (62 − 100)
Residual pulmonary stenosis (mmHg) 9 (3 − 29)
Data given are mean ± SD and median (range)
Cardiac magnetic resonance imaging 
The median value for PR-percentage was 35% (range 0 − 57%). Patient CMR 
data was compared to data from literature assessed in healthy controls (Table 
2).9 Diff erences in CMR fi ndings between patients with and without a TAP are 
shown in Table 3. Abnormal wall motion in the RVOT region was diagnosed 
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in 41(69%) patients. Cumulative incidence of abnormal wall motion was larger 
in patient with a TAP compared to those without (37 out of 42 patients versus 
4 out of 17, χ² < 0.001). Similar diff erences as for patient with or without a TAP 
were found with regard to PR, biventricular size and EF when comparisons 
were made for patients with abnormal RVOT wall-motion versus those with 
normal wall-motion (data not shown).
Table 2. Biventricular CMR results in patients and controls.
TOF patients Controls Abnormal‡
Number patients 59 16
Age (years) 15 ± 5 18 ± 2
Mean ± SD Range Mean ± SD Limit# Number (%)
RVEDV (ml/m²) 139 ± 37* 85 – 237 79 ± 9 97 (UL) 50 (85%)
RVESV (ml/m²) 72 ± 26* 35 – 145 32 ± 7 56 (UL) 50 (85%)
RVSV (ml/m²) 66 ± 14* 36 – 100 49 ± 6 61 (UL) 38 (64%)
RVEF (%) 49 ± 6* 32 – 60 61 ± 6 49 (LL) 29 (49%)
LVEDV (ml/m²) 81 ± 12 61 – 109 79 ± 9 97 (UL) 7 (12%)
LVESV (ml/m²) 36 ± 8* 16 – 53 29 ± 7 43 (UL) 10 (17%)
LVSV (ml/m²) 46 ± 7 31 – 67 49 ± 6 37 (LL) 4  (7%)
LVEF (%) 56 ± 6* 42 – 74 63 ± 6 51 (LL) 7 (12%)
* Signifi cant diff erence (p < 0.05) compared to controls, # Limit of normal, UL (upper limit) 
= mean+2SD, LL (lower limit) = mean-2SD, ‡ Number of patients with abnormal CMR 
results (above UL or below LL of relevance), EDV = end-diastolic volume, EF = ejection 
fraction, ESV = end-systolic volume, SV = stroke volume
The RVEDV was > 170 ml/m² in 14(24%) patients and > 200 in 4(7%). 
Compared to patients with a RVEDV ≤ 170 ml/m², patients with a RVEDV 
> 170 had: smaller RVEF (50 ± 6 versus 44 ± 5 %, p < 0.05), comparable LVEF 
(57 ± 6 versus 55 ± 6 %, n.s.), and worse exercise capacity (percentage of 
predicted VO2max 99 ± 18 versus 90 ± 11 %, p < 0.05). All patients with RVEDV 
> 170 ml/m² had ≥ 12 years of follow-up (median 18 years, range 12 − 23) and a 
PR-percentage > 30% (median 46%, range 31 − 54%).
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Table 3. Comparison of patients according to presence of a TAP in the RVOT# 
No patch 
n = 17 (29%)
TAP repair 
n = 42 (71%)
PR-percentage 14 ± 12 40 ± 11*
Residual pulmonary stenosis 13 ± 7 9 ± 6*
RV EDV (ml/m²) 106 ± 19 152 ± 35*
ESV (ml/m²) 51 ± 12 81 ± 25*
SV (ml/m²) 55 ± 10 71 ± 13*
EF (%) 52 ± 6 47 ± 6*
RVFWM (g/m²) 20 ± 4 26 ± 6*
LV EDV (ml/m²) 82 ± 12 81 ± 12
ESV (ml/m²) 34 ± 8 37 ± 8
SV (ml/m²) 48 ± 8 45 ± 7
EF (%) 59 ± 6 55 ± 5*
LVM (g/m²) 52 ± 9 53 ± 10
Data given are mean ± SD, * Signifi cant diff erence compared to patients without a patch 
in the RVOT (T-test, p < 0.05), # Similar diff erences with regard to PR, biventricular size, 
wall mass and EF were found when comparisons were made for patients with normal and 
abnormal RVOT wall-motion (data not shown). EDV = end-diastolic volume, EF = ejection 
fraction, ESV = end-systolic volume, LVM = LV mass, RVFWM = RV free-wall mass, SV = 
stroke volume (All CMR parameters were indexed for BSA)
ECG and Holter monitoring
All patients were in sinus rhythm. Right bundle branch block was diagnosed 
in 80% of patients. Median QRS-duration was 110 ms (range 82−161 ms), mean 
QTc-duration was 408 ± 32 ms, and mean JTc-duration was 270 ± 23 ms. No 
diff erences were found for QRS-duration (p = 0.47), QTc-duration (p = 0.39) 
and JTc-duration (p = 0.26) between patient with or without a TAP.
During 24-hours Holter monitoring 5 patients showed ≥ 1 cardiac pauses 
> 1.9 sec. The longest observed pause lasted 2.3 sec. Two patients, both with 
a TAP, showed a non-sustained VT run of respectively 3 and 4 complexes at 
heart rates of 174 and 108 beats/min with a QRS duration in sinus rhythm of 
105 and 130 ms respectively.
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Spirometry
Mean FEV1 was 99 ± 12 % of predicted. Mean FVC was 94 ± 12 % of predicted. 
The median FEV1/FVC ratio was 89% (range 75 − 100%). Mean MEF25 was 89 
± 31 % of predicted. Mean FVC of predicted tended to be higher in patients 
without a TAP (97 ± 14 % versus 90 ± 12 %, p = 0.05). The other parameters were 
not diff erent between patients with and without a TAP.
One patient showed severe obstructive abnormalities and exercise results 
of this patient were excluded from analysis. The parameters derived from the 
maximal fl ow-volume loops showed no signifi cant correlations with percentage 
of predicted VO2max. 
Bicycle ergometry
The patient with obstructive airway disease was excluded, 1 patient declined 
the test and 1 patient could not complete the test due to technical problems. 
Exercise data refl ect results of the remaining 56 patients. Mean RQ at peak 
exercise was 1.2 ± 0.1. All patients reached our RQ criteria at peak exercise. 
Age at study correlated positively with RQ at peak exercise (r = 0.44, p < 0.001) 
and RQ during initial recovery (r = 0.69, p < 0.001). Peak oxygen consumption 
(VO2max) was 40 ± 8 ml/kg/min, or 97 ± 17 % of predicted VO2max (p = 0.20), with 
a value < 85% found in 14(25%) patients. Mean peak workload was 149 ± 62 
Watt s, or 89 ± 13 % of predicted (p < 0.05), with value < 85% found in 18(32%) 
patients. 
Percentage of predicted workload and percentage of predicted VO2max 
were not diff erent between patients with a TAP and those without a TAP 
(respectively 88 ± 11 % versus 92 ± 17, p = 0.37) and 96 ± 15 % versus 99 ± 
22, p = 0.59). Percentage of predicted workload and percentage of predicted 
VO2max were smaller in patients with abnormal RVOT wall-motion compared 
to patients with normal motion (respectively 86 ± 12 % versus 95 ± 13, p < 0.05) 
and 94 ± 16 % versus 103 ± 19, p = 0.07).
Determinants of exercise capacity
Factors signifi cantly related to VO2max and percentage of predicted VO2max 
by univariate analysis were determined. Predictor variables originated from 
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the following 3 sets of parameters: A) Parameters determined at pre-repair 
diagnostic heart catheterization (RV peak pressure, arterial oxygen saturation, 
RV/Aorta – pressure ratio), B) Peri-operative parameters (age at repair, TAP 
(1 = present, 0 = absent)), C) Post-operative parameters (PR-percentage, interval 
since repair, RVOT wall-motion (1 = abnormal, 0 = normal), QRS-duration, QTc, 
JTc and all biventricular CMR determined measures).
Table 4. Predictors of peak oxygen consumption
Univariate Analysis Multivariate Analysis
Predictor Regression 
Coeffi  cient ± SE
P-value Regression 
Coeffi  cient ± SE
P-value
Dependent: VO2 ml/kg/min
LVSV (ml/m²) 0.5 ± 0.2 0.002 0.4 ± 0.1 0.001
Gender (male/female) − 7.0 ± 2.2 0.002 5.9 ± 1.8 0.002
Interval since repair (years) − 0.6 ± 0.2 0.004 − 0.5 ± 0.2 0.004
QRS duration (ms) − 0.15 ± 0.06 0.008 − 0.10 ± 0.05 0.04
 Constant 34.9 ± 7.5 −−−−−−
RVEF (%) 0.53 ± 0.16 0.002 n.s.
PR−percentage − 0.17 ± 0.06 0.009 n.s.
TAP (yes/no) − 4.8 ± 2.2 0.04 n.s
RVOT motion (abnormal/normal) − 5.3 ± 2.2 0.02 n.s.
RV peak pressure (mmHg) − 0.18 ± 0.08 0.03 n.s.
Dependent: VO2 percentage of predicted 
RVEF (%) 1.6 ± 0.3 < 0.001 1.3 ± 0.3 < 0.001
QRS duration (ms) − 0.4 ± 0.1 0.001 − 0.2 ± 0.1 0.05
 Constant 59.4 ± 24.1 −−−−−−−
RVESV (ml/m²) − 0.23 ± 0.09 0.009 n.s.
LVSV (ml/m²) 0.8 ± 0.3 0.02 n.s.
LVEF (%) 1.2 ± 0.4 0.002 n.s.
Interval since repair (years) − 1.5 ± 0.4 0.001 n.s.
RV peak pressure (mmHg) − 0.39 ± 0.16 0.02 n.s.
Data given are regression coeffi  cients ± standard errors, R² for the multiple regression 
model of VO2 (ml/kg/min) and VO2 (percentage of predicted) were respectively 0.49 and 
0.36, EF = ejection fraction, ESV = end-systolic volume, LV = left  ventricle, PR = pulmonary 
regurgitation, RV = right ventricle, RVOT = RV outfl ow tract, SV = stroke volume, TAP = 
transannular patch
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Variables with signifi cant relations (at the 0.05 level) identifi ed by univariate 
analysis were used in multiple regression analysis to identify independent 
determinants. Results for both the univariate and multivariate linear regression 
analyses are shown in Table 4.
Determinants of RV CMR measures and PR-percentage
RV CMR parameters and PR-percentage were analysed using the same 
procedures described in the previous paragraph. During analyses on RVEDV, 
RVESV and RVEF the corresponding LV parameter was introduced in the 
model. Mathematically related RV CMR measures were not used in one model. 
Results for both the univariate and multivariate linear regression analyses are 
shown in Table 5.
Table 5. Predictors of RV CMR measures.
Univariate Analysis Multivariate Analysis
Predictor Regression 
coeffi  cient ± SE
P-value Regression
Coeffi  cient ± SE 
P-value
Dependent: RVEDV (ml/m²)
Interval since repair (years) 3.7 ± 0.9 < 0.001 1.4 ± 0.6 < 0.05
PR-percentage (%) 1.5 ± 0.2 < 0.001 1.3 ± 0.2 < 0.001
LVEDV (ml/m²) 1.3 ± 0.4 0.001 1.5 ± 0.2 < 0.001
 Constant − 54.8 ± 18.4 -----
TAP (yes/no) 42 ± 9 < 0.001 n.s.
RVOT-motion (abnormal/normal) 7 ± 9 < 0.001 n.s.
RV peak pressure (mmHg) 1.0 ± 0.3 0.005 n.s.
Dependent: Log10 RVESV (ml/m²)
Interval (years) 0.016 ± 0.003 < 0.001 0.007 ± 0.003 < 0.01
PR-percentage 0.006 ± 0.001 < 0.001 0.005 ± 0.001 < 0.001
LVESV (ml/m²) 0.009 ± 0.002 < 0.001 0.007 ± 0.002 < 0.001
QRS-duration (ms) 0.003 ± 0.001 0.02 0.001 ± 0.001 < 0.05
 Constant 1.15 ± 0.09 -----
RV peak pressure (mmHg) 0.004 ± 0.001 0.003 n.s.
TAP (yes/no) 0.17 ± 0.04 < 0.001 n.s.
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(Continued) Univariate Analysis Multivariate Analysis
Predictor Regression 
coeffi  cient ± SE
P-value Regression
Coeffi  cient ± SE 
P-value
Dependent: RVEF (%)
Interval (years) − 0.59 ± 0.14 < 0.001 − 0.3 ± 0.1 < 0.05
QRS-duration (ms) − 0.12 ± 0.04 0.007 − 0.07 ± 0.03 < 0.05
LVEF (%) 0.49 ± 0.13 0.03 0.5 ± 0.1 < 0.001
RVOT-motion (abnormal/normal) − 5.9 ± 1.6 < 0.001 − 3.1 ± 1.4 < 0.05
 Constant 39.1 ± 7.0 -----
RV peak pressure (mmHg) − 0.13 ± 0.06 0.03 n.s.
PR-percentage − 0.12 ± 0.05 0.03 n.s.
TAP (yes/no) -4.7 ± 1.7 0.007 n.s.
Dependent: PR-percentage 
TAP (yes/no) 22.5 ± 3.4 < 0.001 22.2 ± 3.3 < 0.001
RV peak press (mmHg) 0.39 ± 0.14 0.008 0.3 ± 0.1 0.02
 Constant − 5.7 ± 9.0 -----
RVOT-motion (abnormal/normal) 17.9 ± 4.0 < 0.001 n.s.
Arterial oxygen saturation −  0.57 ± 0.21 0.01 n.s.
Interval since repair (years) 0.83 ± 0.41 0.05 n.s
RV free wall mass (g/m²) 1.1 ± 0.3 0.001 n.s
Data given are regression coeffi  cients ± standard errors, R² for the multiple regression 
models of RVEDV, RVESV, RVEF and PR-percentage were respectively 0.76, 0.72, 0.53 and 
0.53, EF = ejection fraction, ESV = end-systolic volume, LV = left  ventricle, PR = pulmonary 
regurgitation, RV = right ventricle, RVOT = RV outfl ow tract, TAP = transannular patch
Discussion
This study provides quantitative data on clinical status at mid-to-late follow-
up in TOF patients, corrected at a relatively young age by a transatrial-
transpulmonary approach, and without other residual lesions but PR. TOF 
repair almost inevitably results in some degree of PR. Here the median PR-
percentage was 35% (range 0 − 57). As expected with considerable volume 
overload, RV volumes were markedly elevated in our patients, with mean 
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values being approximately twice that in controls, and values above the upper 
limit of normal found in 85% of our patients (Table 2). Furthermore, RVEF 
and LVEF were decreased compared to controls, in respectively 49% and 
12% of our patients. Despite these striking abnormalities, chronic RV volume 
overload seems to be well tolerated by these patients. All were in NYHA class I 
(86%) or II (14%), all were in sinus rhythm and none used cardiac medication. 
Mean percentage of predicted VO2max was not diff erent from controls. Patients 
had normal lung function and no important ventricular arrhythmias were 
encountered.
This study identifi ed independent predictors of several undesirable, but 
common problems during the follow-up of TOF. The most important predictor 
of poorer exercise capacity was a lower RVEF, which in turn was best predicted 
by abnormal RVOT wall motion. Larger RV dilation and poorer RVEF were 
associated with a longer interval since repair. This suggests that, even in Fallot 
patients corrected according to current surgical strategies and with optimal 
surgical result, gradual but slow deterioration of RV function with volume 
overload seems inevitable. Patients with already marked RV dilation subjected 
to chronic PR may develop symptoms over time, which stresses the need for 
serial follow-up.
RVOT function in repaired TOF
Previous studies have demonstrated the negative impact of TAP repair on PR 
and RV size.10 In our study multivariate regression analysis showed that TAP 
repair was the most important independent predictor of PR-percentage, with a 
22 ± 3 % point higher PR-percentage in patients with a TAP compared to those 
without a TAP (Table 5). A higher PR-percentage independently predicted 
larger RV-volumes, but not poorer RVEF. Poorer RVEF was independently 
predicted by abnormal RVOT wall motion. A previous study among adult 
Fallot patients, operated at older age than our patients, also found abnormal 
motion in the RVOT region to predispose for RV dysfunction.10 Both that study 
and ours showed that abnormal wall motion is not restricted to patients with a 
TAP. This suggests wall motion abnormalities can be induced by other factors. 
Remarkably, Davlouros et al. found no diff erence in incidence of wall motion 
abnormalities between patients with and without TAP, while this diff erence 
was clearly present in our patients.10 This may be explained by the diff erent 
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primary surgical approach used, with a primary ventriculotomy used in most 
patients reported by Davlouros et al. However, other factors such as prolonged 
hypoxemia, present in the patients reported by Davlouros et al., cannot be 
ruled out to play a role in RV wall motion abnormalities. The infl uence of 
surgery in the RVOT region on long-term outcome has also been studied by 
comparing transventricularly repaired TOF patients to patients with isolated 
pulmonary valve stenosis treated by pulmonary commissurotomy.11 Freedom 
of adverse events related to RV dilation (defi ned as cardiac death, reoperation 
and NYHA class ≥ II) was bett er in patients aft er isolated commissurotomy 
despite similar degrees of moderate and severe PR found in both patient 
groups. These fi ndings suggest that limited RVOT surgery contributes to 
bett er long-term outcome, which is supported by our study. Whether or not the 
recently described reconstructive technique of the pulmonary valve by Sung 
et al. further contributes to improved outcome remains a matt er of ongoing 
observation.12
QRS-duration
In TOF a QRS-duration > 180 ms in adults and > 170 ms in children is known 
to predispose to malignant ventricular arrhythmia and sudden death.13,14 QRS-
duration did not exceed 170 ms in our patients. Residual PR and subsequent 
RV dilation have been associated with QRS prolongation.14-16 Pulmonary valve 
replacement has been shown to reduce QRS-duration proportionally to the 
degree of RV volume reduction.17,18 In our population QRS-duration was an 
independent predictor of RV-volume, but also of RVEF and exercise tolerance 
(Table 5). These predictive eff ects were present in the range below the reported 
critical values that predispose for arrhythmia and sudden death. 
Prolongation of QRS duration has been related to electrical inhomogeneity.19 
In this regard ventricular dyssynchrony has been observed in TOF. Cardiac 
resynchronisation therapy in heart failure with prolonged QRS-duration 
has been proven benefi cial for ventricular contractile function, symptomatic 
status, and mortality.20,21 Thus far, results in congenital heart disease including 
TOF have been promising.19 The relations found for QRS-duration with RVEF 
and exercise capacity in the present study suggest that functional gain may be 
achieved by cardiac resynchronisation therapy in selected TOF patients.
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Long-term outcome of TOF
Pulmonary valve replacement currently is the only widely accepted treatment 
for residual PR in TOF. Optimal timing of this procedure seems crucial, but 
criteria so far have not been established.4 Newer imaging techniques, such as 
CMR, are expected to supply the data required to design such criteria. Several 
groups studied outcome of pulmonary valve replacement using serial CMR 
data.6,7,22 A RVEDV ≤ 170 ml/m² in adults and ≤ 200 ml/m² in children was found 
to relate to adequate recovery of RV volume.6,7 Our patients with an RVEDV 
> 170 ml/m² had worse exercise capacity. Remarkably, all these patients had an 
interval since repair ≥ 12 years and a PR-percentage > 30%. Patients with a PR-
percentage ≤ 30% PR did not demonstrate an RVEDV > 170 ml/m2, irrespective 
of follow-up duration. Most large CMR based studies report on Fallot patients 
operated according to diff erent surgical strategies than our patients (older 
age at repair, staged repairs, primary RV ventriculotomy, repair with RV to 
pulmonary artery conduits).10,23 We demonstrate that previously obtained 
CMR criteria also identify worse clinical status in patients operated according 
to a currently widely accepted surgical approach. However, the long-term 
prognostic value of these criteria regarding mortality and morbidity still has 
to be determined in patients from any surgical era.7
Study limitations
Because of the potential negative eff ect of a ventriculotomy on long-term 
clinical state a transatrial-transpulmonary approach was chosen in all patients. 
The frequent use of a TAP illustrates total avoidance of a ventriculotomy in 
TOF is not feasible in clinical practice. Furthermore it created the opportunity 
to evaluate the eff ect of a TAP on clinical condition. Inclusion criteria limit this 
study to patients with “isolated” PR. As such our patients represent that part 
of daily clinical practice with optimally repaired initial pathology (VSD and 
RVOT obstruction). Because of the design diffi  culties in data interpretation 
introduced with various forms of ventricular overload are avoided. 
We used CMR reference values from healthy controls of the same age range, 
obtained and analysed in similar ways as in the current study.9 During the 
assessment of functional capacity we did not account for level of physical 
training. The RQ at peak exercise indicates all patients performed maximally. 
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As expected results show higher RQ values in older patients. Therefore peak 
results may bett er refl ect maximal exercise capacity in older patients. This may 
have resulted in a slight underestimation of the magnitude of regression in 
exercise capacity over time.
The debate on optimal age at repair is still ongoing. As all our patients 
were corrected aft er the age of 2 months we can only speculate on further 
improvement of clinical state if patients were to be corrected in the neonatal 
period. We did not fi nd important eff ects of age at repair on the outcome 
measures shown in Tables 4 and 5.
Clinical implications
The current study demonstrates that at mid-to-late follow-up symptomatic 
status, exercise performance and rhythm status remain relatively normal in 
Fallot patients aft er repair according to a transatrial transpulmonary approach. 
Deterioration of RV function and exercise capacity correlate with a longer 
interval since repair, but these moderate associations cannot be used to predict 
the pace of decline in the individual patient. Our results suggest that further 
improvement of clinical condition may be obtained by improving preservation 
of RVOT function and by reducing the eff ect of electrical inhomogeneity. The 
evolution of CMR, ECG and exercise data in this series as well as the need for, 
and eff ects of interventions should be re-evaluated in future studies.
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Abstract
Purpose: To prospectively assess right ventricular (RV) diastolic function aft er 
repair of tetralogy of Fallot (TOF) at rest and during pharmacological stress 
and to study the relationship between end-diastolic forward fl ow in the main 
pulmonary artery (EDFF, indicative of restrictive RV physiology) and clinical 
state.
Materials and Methods: Approval of our institutional medical ethics 
committ ee was obtained. Informed consent was obtained from patients or 
parents. Patients with corrected TOF through the transatrial-transpulmonary 
approach underwent rest and stress (dobutamine 7.5 µg/kg/min) MRI, and 
maximal exercise testing. A 2D cine volumetric data set was acquired. Flow 
measurements were performed using a standard 2D fl ow-sensitized sequence. 
MRI fl ow curves of the tricuspid and pulmonary valve were combined into RV 
time-volume change curves, from which indices of RV fi lling were derived. 
Patients were compared with published control data. Student T-tests, Mann-
Whitney U tests and ANCOVA were used for group comparisons. Paired T-tests 
were used to analyze paired data. One sample T-tests were used to compare 
patients to a reference population. P-value < 0.05 indicates signifi cance.
Results: Thirty-six patients (mean (± SD) age at repair 0.9 ± 0.5 years, median 
age at inclusion 17 (range 7 − 23) years, 26 males and 10 females) were 
included. Abnormalities in RV fi lling included impaired relaxation (prolonged 
deceleration time, p = 0.002; smaller early fi lling fraction, p = 0.02) for the entire 
group compared to published data on healthy controls, and signs of restriction 
to RV fi lling (smaller atrial fi lling fraction, p = 0.002; higher E/A-ratio, p < 
0.001) in patients with EDFF (n = 24) compared to those without EDFF (n = 
12). Stress response was abnormal in patients with EDFF, who developed 
impaired RV relaxation, not appreciated at rest. Patients with EDFF had more 
severe pulmonary regurgitation (p = 0.03) and poorer exercise performance 
(p < 0.001).
Conclusion:  In Fallot patients corrected according to currently widely accepted 
surgical strategies, EDFF in the pulmonary artery relates to worse clinical state 
at mid to long-term follow-up, as indicted by worse exercise capacity and 
more severe PR. Dobutamine stress imaging may “unmask” abnormalities in 
RV diastolic fi lling not appreciated by rest imaging alone.
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Introduction
Outcome aft er surgical correction of tetralogy of Fallot (TOF) is good, despite 
the presence of pulmonary regurgitation (PR) in the majority of patients.1,2 PR 
initially is well tolerated, but long-term negative eff ects of PR on RV dimensions, 
RV systolic function and exercise performance have been well documented.3,4 
Diastolic dysfunction may precede systolic dysfunction and therefore may 
play a role in early detection of ventricular dysfunction. Diff erent types of 
RV diastolic dysfunction have been reported in repaired TOF.5-8 Restriction 
to diastolic RV fi lling, indicated by end-diastolic forward fl ow (EDFF) in 
the main pulmonary artery, has been documented throughout follow-up.5-8 
Reports have been equivocal on how restriction to RV fi lling aff ects functional 
outcome in TOF.5-8
In most patients RV diastolic fi lling can be studied using the Doppler 
echocardiographic fl ow-patt ern across the tricuspid valve. However, in patients 
with PR, RV fi lling occurs through both the tricuspid and pulmonary valve. In 
this sett ing Doppler echocardiography cannot adequately quantify total RV 
diastolic fi lling. Magnetic resonance fl ow-sensitive imaging techniques have 
successfully been validated at rest for the assessment of RV diastolic function 
in patients with PR.6 Stress imaging may provide additional information, 
but to our knowledge has not been used to assess RV diastolic function in 
corrected TOF. Thus, the purpose of our study was to prospectively assess right 
ventricular (RV) diastolic function aft er repair of tetralogy of Fallot (TOF) at 
rest and during pharmacological stress and to study the relationship between 
EDFF in the main pulmonary artery (indicative of restrictive RV physiology) 
and clinical state.
Materials and Methods 
Approval of our institutional medical ethics committ ee was obtained. 
Informed consent was obtained from patients or parents (if patients were not 
of the legal age to provide consent). Forty patients were included between 
October 2002 and February 2004. Patients were selected based on the following 
criteria: total repair before the age of two years, repair through the transatrial-
transpulmonary approach, no residual intra-cardiac shunt, and a residual right 
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ventricular outfl ow tract (RVOT) Doppler gradient ≤ 40 mmHg. One author (JB) 
using patient’s medical records reviewed these criteria as well as the presence 
of a transannular patch in the RV outfl ow tract and the use of medication. 
Patients with pulmonary atresia, absent pulmonary valve syndrome or other 
associated heart defects were excluded. The pre-operative parameters (arterial 
oxygen saturation, RV/Aortic systolic pressure ratio and hemoglobin) shown 
in Table 1 were obtained from diagnostic heart catheterization reports. Patient 
height and weight were measured and body surface area (BSA) was calculated. 
The total population was subdivided in groups: group I containing all patients 
with EDFF and group II containing those without EDFF. EDFF was defi ned 
present when detected at rest in more than 1 time frame at end-expiration. 
Independent of its volumetric amount, EDFF was considered pathologic 
and indicative of restriction to RV fi lling. Patient data obtained at rest was 
compared with published data on healthy controls by one author (JB).6 Clinical 
state was assessed by cardiac MRI, assessing the amount of PR, RV volume and 
RV ejection fraction, and by maximal exercise testing. 
Magnetic resonance imaging protocol
Imaging was performed on a 1.5-Tesla Signa CVi scanner using soft ware releases 
V8 and V9.1 (General Electric Medical Systems, Milwaukee, WI, USA) and a 4-
channel phased array cardiac coil. Standardized localizer imaging planes were 
acquired for fl ow-measurements of the tricuspid valve, pulmonary valve, and 
inferior vena cava, and a volumetric ventricular data set in short axis direction. 
Flow measurements were performed perpendicular to fl ow at end-expiration 
during breath-hold using a standard 2D fl ow-sensitized retrospectively gated 
sequence, starting at the R-wave. Special att ention was given to adequate 
ECG registration and triggering. Thirty cardiac phases were reconstructed 
retrospectively. Imaging parameters were: 2D fast spoiled gradient echo, TR 
= 6 − 7 ms, TE=3 ms, fl ip angle = 20o, readout bandwidth = 90 Khz, 6 mm slice 
thickness, 6 views/segment, a rectangular FOV and a scanning matrix of 256 * 
128.
The volumetric data set was acquired using the 2D fast imaging employing 
steady-state acquisition sequence (SSFP). Imaging parameters were: fl ip angle 
= 45°, TE set at min full, TR = 3.4 – 3.6 ms, 8 – 9 mm slice thickness, 0 − 1 mm 
inter-slice gap, 12 views/segment, readout bandwith = 111Khz, a square FOV 
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(30 − 34 cm), and a scanning matrix of 160 * 128. Twenty-four cardiac phases 
were reconstructed retrospectively.
Scans were performed at rest and repeated during dobutamine stress with 
a maximal dosage of 7.5 µg/kg/min. Heart rate (beats/min), heart rhythm and 
blood pressures (mmHg) were continuously monitored. Administration of 
dobutamine was decreased when heart rate increased > 50%, when systolic 
and/or diastolic blood pressure increased > 50% or decreased > 20%, when 
serious rhythm disturbances were seen and with complaints of the patient. 
No severe adverse eff ects of dobutamine, necessitating discontinuation of MRI 
examination, were seen.
Table 1. Patient characteristics
Total group
(n = 36) 
Group I
(n = 24)
Group II 
(n = 12)
Age at repair (years) 0.9 ± 0.5 1.0 ± 0.5 0.9 ± 0.5
Pre-operative oxygen saturation 87 ± 9 86 ± 9 89 ± 7
Pre-operative RV/Aorta systolic blood 
pressure ratio
0.98 ± 0.12 1.00 ± 0.13 0.95 ± 0.07
Pre-operative hemoglobin (mmol/L) 8.8 ± 1.3 9.0 ± 1.4 8.4 ± 0.9
Age at inclusion (years) 17 (7 − 23) 18 (10 − 23) 13 (7 − 23)
Interval since repair (years) 16 (7 − 22) 16 (10 − 22) 12 (7 − 22)
TAP repair n = 23 (64%) n = 17 (71%) n = 6 (50%)*
BSA (m²) 1.6 ± 0.4 1.7 ± 0.3 1.6 ± 0.5
RV EDV (ml/m²) 138 ± 40 145 ± 41 124 ± 37
RV ESV (ml/m²) 64 (36 − 145) 140 (84 − 237) 56 (36 − 137)
RV EF (%) 49 ± 7 49 ± 6 49 ± 9
RVFWM (gr/m²) 24 ± 6 25 ± 7 23 ± 6
Residual PR (%) 36 (0 − 55) 39 (0 − 55) 17 (1 − 51)*
Residual PS (mmHg) 9 (4 − 29) 9 (4 − 29) 11 (6 − 29)
Data given are: number of patients (%), median (range) or mean ± SD, 
* Signifi cant diff erence (p < 0.05) between groups I and II, BSA = body surface area, 
EDV = end-diastolic volume, EF = ejection fraction, ESV = end-systolic volume, 
RV = right ventricle, PR = pulmonary regurgitation, PS = pulmonary stenosis, 
RVFWM = RV free wall mass, TAP = transannular patch.
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Magnetic resonance image analysis
MRI data analyses were performed by 1 author (JB) with 1 − 3 years of 
MRI experience supervised by a second author (WH) with 10 years of MRI 
experience. Flow images were quantitatively analyzed using the Flow analysis 
soft ware package version 2.0 (Medis Medical Imaging Systems, Leiden, 
The Netherlands). Flow velocity curves were calculated by multiplying the 
manually drawn vessel/valve area on each time frame with the spatial average 
fl ow velocities. EDFF (ml) and PR (ml) were normalized for respectively net 
forward fl ow volume and systolic forward stroke volume measured in the 
pulmonary artery. Presence of retrograde fl ow coincident with atrial systole 
was assessed in the inferior vena cava. The volume of tricuspid insuffi  ciency 
was normalized for total forward fl ow across the tricuspid orifi ce. Volumetric 
data were analyzed using the Mass analysis soft ware package version 3.1 
(Medis Medical Imaging Systems, Leiden, The Netherlands). End-diastolic and 
end-systolic time frames were used according to analysis techniques widely 
reported in literature to assess right ventricular end-diastolic volume, end-
systolic volume, stroke volume, ejection fraction and wall mass.9,10 
Calculations 
RV time-volume change curves were reconstructed by summation of fl ow 
data from the main pulmonary artery and the tricuspid valve as previously 
described.6 Time-volume curves were obtained by integration of the time-
volume change curves (Figure 1). If heart rates (trigger delays) during both 
measurements were not identical the averaged heart rate (trigger delay) was 
calculated and used for the summated curves. From the RV curves the following 
indices of diastolic function were derived; 1) peak early fi lling rate (PeFR) (ml/
s), 2) time to peak early fi lling rate (tt PeFR) (ms) measured from end-systole, 
3) early fi lling fraction (FF) defi ned as volume increase (ml) during the fi rst 
one-third of diastole normalized for ventricular stroke volume, 4) deceleration 
time (Dt) (ms), measuring the time from PeFR to the extrapolation point of 
deceleration of fl ow to the baseline, 5) peak atrial fi lling rate (PaFR) (ml/s), 6) 
time to peak atrial fi lling rate (tt PaFR) (ms) defi ned as time from end-systole 
to maximal increase in ventricular volume aft er atrial contraction, 7) atrial 
fi lling fraction (AFF) defi ned as the increase in ventricular volume aft er atrial 
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contraction normalized for ventricular stroke volume, and 8) the ratio of peak 
early fi lling rate over peak atrial fi lling rate (PeFR/PaFR ratio) (Figure 1). RV 
stroke volume (ml) was defi ned as the maximal ventricular volume measured 
on the ventricular time-volume change curve.
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Figure 1A. RV Time-Volume Change Curve Abbreviations used: 
Dt = deceleration time, PaFR = peak atrial fi lling rate, PeFR = peak early fi lling 
rate, TtPa = time to PaFR, TtPe = time to PeFR
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Figure 1B. RV Time-Volume Curve Abbreviations used: 
AFF = atrial fi lling fraction, FF = early fi lling fraction (fi rst ⅓ of diastole)
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Exercise testing
To assess peak workload (Watt s) and peak oxygen consumption (VO2max) 
all patients performed a maximal exercise test, using a stepwise incremental 
protocol on a Jaëger (Viasys Healthcare, Hoechberg, Germany) Oxycom 
Champion System allowing breath-by-breath-ergometry. Patients were 
encouraged to perform until exhaustion. The respiratory quotient was used 
to objectify maximal performance (respiratory quotient > 1.1 at peak exercise). 
Peak workload was compared to that of a reference population by one author 
(JB).11
Statistical methods 
Results are expressed as mean ± 1SD for normally distributed data, otherwise 
the median and range are shown. Patient characteristics were compared 
between groups using the student T-test or the Mann-Whitney U test. Diastolic 
MRI parameters were compared using analysis of covariance with correction 
for heart rate and BSA to deal with possible confounding introduced by age 
diff erences in this partly pediatric population. To meet the data considerations 
of analysis of covariance all diastolic parameters except tt PeFR and FF had to 
be log10-transformed. Paired measurements were analyzed using the paired 
T-test during which diastolic time-related parameters were normalized for RR-
interval duration and PeFR and PaFR for RV stroke volume. Mean percentage 
of predicted workload (Watt s) was compared with the reference population 
using the one-sample T-test. In our patients the agreement between RV stroke 
volume as determined with tomographic cine MRI and as determined with 
velocity encoded MRI was evaluated using intra-class correlation coeffi  cients 
(ICC). Analysis was performed using the SPSS-PC statistical soft ware package 
version 11.5 (SPSS, Chicago, Illinois, USA). A p-value < 0.05 was considered 
to indicate statistical signifi cance. No adjustments were made regarding the 
multiple tests performed. 
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Results
Patient characteristics
Four patients with incomplete MRI data were excluded from the fi nal analysis 
(see below). Characteristics of the remaining 36 patients (26 (72%) males and 
10 (28%) females) and of the subgroups (Table 1) showed that patients did not 
take medication related to their cardiac condition. Insuffi  ciency of the tricuspid 
valve indexed for forward fl ow across the valve (median 4% (range 1 − 14%)) 
was found in 13(36%) patients: 8 in group I (4% (1 − 14%) and 5 in group II 
(3% (1 − 7%). Group I showed a tendency towards larger RV volumes (the 
respective p-values for RVEDV and RVESV were 0.07 and 0.09).
Magnetic Resonance Imaging
MRI data was incomplete due to bigeminy during stress in 1 patient and 
≥ 1 missing/failed fl ow-measurement in 3 patients. In our patients the mean 
diff erence of RVSV determined using velocity encoded MRI minus RVSV 
determined using tomographic cine MRI at rest was –1 ml, and the SD of 
the diff erence was 8. The resulting ICC was 0.98, demonstrating excellent 
agreement between both methods. Similarly, for RVSV measured with stress 
the mean diff erence was 4 ml with a SD of the diff erence of 12. The associated 
ICC was 0.96, again demonstrating excellent agreement between both methods. 
Right ventricular free wall mass (g/m²) in patients was larger compared with 
published control data (24 ± 6 versus 17 ± 2, p <  0.05). 
RV diastolic function 
Patients had a longer mean deceleration time and smaller FF compared with 
published control data (Table 2). This indicates impairment of RV relaxation. 
With stress (Table 3) increases of PaFR, AFF and deceleration time and decreases 
of tt PeFR, PeFR and PeFR/PaFR-ratio were seen. The change in fi lling-patt ern 
with stress is compatible with further impairment of RV relaxation.
Chapter 3
92
Table 2. Right ventricular indices of diastolic function at rest.
All patients:
(n = 36) 
Group I
(n = 24)
Group II
(n = 12)
Controls 
(n = 12)‡
RVSV (ml/m²) 66 ± 15* 69 ± 14* 60 ± 14 46 ± 6
HR (/min) 75.2 ± 12.4 71.7 ± 11.1 82.1 ± 12.4 74.6 ± 10.9
CO (l/min/m²) 4.9 ± 1.3* 4.9 ± 1.1* 5.0 ± 1.7* 3.4 ± 0.7
FF (%) 47.6 ± 11.4* 52.2 ± 10.6† 38.6 ± 6.5* 55.1 ± 15.7
AFF (%) 23.3 ± 12.0 17.7 ± 7.8† 34.5 ± 11.0* 19.2 ± 8.0 
PeFR/SV (/sec) 4.2 ± 0.8 4.2 ± 0.7 4.3 ± 1.1 4.5 ± 0.9
PaFR/SV (/sec) 2.4 ± 1.1 1.9 ± 0.7† 3.5 ± 1.1* 2.1 ± 1.1
Ratio PeFR/PaFR 2.1 ± 1.2 2.6 ± 1.2† 1.2 ± 0.3* 2.5 ± 1.3 
Dt/RR (10¯¹) 2.7 ± 0.9* 2.5 ± 0.7* 3.0 ± 1.2* 1.9 ± 0.5
TtPeFR/RR (10¯¹) 1.4 ± 0.4 1.3 ± 0.3 1.6 ± 0.4 1.4 ± 0.3
TtPaFR/RR (10¯¹) 4.3 ± 1.0* 4.7 ± 0.8† 3.5 ± 0.9* 5.2 ± 1.5
Data given are: mean ± SD, * Signifi cant diff erence compared to controls (p < 0.05) by 
analysis of covariance with correction for BSA and HR, † Signifi cant diff erence compared 
to group II patients (p < 0.05) by analysis of covariance with correction for BSA and HR. 
Analysis with age as an additional covariate did not appreciably change results. 
‡ Resting data on healthy controls from Helbing et al.6 
AFF = atrial fi lling fraction, CO = cardiac output, Dt = deceleration time, EDFF = end-
diastolic forward fl ow, FF = fi lling fraction, HR = heart rate, PaFR = peak atrial fi lling rate, 
PeFR = peak early FR, RR = duration RR-interval, SV = stroke volume, TtPa = time to PaFR, 
TtPe= time to PeFR.
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Table 3. Right ventricular indices of diastolic function during dobutamine stress.
All patients
(n = 36)
Group I
(n = 24)
Group II
(n = 12)
SV (ml/m²) 76 ± 23* 84 ± 18* 61 ± 26* 
HR (/min) 85.7 ± 15.3* 83.5 ± 13.9* 90.3 ± 17.7 
CO (l/min/m²) 6.6 ± 1.5* 6.9 ± 1.5* 5.9 ± 1.4* 
FF (%) 45.5 ± 9.8 47. 2± 10.0* 41.6 ± 9.2 
AFF (%) 27.7 ± 12.5* 25.0 ± 12.7*† 33.7 ± 9.2 
PeFR/SV 3.9 ± 0.8* 4.0 ± 0.8* 3.9 ± 0.9 
PaFR/SV 2.8 ± 1.1* 2.5 ± 0.9* 3.4 ± 1.2 
Ratio PeFR/PaFR 1.7 ± 1.0* 1.9 ± 1.1*† 1.3 ± 0.5 
Dt/RR (10¯¹) 3.3 ± 1.0* 3.4 ± 1.0* 3.1 ± 0.9
TtPeFR/RR (10¯¹) 1.2 ± 0.2* 1.2 ± 0.2 1.3 ± 0.2* 
TtPaFR/RR (10¯¹) 4.1 ± 0.9 3.9 ± 1.0* 4.2 ± 0.9
Data given are: mean ± SD, * Signifi cant change compared to rest (p< 0.05);  = increase,  
= decrease. † Signifi cant diff erence compared to group II patients (p< 0.05) during stress by 
analysis of covariance with correction for BSA and HR. Analysis with age as an additional 
covariate did not appreciably change results.
AFF = atrial fi lling fraction, CO = cardiac output, Dt = deceleration time, EDFF = end-
diastolic forward fl ow, FF = fi lling fraction, HR = heart rate, PaFR = peak atrial fi lling rate, 
PeF = peak early FR, RR = duration RR-interval, SV = stroke volume, TtPa = time to PaFR, 
TtPe = time to PeFR.
Patients with and without EDFF 
At rest 24(67%) patients showed EDFF (group I). In 20(83%) group I patients 
fl ow was measured in the inferior vena cava which showed retrograde fl ow 
coinciding with atrial contraction in 16(80%) subjects. Twelve (33%) patients 
did not have EDFF (group II). In 7(58%) of them inferior vena cava fl ow-
measurements were performed and retrograde fl ow was absent in all. Median 
contribution of EDFF to net forward fl ow in subgroup I was 6% (range 1 – 24%) 
and did not change signifi cantly during stress (median 4%, range 0 – 18%). In 
3 patients with EDFF present at rest, EDFF was absent during stress, while 3 
patients without EDFF at rest showed EDFF during stress. 
At rest, group II showed a larger mean AFF, smaller FF, smaller PeFR/PaFR-
ratio, higher PaFR and shorter tt PaFR compared to group I (Table 2). Compared 
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to published data on healthy controls group II patients had a larger mean AFF, 
higher PaFR, longer deceleration time, smaller FF, and smaller PeFR/PaFR-
ratio (Table 2). Group I only showed a longer deceleration time compared to 
published data on healthy controls.
With stress (Table 3) group I showed increases of AFF, PaFR, and deceleration 
time, while decreases were noted for FF, PeFR, PeFRc/PaFRc ratio, and tt PaFR. 
Group II had a shorter tt PeFR with stress without changes in any of the other 
RV diastolic parameters. 
Exercise capacity 
All patients successfully performed a maximal exercise test. Percentage of 
predicted workload for the total population was 92 ± 13%, which is signifi cantly 
(p < 0.01) smaller than the predicted 100%. In group I this percentage was 
89 ± 11% (p < 0.001 compared to 100%) and in group II it was 97 ± 17% (p = 0.67). 
Percentage of predicted workload was not signifi cantly diff erent (p = 0.08) 
between both subgroups. Mean VO2max was 39 ± 9 ml/kg/min in group I and 
45 ± 8 in group II (p = 0.09). 
Discussion
Our study demonstrates that RV diastolic fi lling abnormalities are present in 
TOF at mid- to long-term follow-up, even in patients operated according to 
currently widely accepted surgical strategies. Diastolic fi lling results from (in 
part) active relaxation in early diastole, and passive fi lling in the later parts of 
diastole. Compared with published control data, RV diastolic fi lling at rest in 
our total population demonstrated signs of impaired relaxation (prolonged 
deceleration time, smaller early fi lling fraction). EDFF, a generally recognized 
marker of restriction to RV fi lling,5,7,12 was found in ⅔ of our patients (group 
I). Compared to group II (no EDFF), group I showed signs of restriction to RV 
fi lling, had more severe PR and tended to have a more dilated RV. Furthermore 
patients with EDFF had the poorest exercise performance compared to a 
reference population, which was not explained by a diff erence in global systolic 
RV function. Moreover, in direct comparison with published control data 
RV diastolic fi lling at rest was most abnormal in group II. Somewhat to our 
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surprise, considering the abnormal fi nding of EDFF, RV fi lling in group I was 
fairly normal compared with published control data. However dobutamine 
stress imaging revealed important RV diastolic fi lling abnormalities in this 
subgroup, which fi t an increase in relaxation related abnormalities. In the group 
without EDFF, RV diastolic fi lling did not change, although EDFF occurred 
during stress in three patients without EDFF at rest. 
End-diastolic forward fl ow and outcome in repaired TOF
The presence of EDFF, a marker of restriction to RV fi lling, immediately aft er 
TOF repair has been associated with longer ICU and hospital stays.5 EDFF 
tends to disappear in the fi rst weeks following repair,5 but has been shown to 
predict presence of EDFF at midterm follow-up.13 Reports have been equivocal 
on how restriction to RV fi lling, as evidenced by EDFF, eff ects long-term clinical 
state in repaired TOF. Gatzoulis et al. found patients with EDFF had shorter PR 
duration, less cardiomegaly and bett er exercise capacity, suggesting a protective 
eff ect of restriction to RV fi lling.7 Other studies only partly confi rmed these 
results.8,13,14 At long-term follow-up our patients with EDFF had more severe 
PR compared to patients without EDFF, and had worse exercise capacity 
compared to a reference population. In a small and somewhat younger TOF 
population to ours, but using similar MRI techniques, exercise capacity was 
also found to be worse in patients with EDFF.6 This observation could not be 
explained by diff erences in severity of PR, RV dilation or RV global systolic 
function.6 In agreement with our study, and somewhat unexpected, RV diastolic 
fi lling abnormalities at rest were clearest in patient without EDFF. Considering 
the abnormal fi nding of EDFF we would expect most abnormal fi ndings in 
patients with EDFF. In our study the use of stress imaging “unmasked” highly 
abnormal RV fi lling in the EDFF positive patients, which may serve to explain 
the observed exercise limitation.
The diff erences in results between studies on RV diastolic fi lling in repaired 
TOF may be due to diff erences in studied populations (age at repair, surgical 
techniques used, duration of follow-up since repair) and diagnostic tools 
used. We measured EDFF during breath-holds at end-expiration, as EDFF 
at inspiration is also seen in healthy subjects. In 16 (80%) out of 20 patients 
with EDFF in whom IVC fl ow was assessed, EDFF coincided with reverse 
IVC fl ow, a combination previously associated with restriction to RV fi lling.5,7 
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Detection of EDFF by MRI velocity mapping and Doppler echocardiography 
has been shown to be in good agreement.6 In contrast to echocardiography 
fl ow-sensitized MRI off ers volumetric fl ow quantifi cation, which enables 
the inclusion of both tricuspid and pulmonary fl ow into the analysis of RV 
fi lling. Furthermore our study selectively studied patients operated according 
to current surgical strategies. Therefore ventricular dysfunction cannot 
be ascribed to myocardial damage aft er extensive ventriculotomies, or to 
longstanding pre-repair hypoxemia, or high RV pressures. Our results apply to 
TOF patients with residual PR and mild to moderate pulmonary stenosis only. 
We thus avoid diffi  culties in interpretation of results due to mixed pressure 
and volume overload eff ects.
Mechanisms of RV diastolic dysfunction
The substrate of restriction to RV fi lling in Fallot patients remains unknown. 
Potential relationships have been reported with age at repair, staging and 
timing of repair, degree of preoperative pulmonary stenosis and amount of 
post-operative PR.5,8,13,14 In our study severity of PR was the only signifi cantly 
diff erent factor between patients with and without EDFF. Mechanisms 
underlying abnormalities of diastolic fi lling are complex. Combined hypoxemia 
and pressure overload, as present preoperatively in TOF, result in increased 
fi brosis of the RV.15 However, it is unknown how these pre-operative factors 
contribute to postoperative diastolic abnormalities. Data on the eff ects of 
chronic volume overload on RV diastolic function are limited. Experimentally 
induced sub-acute PR resulted in increased RV myocardial compliance,16 while 
RV diastolic function was well preserved aft er three months of RV volume 
overload in growing swine.17 Chronic LV volume overload in rats resulted in 
diastolic fi lling abnormalities, with dynamic shift ing of infl ow patt erns.18 These 
models however only partly mimic the chronic and progressive RV volume-
overload seen in TOF patients. For the LV hypertrophy is a common cause of 
diastolic fi lling abnormalities and heart failure.19 The RV hypertrophy present 
in our TOF patients could not be associated to a particular type of diastolic 
fi lling abnormalities.
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Changes in diastolic function with stress and aging
Changes observed with dobutamine stress in our patients are compatible with 
impaired relaxation. This is a highly abnormal fi nding since dobutamine is 
considered to improve diastolic relaxation.20,21 In response to dobutamine 
stress healthy subjects show an increase of PeFR and/or PaFR, while the PeFR/
PaFR-ratio remains unchanged or increased.21,22
In adults relaxation related impairment is observed with aging.23 In children 
changes in diastolic function mainly appear during the fi rst 3 years of life.24,25 
Therefore age is not a likely explanation for the diff erences found in diastolic 
fi lling between our subgroups.
Study limitations
The evaluation of diastolic function should include indices of isovolumic 
relaxation. However in the absence of normal pulmonary valve closure, as 
is the case in most operated TOF patients, isovolumic relaxation cannot be 
assessed. 
Physical stress in the MR environment has been reported feasible.26 We used 
pharmacological stress because of the limited bore diameter of the available 
MR-scanner. Ethical limitations of administrating dobutamine to healthy 
children prevented their inclusion. Therefore we compared our patient data at 
rest with published control data from a previous study performed in another 
center on another type of MRI-system but using similar techniques.6
A limitation of all non-invasive studies is the lack of pressure measurements. 
Increased RV fi lling pressures augments the eff ect of restriction to fi lling 
and may mask signs of impaired RV relaxation. However RV end-diastolic 
pressure usually is normal in post-operative TOF, as is the pulmonary vascular 
resistance in the absence of pulmonary valve stenosis. 
To quantify blood fl ow we used phase velocity encoded (VEC) MRI which 
is regarded a valuable tool in congenital heart disease.27,28 VEC MRI has many 
possible sources of errors including; technical issues (mismatched encoded 
velocity, inadequate temporal resolution, inadequate spatial resolution, phase 
off set errors, low signal-to-noise ratio), local fl ow/anatomy related issues 
(accelerated fl ow, vessel motion) and issues of proper imaging plane delineation 
(valve motion, deviation of the imaging plane).27,29,30 Proper sequence set up 
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combined with careful planning can keep the overall error in the great vessels 
below 10%.27,30 We have shown our RVSV results determined with VEC MRI 
are in excellent agreement with those determined using the current reference 
standard, multi-slice tomographic cine MRI.
Conclusion
In Fallot patients corrected according to currently widely accepted surgical 
strategies, EDFF in the pulmonary artery relates to worse clinical state at mid 
to long-term follow-up, as indicted by worse exercise capacity and more severe 
PR. Dobutamine stress imaging may “unmask” abnormalities in RV diastolic 
fi lling not appreciated by rest imaging alone.
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Abstract 
Aims: To assess a.) neurohormonal activation, b.) biventricular contractile 
reserve (CR) and c.) exercise performance, in relation to PR-percentage and 
right ventricular volume in patients with tetralogy of Fallot (TOF) aft er repair 
at young age.
Methods and Results: In 53 TOF patients (maximal age at repair 2.0 years, 
interval since repair 15 (5) years) without residual lesions except PR, MR-
imaging at rest and during dobutamine stress was performed. Ventricular 
CR,maximal workload, peak oxygen uptake and circulating levels of natriuretic 
peptides, catecholamines and infl ammatory markers were assessed.
Median PR-percentage was 37% (range 0 − 57%). Levels of neurohormonal 
and infl ammatory markers were normal in most patients, and did not correlate 
with PR-percentage or right ventricular size. High-risk levels of NT-proBNP 
indicated a smaller RV-CR and a smaller decrease of biventricular ESV. 
Biventricular systolic stress response was normal: mean (SD) ESV decreased 
(ΔRVESV –17 (8) ml/m², ΔLVESV –11 (5)), SV increased (ΔRVSV +12 (9) ml/m², 
ΔLVSV +9 (6)), CR was positive in all (RVCR +11 (5) %, LVCR +13 (6) %). Mean 
(SEM) VO2max was 96 (3) %, mean workloadmax 89 (2) % of predicted. 
Conclusion: In TOF repaired at young age overall neurohormonal markers 
are normal and cardiac functional reserve and exercise tolerance are well 
preserved, irrespective of PR-percentage and RV volume. 
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Introduction
Chronic pulmonary regurgitation (PR) in tetralogy of Fallot (TOF) has been 
associated with deleterious changes in right, and also left , ventricular size 
and function.1 In LV disease states, it is commonly accepted that a chronic 
insult to the myocardium will result in changes in geometry and structure 
of the ventricle that is accompanied by neurohormonal activation.2 The 
neurohormonal concept has guided treatment guidelines for heart failure.3,4 
This concept has also been applied to the RV in congenital heart disease.5 The 
level of neurohormonal activation has prognostic value in acquired and adult 
congenital heart disease, and has been suggested an early sign of impending 
heart failure.5,6 Currently, pulmonary valve replacement is the only accepted 
treatment for chronic PR in TOF patients. Clinical indications for pulmonary 
valve replacement included clinical signs and symptoms, exercise performance, 
tricuspid regurgitation and biventricular function.1,7 Surprisingly, few data 
is available on the relation between RV remodelling as a result of chronic 
PR and the level of neurohormonal activation and functional ventricular 
impairment. It is unclear whether the amount of PR and /or biventricular size 
in patients operated for TOF relate to neurohormonal activation and functional 
decline. Considering treatment guidelines in other cardiac disease states, this 
information is required.3,4
We hypothesize that increases of PR-percentage and/or RV volume result in 
increased neurohormonal levels and decreased functional reserve, as assessed 
by exercise testing and cardiac stress imaging. Aim of the study was to assess 
the level of a) neurohormonal activation, b) biventricular contractile reserve 
and c) exercise performance, in relation PR-percentage and RV volume in 
patients with TOF aft er repair at young age.
Methods
Patients
In a cohort study of patients aft er surgical correction of TOF, patients were 
invited to undergo CMR, maximal exercise testing and assessment of circulating 
neurohormonal levels. Inclusion criteria used were: 1) complete repair of TOF 
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without associated cardiac lesions, including double outlet right ventricle, 2) 
total surgical correction ≤ 2 years, 3) transatrial-transpulmonary approach to 
repair, and 4) post-operative time interval ≥ 5 years. Patients with one or more 
of the following criteria were excluded: 1) residual VSD, 2) residual pulmonary 
stenosis (echo Doppler mean gradient > 30 mm Hg), 3) repair with a homograft , 
4) mental retardation, and 5) known extra-cardiac pathology. The local medical 
ethics committ ee approved our study protocol. Patients were included between 
September 2002 and November 2004 aft er writt en informed consent.
Exercise test 
A Jaëger Oxycom Champion System (Viasys Healthcare, Hoechberg, 
Germany), allowing breath-by-breath-ergometry, was used for maximal 
exercise testing. Workload was increased stepwise with 10 − 20 watt s/minute. 
Patients performed until exhaustion, as assessed using a cut-off  ≥ 1.05 for the 
respiratory quotient (RQ) at peak exercise. Exercise capacity was compared 
to results from normal individuals.8 Peak workload (Watt s) and peak oxygen 
consumption (ml/kg/min) were obtained and expressed as percentages of 
predicted values, respectively referred to as Workloadmax and VO2max. A 12-
lead ECG was continuously monitored and QRS-duration was measured at 
rest.
Cardiac Magnetic Resonance Imaging 
A 1.5-Tesla Signa CVi scanner was used, with soft ware releases V8.4 and V9.1 
(General Electric Medical Systems, Milwaukee, WI, USA) and a 4-channel 
phased array cardiac coil. Standardized localizer imaging planes were acquired 
to plan pulmonary and tricuspid valve fl ow-measurements, and a volumetric 
ventricular data set in short axis direction. Data was gathered during breath-
holds at end-expiration.
Multi-phase, multi-slice volumetric data was acquired using a fast 2D cine 
scan employing steady-state free precession (SSFP). Imaging parameters: fl ip 
angle = 45°, TE set at min full, TR = 3.4 – 3.6 ms, 8 − 9 mm slice thickness, 0 − 1 
mm inter-slice gap, 12 views/segment, readout bandwidth = 111Khz, square 
FOV (30 − 34 cm), scanning matrix of 160 * 128. Twenty-four phases per cardiac 
cycle were reconstructed retrospectively. 
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Flow measurements were performed perpendicular to fl ow using a 
standard 2D fl ow-sensitized scan. Scans were retrospectively gated starting 
the acquisitions on the R-wave. Temporal resolution was approximately 40 ms 
per cardiac phase and 30 phases were reconstructed retrospectively. Imaging 
parameters were: 2D FSPGR, TR = 6 − 7 ms, TE = 3 ms, fl ip angle = 20o, readout 
bandwidth = 90 Khz, 6 mm slice thickness, 6 views/segment, rectangular FOV 
(75% in phase encoding direction), scanning matrix of 256 *128.
All scans were performed at rest and repeated during dobutamine stress 
(maximal dose 7.5 µg/kg/min. Dobutamine infusion was decreased when heart 
rate increased > 50%, when systolic and/or diastolic blood pressure increased 
> 50% or decreased > 20%, when serious rhythm disturbances were seen, or 
with complaints of the patient.
CMR data-analysis
CMR studies were analyzed on a commercially available workstation 
(Advanced Windows, General Electric Medical Systems, Milwaukee, WI, USA). 
Flow images were quantitatively analyzed using the Flow analysis soft ware 
package V2.0 (Medis Medical Imaging Systems, Leiden, The Netherlands). 
The amount of pulmonary regurgitation was normalized for forward systolic 
stroke volume in the main pulmonary artery (= PR-percentage). The amount 
of tricuspid regurgitation was normalized for the amount of forward fl ow 
over the tricuspid valve (= TR-percentage). The ventricular volumetric data 
set was quantitatively analyzed using the Mass analysis soft ware package 
V3.1 (Medis Medical Imaging Systems, Leiden, the Netherlands).9 Volumetric 
data was indexed for body surface area (m²) unless stated otherwise. Changes 
in CMR parameters were calculated: Parameter Change (Δ) = Parameterstress 
– Parameterrest, Contractile Reserve (CR) = EFstress – EFrest. As in other studies 
CR was defi ned to be preserved with values > 0.10,11 Previously Therrien et 
al. described patients with a RVEDV > 170 ml/m² did not show recovery 
of RV volume to normal (RVEDV < 108 ml/m²) following pulmonary valve 
replacement for PR.12 Based on RVEDV patients were divided into 3 groups: 
RVEDV < 108 ml/m², RVEDV 108–170 ml/m2, and RVEDV > 170 ml/m2. 
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Neurohormonal markers
Blood samples were drawn from a peripheral vein aft er 30 minutes rest 
in supine position. Plasma or serum were separated immediately aft er 
sample collection and stored at −70°C. Determination of catecholamines 
((nor) epinephrine) was done by high-performance liquid chromatography 
(HPLC) with fl uorometric detection.13 Renin was determined by measuring 
the Angiotensin I generated during incubation in the presence of excess 
substrate with an in-house radioimmunoassay as described previously.14 
Natriuretic peptides (N-ANP and NT-proBNP), TNF-alpha, endothelin 
and high sensitive CRP (hsCRP) were measured using the following 
commercially available kits: Endothelin: quantiGlo immunoassay kit (R&D 
Systems, Abingdon, UK), BNP and ANP, immunoradiometric methods 
(Shionoria, Osaka, Japan), N-ANP, radioimmunoassay kit (Biotop, Oulu, 
Finland), NT-proBNP, electrochemiluminescence immunoessay (Elecsys, 
Roch Diagnostics, Mannheim, Germany), hsCRP, immunophelometric essay 
(Elecsys, Roch Diagnostics, Mannheim, Germany), TNF-alpha, immunometric 
essays (Immulite Diagnostic Products Corporation, Los Angeles, CA, USA), 
Aldosterone, radioimmunoassay kit (Diagnostic Products Corporation, Los 
Angeles, CA, USA). 
Statistical analysis
When appropriate, data was log10-transformed to obtain approximately normal 
distribution. Results are expressed as mean (SD) for normally distributed data, 
otherwise the median (range) is shown. Paired data analysis was performed 
using the paired T-test. Comparisons between 2 groups were performed 
using the student T-test. Analysis of covariance was used for multiple group 
comparisons corrected for multiple testing by Bonferroni’s method. Correlation 
coeffi  cients were calculated using Spearman’s method (rs). Multiple linear 
regression analysis was used to study the association of neurohormonal and 
infl ammatory makers with CMR measures and exercise capacity. Analysis 
was performed using the SPSS-PC statistical soft ware package version 11.5 
(SPSS, Chicago, Il, USA). A p-value < 0.05 was considered to indicate statistical 
signifi cance.
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Results
Fift y-three patients surgically repaired between 1980 and 1997 were included 
(median age at repair 0.8 (0.2 − 2.0) years, follow-up since repair 15 (6 − 23) 
years). No serious adverse eff ects to dobutamine were encountered. Two 
patients were excluded because of insuffi  cient CMR stress data quality. Results 
relate to the remaining 51 patients. Patient characteristics are shown in Table 
1.
None of our patients used cardiac medication. All were in sinus rhythm. 
Median QRS-duration was 111 ms (range 87 − 161 ms). One patient declined 
to perform a maximal exercise test. Exercise data from a second patient with 
severe obstructive abnormalities was excluded from analysis. Exercise results 
in Table 1 relate to the remaining 49(96%) patients. 
Table 1. Patient characteristics
General parameters N = 51 
Gender (M/F) 37 / 14
Age at repair (years) 0.8 (0.2 – 2.0)
Age at study (years) 15 (7 – 26)
Interval since repair (years) 15 (7 – 23)
Body Surface Area (m²) 1.6 (0.4)
Transannular patch repair 36 
Blalock-Taussing shunt 2 
Exercise Test N = 49 
Respiratory quotient at peak exercise 1.2 (0.1)
Peak oxygen consumption (ml/kg/min) 40 (8)
VO2max (%) 96 (18)
Workloadmax (%) 89 (13)
Data given are: number of patients (%), median (range) or mean (SD)
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CMR results
Biventricular CMR results are shown in Table 2. With dobutamine-stress mean 
heart rate increased from 76 (13) to 88 (17) beats/min (p < 0.001). Both ventricles 
responded to stress with a signifi cant increase in global systolic performance. 
Biventricular CR was preserved (positive) in all patients (Figure 1A and 1B). 
We established 3 subgroups based on RVEDV: group I (n = 10) with RVEDV 
< 108 ml/m², group II (n = 29) with RVEDV 108 − 170 ml/m², and group III 
(n = 12) with RVEDV > 170 ml/m². CMR measurements for these subgroups are 
shown in Table 2. CMR parameter changes with stress were not signifi cantly 
diff erent between subgroups, nor were VO2max and Workloadmax.
PR-percentage was also used to categorize patients. Three subgroups were 
established; mild PR (< 20%, n = 13), moderate PR (20 – 40%, n = 20) and severe 
PR (> 40%, n = 18). CMR parameter changes with stress were not signifi cantly 
diff erent between subgroups, nor were VO2max and Workloadmax (Data not 
shown). 
Patients with a transannular patch (n = 36) showed more severe PR than 
those without (n = 15) a patch (median PR-percentage 41% (range 11 − 57) 
versus 16% (0 − 40), p < 0.05), had a larger RV (RVEDV 154 (34) ml/m² versus 
105 (19), p < 0.05) and poorer RVEF (47 (6)% versus 53 (6), p < 0.05). CR of both 
ventricles was not diff erent between patients with and without a transannular 
patch. 
Twenty (39%) patients showed tricuspid regurgitation with a median TR-
percentage of 3.6%. Patients TR showed comparable PR compared to those 
without TR (median PR-percentage 39% (range 1 − 57) versus 34% (0 − 54), 
p = 0.21), had a larger RV (RVEDV 155 (42) ml/m² versus 130 (33), p < 0.05) 
and tended to have poorer RVEF (47 (5)% versus 50 (7), p = 0.06). CR of both 
ventricles was not diff erent between patients with and without TR. 
Neurohormonal markers
Blood sample collection failed in two subjects. Measurements are shown in 
Table 3 with the large majority of values within normal limits. TNF-alpha 
signifi cantly decreased with age (rs= −.57, p < 0.001), hsCRP signifi cantly 
increased with age (rs= 0.41, p < 0.05) and log10NT-proBNP showed a signifi cant 
non-linear relation with age (age²-factor required during analysis). No further 
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relations were found with age. Mean log10NT-proBNP level was signifi cantly 
higher in females (mean (±SE) diff erence log10NT-proBNP (pmol/L) 0.34 
(±0.08), p < 0.001). Mean log10 renine level was signifi cantly lower in women 
(mean (±SE) diff erence –0.23 (±0.08), p < 0.01). No further gender determined 
diff erences were found.
No diff erences were found for any of the neurohormonal markers between 
subgroups based on RVEDV (Table 3) or subgroups based on PR-percentage 
(Data not shown). Neurohormonal marker levels were not diff erent between 
patients with or without a transannular patch, or patients with or without 
tricuspid regurgitation.
In adulthood an NT-proBNP > 18 pmol/L in females and > 12 pmol/L in 
males indicate an increased risk for cardiac events such as heart failure.15 Eight 
(62%) females and 14 (28%) males showed high-risk levels respectively. These 
22 patients showed smaller RV-CR (9 (5) versus 12 (5) %, p < 0.05), smaller 
ΔRVESV (−14 (8) versus −19 (8) ml/m², p < 0.05) and smaller ΔLVESV (−9 (4) 
versus −13 (6) ml/m², p < 0.05) compared to patients without high-risk NT-
proBNP levels.
The median hsCRP level was 0.7 mg/L (range 0.2 − 17.5). Mean interval 
since repair was longer in patients with levels > 0.7 mg/L compared to patients 
with hsCRP levels ≤ 0.7 mg/L (16 (5) versus 13 (5) years, p < 0.05). Patient with 
higher hsCRP levels tended to have worse VO2max (92 (17)% versus 86 (13)%, p 
= 0.05) and workload max (86 (13)% versus 92 (12)%, p = 0.09). No diff erence in 
any of the CMR parameters was found between both groups.
CMR stress response: relation to function and follow-up time
Relation to interval since repair: Biventricular CR did not correlate with 
interval since repair. Larger ΔESV and ΔCI correlated with a longer interval 
since repair (ΔRVESV: rs = 0.39, p < 0.01, ΔRVCI: rs = 0.35, p < 0.05, ΔLVESV: 
rs = 0.30, p < 0.05, ΔLVCI: rs = 0.32, p < 0.05). 
Relation to exercise capacity: Larger ΔRVESV correlated with worse VO2max 
(rs = −0.29, p < 0.05) and Workloadmax (rs = −0.35, p < 0.05). RV-CR did not correlate 
with VO2max or Workloadmax. Larger ΔLVSV correlated with worse VO2max 
(rs = −0.34, p < 0.05). Larger ΔLVESV correlated with worse Workloadmax (rs= 
−0.34, p < 0.05). Larger LV-CR correlated with worse VO2max (rs= −0.34, p < 0.05) 
and Workloadmax (rs = −0.40, p < 0.05). 
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Relation to RVEF and LVEF at rest: Larger ΔRVESV (rs= −0.45, p < 0.001) and 
larger ΔRVSV (rs = −0.35, p < 0.05) correlated with worse RVEF. Worse LVEF 
correlated with larger ΔRVESV (rs= −0.38, p< 0.01), ΔRVSV (rs=−-0.41, p < 0.01), 
ΔLVESV (rs = −0.36, p < 0.01), Δ LVSV (rs = −0.49, p < 0.001) and LV-CR (rs = −0.38, 
p < 0.01).
Discussion
At mid-term follow-up since surgical correction this study assessed levels of 
neurohormonal markers, biventricular systolic stress response and exercise 
performance in a relatively large population of TOF patients and related results 
to RV size and PR-percentage. This population generally is considered to 
have an increased risk for heart failure development.1,7,12,16 Despite important 
dilatation of the RV in these patients with a median PR-percentage of 37%, 
the neurohormonal levels and biventricular CR were remarkably normal. 
Neurohormonal levels, biventricular CR and VO2max did not directly relate 
to amount of PR, RV size or longer duration of follow-up. The magnitude 
of the RV response was not diff erent between patients with and without a 
transannular patch.
Neurohormonal markers and cardiac function
Increased levels of neurohumoral markers have been recognized as (early) signs 
of heart failure in acquired cardiac disease.17-21 Elevated levels of these markers 
have prognostic value for decreased ventricular performance, functional class 
and survival.2,17-21
Adults with congenital heart disease, even when asymptomatic, were 
shown to have elevated levels of neurohormones, which related to decreases in 
NYHA class, systemic ventricular function and exercise capacity.5 In children 
with various types of heart disease BNP levels correlated with clinical signs of 
heart failure and with systemic ventricular function.22 In (asymptomatic) adults 
with isolated RV pressure (or volume) overload levels of natriuretic peptides 
inversely related to RVEF.6 The large majority of our patients had normal 
levels of neurohormones. None of the markers showed signifi cant relations 
to the degree of RV dilation, to biventricular systolic function (EF), or to the 
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magnitude of biventricular CR. A weak, but statistically signifi cant positive 
association was established between NT-proBNP levels and the amount of PR 
measured, confi rming stronger relationships assessed in adults.6 Risk levels of 
NT-proBNP were found in 22(44%) patients.15 These patients showed smaller 
biventricular ΔESV with stress and smaller RV-CR compared to other patients. 
Patients with hsCRP levels above the median tended to have worse exercise 
capacity compared to the others. Despite the overall normal CR, exercise 
performance and levels of neurohormones, the (limited) changes in biomarker 
levels found related to relevant RV loading condition abnormalities, decreased 
ventricular stress reserve and worse functional capacity. This can be interpreted 
as confi rmation of the diagnostic potential of cardiac biomarkers, especially 
hsCRP and NT-proBNP, as early signs of activated compensatory mechanisms 
in abnormal ventricular loading conditions.17,19 However, correlations were 
poor and these markers did not correlate with resting ventricular size and EF.
Ventricular stress response
Previous studies have documented an impaired RV systolic stress response 
in TOF patients.23,24 In our study the changes of end-systolic volume, stroke 
volume and EF with stress were comparable to those commonly found in 
healthy young subjects.23,24 The diff erent results most likely refl ect diff erences 
in populations studied. While most studies commonly include patients 
operated at various ages and with a variety of residual lesions, we selected 
patients treated according to recent surgical strategies, operated below the age 
of 2 years, and with few residual lesions. 
The left  ventricular analogue of PR is chronic aortic regurgitation. In 
asymptomatic patients with aortic regurgitation impaired LV stress reserve 
predicted LV dysfunction, development of symptoms and cardiac death.11,25 
Importantly, positive LV stress reserve before aortic valve replacement, 
predicted favourable post-operative LV function.11 Data on RV stress reserve 
is limited. In patients with congenital heart disease and a negative CR, a 
higher CR (closer to zero) was associated with a higher VO2max, while as in 
our patients there was no correlation between positive values of RV-CR and 
VO2max.10 Blunted response to beta-adrenergic stimulation in heart failure is 
considered an early sign of ventricular dysfunction.11,25,26 Despite considerable 
RV dilatation our patients showed well preserved ventricular functional 
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reserve. Larger CMR parameter changes occurred in patients with a longer 
interval since repair, with worse VO2max and with poorer biventricular EF. It 
could be speculated this indicates up-regulation of pathways that promote 
ventricular contractility, such as the beta-adrenergic receptor pathway. This 
hypothesis is supported by recent fi ndings in rats that showed up-regulation 
of the β-adrenergic receptor signal transduction pathway in failing hearts and 
an augmented inotropic response to isoproterenol.27 Results on this subject 
however are equivocal, which calls for future studies on adaptations in the 
beta-adrenergic signalling pathway with progression of heart failure in TOF. 
Our data certainly do not support a PR or RV ventricular volume related 
blunting of stress response. Of note, Geva and co-workers in one of the largest 
studies in TOF so far, could not establish a relationship between PR fraction 
and RV dimensions with impaired clinical status.28 
Limitations
We used pharmacological stress rather than physical stress because of the 
limited bore diameter of our MRI-scanner, preventing adequate physical 
stress. The ventricular response to physical exercise and to dobutamine stress 
corresponds well in healthy controls.23,24 Ethical limitations prevented the 
inclusion of healthy children.
Compared to ischemic heart disease testing we used low dobutamine 
doses. In paediatric practice, doses above 10 microgram/kg/min are poorly 
tolerated.29 For assessment of abnormal stress reserve, low dose dobutamine 
is suffi  cient.29
The cross-sectional study design prevented assessment of possible relations 
between our results and important outcome measures such as mortality, 
ventricular arrhythmia’s or re-operation, including pulmonary valve 
replacement. In contrast to most studies in the fi eld this study prospectively 
included a homogeneous patient population. Results therefore apply to a large 
set of the current population of Fallot patients, not confounded by a mix of 
diff erent operative strategies and various types of residual lesions. 
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Clinical implications
Most studies on pulmonary valve replacement in TOF emphasize the 
importance of RV size as criterion for replacement and have used a mixture 
of additional criteria, acknowledging the limited value of clinical signs and 
symptoms in congenital heart disease.7,12,16,30 Our study demonstrates that 
resting RV size and PR fraction do, at best, have poor correlation with impaired 
exercise capacity, biventricular stress response or neurohormonal activation, in 
a population operated according to current surgical strategies. In our opinion, 
this implies that patients should not undergo pulmonary valve replacement 
based on RV volume or PR fraction criteria.16 Clear signs for structural heart 
disease resulting in neurohormonal activation and blunted stress response 
should be looked for.3,4 Prospective longitudinal studies based on this concept, 
benefi cially applied in LV disease states, should provide improved criteria 
for treatment strategies in the growing population of patients operated for 
tetralogy of Fallot.
Conclusions
In TOF repaired at young age overall neurohormonal markers are normal 
and cardiac functional reserve and exercise tolerance are well preserved, 
irrespective of PR-percentage and RV volume. This questions the validity of 
PR or RV volume criteria for pulmonary valve replacement in this age group. 
Low-dose dobutamine stress testing is well tolerated and may be a useful 
additional tool for clinical decision making. 
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Abstract
Purpose: Our study aimed to assess pro-arrhythmogenic electrocardiographic 
changes during maximal physical exercise in patients operated for Tetralogy 
of Fallot (TOF).
Methods: TOF patients prospectively underwent: 1) bicycle ergometry, 2) 
cardiac MRI, and 3) 24-hours Holter. ECG data was analyzed at rest, at 60% of 
peak exercise and at peak exercise. R-R duration, QRS-, QT- and JT-duration and 
dispersions were assessed. Changes of ECG parameters during exercise were 
calculated and correlated to RV volume, RVEF, RV wall-mass, PR-percentage 
and VO2max. Exercise ECG data from healthy controls were used as reference.
Results: Thirty-one patients (mean age at repair (SD) 0.8 (0.5) years, age at 
study 16 (5) years) and 25 controls (age 12 (2) years) were included. With 
exercise mean QTc and JTc dispersions increased in patients (p < 0.001), but 
not in controls. At peak exercise JTc dispersion was larger in patients (p < 
0.01). QTc did not change with exercise in patients (p = 0.14) and decreased in 
controls (p < 0.05). At all levels of exercise mean QTc, QRS and QRS dispersion 
were larger in patients (all p < 0.001). Signifi cant associations were found for; 
1) A larger increase of JTc dispersion with a higher PR-percentage, a larger 
RV volume, a larger RV wall-mass, 2) A larger QTc increase with a larger RV 
volume and worse RVEF.
Conclusion: During physical exercise inhomogeneity of repolarisation, known 
to predispose for re-entry ventricular arrhythmia, increases in repaired TOF. 
Larger inhomogeneity is found with more severe PR.
ECG changes during exercise in repaired Tetralogy of Fallot
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Introduction
Long-term survival aft er repair of tetralogy of Fallot (TOF) is good but below 
life expectancy in the general population.1,2 Sudden cardiac death (SCD), a 
major cause of late mortality in repaired TOF,1,2 oft en is att ributed to ventricular 
arrhythmia.3 Several factors have been associated with ventricular arrhythmia 
including elevated RV pressures, RV scarring, RV outfl ow tract patches, older 
age at repair, residual pulmonary regurgitation (PR), ventricular dilation and 
dysfunction.3-6 Risk stratifi cation for SCD in repaired TOF successfully focused 
on indicators of electrical inhomogeneity in the surface electrocardiogram 
(ECG) to predict ventricular arrhythmia.3,5,7 QRS prolongation is considered the 
main marker associated with an increased risk of ventricular arrhythmia,3,5,7-9 
but other markers, such as prolonged QT-duration and increased dispersions 
of QT, JT and QRS have also been reported.5,7,9 Residual PR appears the most 
important hemodynamic lesion associated with ventricular tachycardia (VT) 
and SCD in repaired TOF.3 The contribution of PR to electrical inhomogeneity 
is refl ected by prolonged QRS duration and increased QRS dispersion 
associated with RV dilation.5,6,10,11 Exercise is considered a predisposing factor 
for ventricular arrhythmia in congenital heart disease.12,13 
However, ECG markers for arrhythmia risk in TOF have all been established 
at rest in patients aft er (staged) transventricular repair performed at a relatively 
old age. Almost no data is available on electrocardiographic changes during 
physical exercise. One recent study showed that QRS shortening during 
exercise related to bett er exercise capacity.14 Our study aimed to assess pro-
arrhythmogenic electrocardiographic changes during maximal physical 
exercise in TOF repaired according to contemporary surgical techniques.
Methods
Patients
Between September 2002 and November 2004 a cross-sectional study was 
performed at our institution among 59 Fallot patients (41 males, 18 females; 
median age 15 years (range 6 − 23 years); median interval since repair 14 years 
(range 6 − 23 years). Patients prospectively underwent 1) bicycle ergometry, 2) 
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cardiac magnetic resonance imaging (CMR), and 3) 24-hours Holter monitoring. 
Patients were selected using the following criteria: 1) total surgical correction 
before the age of 2 years, 2) surgical correction by a transatrial-transpulmonary 
approach, 3) absence of residual intra-cardiac shunts, 4) a residual RV outfl ow 
tract Doppler gradient < 30 mmHg, 5) no associated cardiac anomalies. To 
be included in the present study a complete set of exercise ECG data, as 
defi ned in the ‘ECG data analysis’ section, was required. The local medical 
ethics committ ee approved the study protocol. Writt en informed consent was 
obtained from patients and/or parents (if patients were not the legal age to 
provide consent). Complete ECG data from 24 healthy controls that performed 
a maximal bicycle exercise test were retrospectively analysed for the present 
study.
Exercise testing
Patients performed a maximal bicycle exercise test on a Jaëger Oxycom 
Champion System (Viasys Healthcare, Hoechberg, Germany) allowing breath-
by-breath monitoring. Workload was increased with 10 − 20 Watt s/minute. 
Blood pressure, heart rate, oxygen saturation and a standardised 12-lead ECG 
(25 mm/s) were continuously monitored. Oxygen consumption (VO2/kg) and 
carbondioxide excretion (VCO2/kg) were measured. The respiratory exchange 
ratio (RER) was calculated (VO2/VCO2 = RER) to verify true maximal 
performance. The lower limit for RER was set at 1.0 in children and 1.1 in 
adults. Peak workload (Watt s) and peak oxygen consumption (ml/kg) were 
compared to reference values, expressed as percentages of predicted, and are 
respectively referred to as Wmax and VO2max.15
ECG data analysis
ECG data were analysed by one observer at 3 predefi ned points of exercise: 
1) at rest, 2) at the retrospectively determined 60% point of peak exercise, and 
3) at peak exercise. ECG exercise data was defi ned complete when ≥ 10 out of 
12 leads could be analysed at all predefi ned points. In every lead RR-interval, 
QRS-, QT- and JT-duration were manually measured. QT and JT duration 
were corrected for heart rate using Bazett ’s formula: QTc = QT/ √(RR-interval) 
and JTc = JT / √(RR-interval). Interlead dispersions of QRS, QTc, and JTc were 
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defi ned as the maximal minus the minimal interval. End of the T-wave was 
defi ned as the point where it crossed the iso-electric baseline, or where the 
tangent of it’s downward slope crossed the iso-electric baseline. When the end 
of the T-wave was unclear QTc and JTc intervals were excluded from analysis 
for this lead. ECG parameter changes were calculated by subtraction of rest 
values from values at peak exercise.
Holter 
A 24-hours Holter monitoring was performed. Patients were encouraged to 
participate normally in daily activities during the test. 
Magnetic resonance imaging
Imaging was performed on a 1.5-Tesla Signa CV/i scanner using soft ware 
releases V8.4 and V9.1 (GE Healthcare, Milwaukee, Wisconson, USA). 
Standardized localizer imaging planes were acquired for a fl ow-measurement 
of the pulmonary valve and a volumetric ventricular data set in short axis 
direction. Data was acquired during breath-holds at end-expiration. The 
volumetric data set was acquired using a 2D fast imaging employing steady-
state free precession acquisition sequence (SSFP). Imaging parameters were: 
fl ip angle = 45º, TE set at min full, TR = 3.4 − 3.6 ms, 8 − 9 mm slice thickness, 
0 − 1 mm inter-slice gap, 12 views/segment, readout bandwidth = 111Khz, a 
square FOV (30 − 34 cm), and a scanning matrix of 160 * 128. Twenty-four 
phases per cardiac cycle were reconstructed retrospectively.
Pulmonary valve fl ow measurements were performed perpendicular to fl ow 
using a standard 2D fl ow-sensitised retrospectively gated sequence starting 
the acquisitions on the R-wave. Flow sensitivity was set at 180 cm/sec and was 
increased if phase aliasing occurred. Thirty cardiac phases were reconstructed 
retrospectively. Imaging parameters were: 2D fast spoiled gradient echo, 
TR = 6 − 7 ms, TE = 3 ms, fl ip angle = 20o, readout bandwidth = 90 Khz, 6 mm 
slice thickness, 6 views/segment, a rectangular FOV and a scanning matrix of 
256 *128.
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CMR data analysis
CMR data analyses were performed by one observer on an Advanced Windows 
workstation (GE Healthcare, Milwaukee, Wisconson, USA). Flow images were 
quantitatively analysed using the Flow analysis soft ware package V2.0 (Medis 
Medical Imaging Systems, Leiden, The Netherlands). Flow velocity curves 
were calculated by multiplying the manually drawn vessel area on each time 
frame with the spatial average fl ow velocities. The pulmonary regurgitant 
volume was divided by the systolic stroke volume in the main pulmonary 
artery to calculate PR-percentage. Patients were divided according to severity 
of residual PR: group A with mild PR (PR-percentage < 20%), group B with 
moderate-severe PR (PR-percentage 20 − 40%) and group C with severe PR 
(PR-percentage > 40%).16
The volumetric data set was quantitatively analysed using the Mass 
analysis soft ware package V3.1 (Medis Medical Imaging Systems, Leiden, The 
Netherlands). End-diastolic and end-systolic time frames were used according 
to analysis techniques widely reported in literature to assess biventricular end-
diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV), ejection 
fraction (EF) and wall mass.17 Volumes were indexed for body surface area 
(BSA) unless stated otherwise. Patient data were compared to published CMR 
reference values from healthy controls of the same age range.18 Patient data 
outside the mean ± 2SD range found in controls were considered abnormal.
Statistical analysis
Results were expressed as mean (SD) unless stated otherwise. Electro-
cardiographic data was compared between patients and controls using analysis 
of covariance with adjustment for current age. Changes in ECG parameters 
with exercise in our population were found not to relate with age and therefore 
were compared using Student T-tests or Mann-Whitney U tests (in case of non-
normal distributed data). Paired data analyses were performed using paired 
T-tests or Wilcoxon Signed rank tests. Spearman’s correlation coeffi  cients (rs) 
were used to assess relations between two parameters. Subgroups based on 
PR-percentage were compared using analysis of variance with the Bonferroni 
method used to deal with multiple group comparisons.
ECG changes during exercise in repaired Tetralogy of Fallot
127
Analyses were performed using the SPSS-PC statistical soft ware package 
version 11.0 (SPSS, Chicago, Il, USA). A p-value < 0.05 was considered to indicate 
signifi cance for patients characteristics. In view of the multiple comparisons 
made for the ECG parameters (table 2), p < 0.01 (two-sided), was considered 
the limit of signifi cance.
Results
Patients
A complete ECG data set, as defi ned in the ECG data analysis paragraph of 
the methods section, was available in 31 (53%) out of the 59 Fallot patients. 
Results apply to patients with complete ECG data. Characteristics of patients 
and controls are shown in table 1. 
Exercise test 
Due to technical problems breath-by-breath measurements failed in one 
patient. This 10-year-old patient reached a peak heart rate of 194 beats/min 
and was considered to have performed maximally. Based on our RER criteria 
the remaining 30 patients and all controls performed a maximal exercise test. 
Patients reached a lower Wmax (p < 0.05) and VO2max (p = 0.07) compared to 
controls. No exercise induced ventricular arrhythmias were seen.
Holter
During 24-hours Holter monitoring 1 patient had 1 episode of VT (3 complexes 
at 174 beats/min) and 1 patient had 29 episodes of VT (all 3 complexes, maximal 
rate 166/min).
CMR examination
Due to claustrophobia CMR was terminated prematurely in 1 patient. A median 
PR-percentage of 33% was found (range 0 − 53%). Patients were grouped 
according to severity of residual PR. PR-percentage was mild in 8(27%) patients 
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(group A), moderate-severe in 14(47%) patients (group B) and severe in 8(27%) 
patients (group C). 
Mean RV end-diastolic volume was 139(± 41) ml/m². Twenty-fi ve (83%) 
patients had a dilated RV compared to published data on healthy controls 
(RV end-diastolic volume > 97 ml/m² or > mean +2SD).18 Mean RV end-systolic 
volume was 73(±27) ml/m². Mean RVEF was 49(±6) %. Sixteen (53%) patients 
had a decreased RVEF compared to published data on healthy controls (RVEF 
< 49% or < mean –2SD).18 RV free wall-mass was 24(±6) g/m².18
PR-percentage correlated positively with RVEDV (rs= 0.59, p < 0.01) and 
negatively with RVEF (rs= −0.48, p < 0.01).
Table 1. Patient characteristics 
Baseline Patients (N = 31) Controls (N = 24)
Male / Female 22 (71%) / 9 (29%) 15 (63%) / 10 (40%)
Age at study (years) 16 (5)* 12 (2)
BSA (m2) 1.6 (0.4) 1.5 (0.2)
Age at repair (years) 0.8 (0.5) -----------
Interval since repair (years) 15 (5) -----------
Staged repair† 2 (6%) -----------
Transatrial patch 20 (65%) -----------
Exercise Patients (N = 31) Controls (N = 24)
Peak heart rate (beats/min) 180 (12) 180 (12)
Peak workload (Watt s) 158 (60) 152 (39)
Wmax (%) 90 (13)* 99 (15)
Peak oxygen consumption (ml/kg/min) 39 (9) 42 (8)
VO2max (%) 93 (17) 102 (20)
RER 1.20 (0.08)* 1.15 (0.08)
Data given are: number of patients (%) and mean (SD)
* Signifi cant diff erence (p< 0.05) compared to controls
† Blalock Taussig shunt.
BSA= body surface area; EDV = end-diastolic volume; ESV = end-systolic volume; 
EF = ejection fraction, RER = respiratory exchange ratio, Wmax = percentage of predicted 
peak workload, VO2max= percentage of predicted peak oxygen consumption
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ECG data analysis 
ECG results are shown in Table 2. For ECG parameters that showed a signifi cant 
change during exercise or a signifi cantly diff erent change with exercise 
compared to controls, relations were explored with: RVEDV, RV wall-mass, 
RVEF, PR-percentage and VO2max.
Ventricular depolarisation
Mean QRS duration and dispersion were signifi cantly (p < 0.001) longer in 
patients than controls at all levels of exercise. QRS duration in none of the 
patients exceeded 170 ms. During exercise no signifi cant change for mean 
QRS duration and dispersion were found within either patients (respective 
p-values; p = 0.86 and p = 0.10) or controls (respective p-values; p = 0.18 and 
p = 0.26). Mean changes for both parameters were also not diff erent between 
patients and controls (respective p-values; p = 0.43 and p = 0.14).
Ventricular repolarisation
During exercise patients showed no mean change in QTc duration (p = 0.14), 
while in controls QTc tended to decrease (p = 0.02), which resulted in a 
signifi cantly diff erent mean change in QTc duration. In patients the change 
in QTc duration correlated positively with RVEDV (rs= 0. 42, p = 0.02) and RV 
wall-mass (rs= 0.43, p = 0.02), and correlated negatively with RVEF (rs= −0.46, 
p = 0.01). 
Patients showed a signifi cant increase of QTc dispersion (p < 0.001) with 
exercise, while in controls the increase in QTc dispersion approached the 
level of signifi cance (p = 0.02). Mean QTc dispersion at peak exercise was not 
diff erent at peak exercise (p = 0.05). Patients already showed a signifi cant 
increase in QTc dispersion from rest to submaximal exercise (p = 0.001). The 
change in QTc dispersion showed no signifi cant correlation with any of the 
clinical parameters.
Patients showed a signifi cant increase in mean JTc dispersion (p < 0.001) 
while controls showed no change (p = 0.07). Mean JTc dispersion at peak 
exercise was larger in patients compared to controls (p < 0.01). In patients 
a larger increase of JTc dispersion correlated with a larger RVEDV (rs= 0.50, 
p = 0.005), a larger RV wall-mass (rs= 0.47, p = 0.009) and a larger PR-percentage 
(rs= 0.41, p = 0.03). 
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In addition diff erences among PR subgroups for ECG parameter changes 
from rest to peak exercise were explored. As is shown in Figure 1 the change 
in JTc dispersion with exercise was larger in group C (severe PR) compared to 
groups A (mild PR) and B (moderate PR). No further signifi cant diff erences 
were found among subgroups. JTc dispersion at peak exercise was larger in 
group C compared to group A (88 (±27) ms versus 57 (±11), p = 0.03). 
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Figure 1. PR related changes of JTc dispersion from rest to peak exercise. 
Data are expressed as mean ± SEM
PR subgroups; A – Mild PR (< 20%); B – Moderate PR (20 – 40%); C – Severe PR (> 40%)
Discussion
Our study assessed changes in the surface ECG of Fallot patients during 
maximal physical exercise to assess pro-arrhythmogenic electrocardiographic 
signs. Findings in patients were compared to fi ndings in healthy controls. 
Diff erences found at rest between patients and controls confi rmed those of 
earlier studies.4,19,20 Diff erences in ECG changes with exercise between TOF 
patients and healthy controls pointed towards inhomogeneity of repolarisation, 
known to predispose for re-entry ventricular arrhythmia. During exercise both 
QTc and JTc dispersion increased in patients, while controls showed no change. 
At peak exercise this resulted in a signifi cantly larger mean JTc dispersion 
in patients and the tendency for a larger mean QTc dispersion compared to 
controls. Furthermore patients showed signifi cant lengthening of mean QTc 
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during exercise, while in controls QTc remained unchanged, which resulted 
in a signifi cantly diff erent change of mean QTc duration between patients and 
controls.
In addition our study explored possible relations of the observed ECG 
changes during exercise in patients with other parameters of clinical state. 
A larger increase in QTc correlated with a larger RV volume and worse RV 
systolic function. A larger increase in JTc dispersion correlated with more 
severe PR, a larger RV volume and larger RV wall-mass. In our population PR 
was the only residual defect of importance aft er correction. Therefore, patients 
were compared according to severity of PR. Patients with severe PR showed a 
signifi cantly larger increase of JTc dispersion, and had a larger JTc dispersion 
at peak exercise compared to patients with mild PR. 
Ventricular depolarisation
QRS duration and dispersion refl ect ventricular depolarisation. Prolonged QRS 
duration, > 170 ms in children and > 180 ms in adults, is regarded the main risk 
factor for arrhythmia and SCD in repaired TOF.3,5,7-9 As in previous studies 
mean QRS duration in our Fallot patients was signifi cantly longer compared 
to controls.4,6 However QRS duration did not exceed 170 ms in any of our 
patients. Previous papers reported a decrease of QRS duration with exercise 
in healthy subjects.21-23 In coronary artery disease QRS prolongation during 
exercise indicated ischemia,22,24 with the largest increase found in patients with 
documented exercise induced ventricular arrhythmia.25 These observations 
have been explained by local exercise induced ischemia with subsequent local 
conduction delay.25 We did not fi nd evidence for altered conduction delay 
with exercise in repaired TOF or our controls. Recently, Budts et al. found QRS 
shortening with exercise relates to bett er exercise performance in repaired 
TOF. We did not fi nd a relation of the change of QRS with VO2max.14 This may 
in part be explained by our relatively narrow range of QRS changes. 
Like others we found that at rest TOF patients have signifi cantly larger QRS 
dispersion than controls.6 A larger QRS dispersion predicted (sudden) cardiac 
death in chronic heart failure.26,27 In TOF a larger QRS dispersion was found 
in patients with VT compared to patients without VT.7 A QRS dispersion > 35 
ms (retrospectively) identifi ed TOF patients with sustained VT.7 Compared 
to patients with normal wall motion TOF patients with local RV wall-motion 
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abnormalities were shown to have larger dispersions of QRS, QT and JT.28 
This suggests a link between inhomogeneous RV mechanics (and possibly 
myocardial structure) and inhomogeneous RV conduction. Our range of 
fi ndings for QRS dispersions at rest is comparable to the fi ndings of Gatzoulis 
et al. in patients without VT.7 In addition we showed QRS dispersion does not 
change during exercise in TOF repaired according to contemporary surgical 
techniques, even with PR fraction exceeding 40%. Based on our data, exercise 
does not seem to increase depolarisation inhomegeneity in these patients. 
Ventricular repolarisation
QT(c) and JT(c) duration and dispersions represent ventricular repolarisation 
and can be used eff ectively to identify susceptibility for ventricular re-entry 
and sustained ventricular tachycardia.4 As in previous reports we found mean 
QTc is prolonged in TOF (p = 0.01 at rest).4,6 Gatzoulis et al. found that patients 
with documented sustained VT have a longer QT duration compared to other 
Fallot patients.7 With exercise QTc shortened in our healthy subjects, while we 
found no mean change of QTc in Fallot patients. Nevertheless, a larger change 
in QTc duration with exercise correlated with more severe RV dilation and 
worse RV systolic function.
Larger dispersions of QTc and JTc represent inhomogeneity of repolarisation 
and increase the risk for ventricular arrhythmias.29,30 Compared to controls 
a larger dispersion of ventricular repolarisation was found in patients with 
ventricular tachycardia/fi brillation.29 QTc dispersion increased during exercise 
in patients with angina pectoris as well as in patients with isolated myocardial 
bridging,31,32 while no change or a decrease was seen in healthy controls.30-32 In 
chronic heart failure a larger QTc dispersion predicted SCD.27 In TOF increased 
values for QT(c) and/or JT(c) dispersion were found.4,6,33 Fallot patients with 
sustained VT had larger QT and/or JT dispersions than other Fallot patients.7,33 
In our patients QTc and JTc dispersions increased during exercise while 
controls showed no change for both parameters. Furthermore patients with 
severe PR showed a larger increase in JTc dispersion compared to those with 
mild or moderate residual PR. As such our fi ndings indicate possible increased 
susceptibility to arrhythmia associated with physical exercise in Fallot patients, 
especially in those with severe PR. 
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Clinical relevance
We found mean QRS duration, QTc duration and QRS dispersion in our 
patients were signifi cantly larger compared to controls. However individual 
values for QRS duration (considered the simplest and most practical predictor 
of sustained VT) remained well below the previously determined risk limits.7 
Our fi ndings may refl ect the positive infl uence of the surgical technique used, 
as less QRS prolongation and life threatening arrhythmia have been reported 
aft er transatrial-transpulmonary repairs of TOF compared to transventricular 
repairs.4,34 
Physical exercise is considered a provocative factor for arrhythmia and SCD 
in a variety of congenital heart diseases.12,13 Our study established an increase 
in electrical inhomogeneity of repolarisation with exercise, which is know 
to predisposes for ventricular re-entry arrhythmia.4 Furthermore our data 
showed more severe PR and more severe RV dilation correlated with larger 
electrocardiographic abnormalities during exercise, although the relations 
found were generally weak. As such our study may contribute to an improved 
rationale for the recommendations made on exercise restriction in TOF patients 
with severe PR.13 Our data may be interpreted as additional suggestion for the 
importance of correction of PR in arrhythmia management. Pulmonary valve 
replacement has been shown eff ective for elimination of PR and reduction of 
QRS-duration.35,36 However eff ects of pulmonary valve replacement on long-
term functional status and survival are not yet clear and criteria for optimal 
timing have not yet been established. To further determine the potential role of 
ECG changes with exercise in the management of patients with repaired TOF, 
we propose these measurements should be included in future studies on risk 
stratifi cation for ventricular arrhythmia and/or optimal timing of pulmonary 
valve replacement.
Study design and limitations
We selected our TOF patients to represent the optimal result (no residual 
VSD or pulmonary stenosis of clinical importance) of generally accepted 
contemporary surgical techniques and focussed on PR related cardiac disease. 
We acknowledge our population represents only part to the total population 
seen in daily practice. However diffi  culties in data interpretation introduced 
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with various forms of ventricular overload, as apply to most studies in the 
fi eld, are avoided by this study design. Furthermore residual PR is considered 
the most important hemodynamic lesion associated with both VT and SCD in 
repaired TOF.3 
Our study does not contain longitudinal data and was not designed to 
determine cut off  values for changes in ECG parameters with exercise predictive 
of ventricular arrhythmia or SCD.
Conclusions
During physical exercise inhomogeneity of repolarisation, known to predispose 
for ventricular arrhythmia, increases in repaired TOF. Larger electrical 
inhomogeneity is found with more severe PR. 
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Abstract
In the Turner syndrome (TS) an increased risk for cardiovascular malformations 
exists, including aortic dilation of unknown etiology. Abnormal biophysical 
wall properties may play an important role. Magnetic resonance imaging (MRI) 
has successfully been used to assess aortic size and wall distensibility. The aim 
of this study was to assess aortic biophysical properties and dimensions in the 
TS. We enrolled 38 former participants of our growth hormone (GH) dose-
response study in the TS (age 12 ± 2, BSA 1.7±0.2), and 27 controls (age 21 ± 2, 
BSA 1.8 ± 0.1). Previously patients had been assigned to 1 of 3 groups, treated 
with diff erent GH-dosages: group A − 0.045, B − 0.067 and C − 0.09 mg/kg/d. All 
underwent MRI at least 6 months aft er GH discontinuation to determine aortic 
dimensions and distensibility at 4 predefi ned levels: 1) ascending aorta, 2) 
descending aorta, 3) level of the diaphragm, 4) abdominal aorta. Patients had 
larger aortic diameters at all but level 4, and tended to have lower distensibility 
at level 3. Distensibility in group A was signifi cantly lower compared to group 
C at level 4. Compared to controls group A had larger aortic diameters at 
all but level 4, and lower distensibility at level 4. Results in groups B and C 
were not diff erent from controls. In conclusion, patients with the TS, formerly 
treated with GH, have a dilated aorta and signs of impaired wall distensibility. 
Severity of abnormalities seems related to GH dose, with a benefi cial eff ect of 
a higher GH dose on the abnormalities.
Aortic Distensibility and Dimensions in Turner Syndrome
143
Introduction
Structural cardiovascular malformations occur in up to 76% of patients with 
the Turner syndrome (TS).1,2 Coarctation of the aorta and bicuspid aortic 
valve are most common and represent respectively 25 − 30% and 25 − 35% of 
cardiovascular malformations in the TS.1-3 Aortic dilation has been regarded 
as less common (6.5%).2 However, in recent studies using magnetic resonance 
imaging (MRI), aortic dilation was found in 25 − 50 % of patients with the 
TS and cardiovascular malformations.1,3,4 The most common non-structural 
cardiovascular disease in the TS is arterial hypertension.5 The number of 
reports on aortic dissection in the TS is increasing.2,6 A function of the large 
arteries is the transformation of pulsatile fl ow into continuous fl ow, known 
as the “Windkessel” phenomenon. This phenomenon is determined by the 
biophysical properties of the aortic wall. Biophysical wall properties can be 
assessed using non-invasive imaging tools and allow in vivo quantifi cation of 
the eff ects of altered arterial wall composition.7 MRI has been proven accurate 
and reproducible for this purpose.7 The aim of this study was to assess 
biophysical properties and dimensions of the aorta in TS.
Methods
For this prospective MRI-evaluation study we approached all 64 participants 
that completed our previous growth hormone (GH) dose response study in 
the TS.8 Thirty-eight patients (59%) agreed to participate. During the GH-trial, 
biosynthetic human GH (Norditropin; Novo Nordisk A/S, Bagsvaerd, Denmark) 
was given in 3 diff erent dosages; group A received 1.3 mg, B 2 mg, and C 
2.7 mg GH/ m2 body surface area/ day (~ 0.045, 0.067, or 0.09 mg/kg/day), as 
described previously by van Pareren et al.8 To induce puberty, micronized 17β-
estradiol was given orally from the age of 12 years, aft er at least 4 years of GH-
treatment. At start of GH-therapy diastolic blood pressure was signifi cantly 
lower in group C compared to both other subgroups, resulting in a lower mean 
blood pressure in group C compared to group A. GH-therapy was continued 
until fi nal height. All patients were at least 6 months aft er discontinuation of 
GH-treatment. 
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Twenty-seven healthy age, gender and body surface area (BSA) matched 
controls were included. Height, weight and blood pressures were measured, 
BSA was calculated. Besides the generally accepted contra-indications for MRI 
no exclusion criteria were used. The Medical Ethics Committ ee approved MRI-
evaluation. Writt en informed consent was obtained from all participants.
MRI protocol
Imaging was performed on a General Electric 1.5 Tesla CV/i scanner (soft ware 
release V9.1, Milwaukee, USA) using a 4-channel phased array torso coil. An 
anatomical overview of the area of interest was obtained in multiple directions 
using a bright blood imaging protocol, based on an ECG gated fat suppressed 
2D single shot steady-state free precession technique. These images were used 
for planning subsequent scans. The aortic anatomy was imaged for reference 
using a high resolution magnetic resonance 3D angiography protocol and a 
double dose of Gd-DTPA (0.2 mmol/kg, Magnevist, Schering, Germany). Flow 
measurements were performed using a standard 2D fl ow-sensitized scan. The 
scans were planned perpendicular to the aorta at 4 predefi ned locations: 1) 
ascending aorta, level of the pulmonary artery bifurcation; 2) descending aorta, 
level of the pulmonary artery bifurcation; 3) descending aorta, diaphragm 
level; 4) abdominal aorta, level of the superior mesenteric artery (Figure 
1A.). The fl ow sensitivity of the sequence was set to 180 cm/sec (increased 
if phase aliasing occurred) and the in-plane spatial resolution to 1 mm with 
a 256x256 scanning matrix.7 Temporal resolution was approximately 50 ms 
and thirty cardiac phases were reconstructed retrospectively.7 Breath-hold 
time varied between 25 − 40 sec per measurement depending on heart rate. 
Imaging parameters were: 2D FSPGR, TR = 6 − 7 ms, TE = 3 ms, fl ip angle = 20o, 
readout bandwidth = 90 Khz, 6 mm slice thickness and 4 lines/segment. A fi ft h 
measurement was performed through the sinus of Valsalva to quantify aortic 
valve gradients. During each fl ow measurement, peripheral blood pressure 
was measured at the level of the brachial artery using a sphygmomanometer 
cuff . 
Aortic Distensibility and Dimensions in Turner Syndrome
145
Figure 1. MRI angiography of the angiography of the in the Turner syndrome: 
a typical example.
A. The predefi ned levels of measurement
1. Ascending aorta. 2. Descending aorta. 3. Level of the diaphragm, and 
4. Abdominal level
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Image analysis and calculations
Flow images were quantitatively analyzed using the Flow analysis soft ware 
package version 2.0 (Medis medical systems, Leiden, the Netherlands). Vessel 
areas were manually drawn for each cardiac phase (30 phases) and maximal 
and minimal aortic areas were selected (Figure 1B). Distensibility (10¯³ mmHg¯¹) 
defi ned as the relative area change for a pressure increment, was calculated by 
means of the following equation:9
D = (Amax−Amin) ÷ [Amin*(Pmax − Pmin)].
D = distensibility, Amax = maximal (systolic) aortic area (mm²), 
Amin = minimal (diastolic) aortic area, Pmax = systolic blood pressure 
(mmHg), and Pmin = diastolic blood pressure. Mean blood pressure was 
calculated using the equation: 
Mean Blood Pressure = [(2*Pmin)+Pmax]/3.
Aortic diameters (mm²), aortic diameters indexed for BSA (mm/m²), and 
the ascending/descending aorta diameter-ratio were calculated using vessel 
areas. Patient values outside the mean ± 2SD range from our controls were 
considered abnormal. Pressure-gradients were calculated using the simplifi ed 
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Bernoulli equation (ΔP = 4*Vmax²). At the sinus of valsalva, a maximal fl ow 
velocity of 3 m/s (gradient > 36 mmHg) was regarded to indicate an aortic 
valve stenosis of importance. A coarctation of the aorta was defi ned to be 
hemodynamically important in the presence of a pressure gradient > 20 mmHg 
(based on measurement of maximal fl ow velocity). 
Statistical analysis
Analysis was performed using the SPSS-PC statistical soft ware package version 
11.5 (SPSS Inc, Chicago, Illinois). Results are expressed as mean ± SD. A P-value 
≤ 0.05 was considered to indicate signifi cance unless specifi ed otherwise. 
Diff erences in aortic diameter and aortic distensibility between patients and 
controls were respectively tested using the independent t-test and analysis 
of covariance (with correction for systolic and diastolic blood pressures). To 
deal with multiple comparisons a p-value ≤ 0.0167 were considered to indicate 
signifi cance when an individual GH-dosage group was compared to the 
controls. Diff erences between dosage groups were tested using analysis of 
variance for diameters and analysis of covariance (with correction for systolic 
and diastolic blood pressure) for distensibility. Two dummy variables were 
designed to distinguish between dosage groups. We corrected for multiple 
group comparisons by using the Bonferroni method. Spearman correlation 
coeffi  cients were calculated for the assessment of bivariate correlations.
Results
Patients
The 38 TS patients included in the present study are a representative sample 
of the original population (see methods) based on voluntary participation in 
this MRI-evaluation. One patient previously received metal implants during 
scoliosis surgery and was excluded from fi nal analysis because of substantial 
MRI artifacts. Characteristics of patients and controls are shown in Table 1. 
Between subgroups diff erences were only found for fi nal height and blood 
pressure (Table 1). Mean plasma levels of high-density lipoproteins, low-
density lipoproteins, triglycerides, Apolipoprotein A1, and Apolipoprotein B 
were normal and did not diff er between subgroups (data not shown). 
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Cardiac history showed the following: bicuspid aortic valve in 10(26%), 
tricuspid aortic valve in 25(66%), and non-conclusive valve anatomy in the 
remaining 3 patients (one in each GH-subgroup). A bicuspid valve was 
diagnosed in 3 patients in group A, 5 patients in group B, and 2 patients in 
group C (n.s). In all but one patient the aortic valve pressure gradient was 
< 35 mmHg. One patient had severe aortic valve stenosis (Doppler peak 
velocity 5 − 6 m/s). One atrial septal defect type II had been surgically closed. 
Three other patients underwent surgical repair for aortic coarctation, with a 
residual but stable Doppler gradient of 15 − 20 mmHg in one.
Aortic anatomy
In 5 patients an anatomical aortic coarctation was diagnosed on MRI. Of 
these patients 2 had had a previous surgical coarctectomy. In 1 patient the 
aortic coarctation had not previously been diagnosed. A pressure gradient 
of importance was found in 2 of 5 patients (27 mmHg and 28 mmHg). In a 
sixth patient tapering of the descending thoracic aorta over a length of about 
8 centimeters starting at the isthmus was observed. One patient had a right 
aortic arch. Peak velocity measurement at the sinus of Valsalva in the patient 
with known severe aortic valve stenosis was > 5.5 m/s (maximal sett ing) and 
< 3.0 m/s in all others. No pathology was found in controls.
Aortic diameters
The patient with severe aortic valve stenosis was excluded from analysis 
of ascending aorta diameters and the two patients with aortic coarctation 
with a gradient > 20 mmHg were excluded from the analysis of descending 
aorta diameters. All three were excluded from the analysis of the ascending/
descending aorta diameter-ratio. Aortic diameters are shown in Table 2. The 
absolute ascending aorta diameter was dilated (> mean plus 2SD in controls) 
in 11(30%) patients, and the diameter indexed for BSA was dilated in 18(49%) 
patients. Ascending/descending aorta diameter-ratio was larger in patients 
(1.5 ± 0.3 in patients versus 1.4 ± 0.1 in controls, p = 0.05). In 13(35%) patients 
this ratio was abnormally high (> mean plus 2 SD in controls). No diff erences 
between subgroups were found.
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Table 2. Aortic diameters (mm/m²)
Controls Total patients Group A Group B Group C
Level 1 15.2 ± 1.2n = 27 (100%)
17.6 ± 2.6*†
n = 36 (97%)
17.4 ± 2.0†
n = 13 (100%)
18.2 ± 3.3*†
n = 12 (92%)
16.5 ± 1.6†
n = 11 (100%)
Level 2 10.9 ± 1.2n = 27 (100%)
11.8 ± 1.9†
n = 35 (95%)
12.8 ± 2.2†
n = 11 (85%)
10.9 ± 1.6
n = 13 (100%)
11.7 ± 1.4
n = 11 (100%)
Level 3 9.6 ± 0.7n = 27 (100%)
10.4 ± 1.2*
n = 36 (97%)
11.2 ± 1.4*†
n = 13 (100%)
9.8 ± 0.6
n = 13 (100%)
10.3 ± 1.0
n = 10 (91%)
Level 4 8.5 ± 0.6n = 27 (100%)
8.7 ± 0.9
n = 34 (92%)
9.1 ± 1.0
n = 13 (100%)
8.5 ± 0.7
n = 10 (77%)
8.6 ± 1.0
n = 10 (91%)
* Statistically signifi cant diff erence compared to controls, absolute diameters (mm²)
† Statistically signifi cant diff erence compared to controls, diameters normalized for BSA 
(mm/m²)
Table 3. Aortic distensibility (10−³ * mm Hg−¹) 
Controls Total patients Group A Group B Group C
Level 1 5.3 ± 1.2n = 27 (100%)
4.7 ± 2.3*
n = 36 (97%)
4.1 ± 1.7*
n = 13 (100%)
4.7 ± 2.5 
n = 13 (100%)
5.5 ± 2.7 
n = 10 (91%)
Level 2 5.2 ± 1.2 n = 27 (100%)
5.7 ± 2.4 
n = 35 (95%)
5.0 ± 2.3 
n = 11 (85%)
5.9 ± 2.4 
n = 13 (100%)
6.3 ± 2.6
n = 11 (100%)
Level 3 7.5 ± 2.2n = 27 (100%)
6.4 ± 1.9*
n = 36 (97%)
5.4 ± 2.0*
n = 13 (100%)
6.5 ± 1.5 
n = 13 (100%)
7.4 ± 1.7†
n = 10 (91%)
Level 4 8.4 ± 2.2n = 27 (100%)
7.3 ± 2.5 
n = 32 (86%)
5.8 ± 2.4*‡
n = 13 (100%)
8.1 ± 2.4 
n = 10 (77%)
8.6 ± 1.9†§
n = 9 (82%)
* Statistically signifi cant diff erence compared to controls 
† Statistically signifi cant diff erence compared to group A 
‡ Statistically signifi cant diff erence compared to controls with correction for diastolic 
blood pressure and systolic blood pressure
§ Statistically signifi cant diff erence compared to group A with correction for diastolic 
blood pressure and systolic blood pressure
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Aortic distensibility
The two patients with aortic coarctation were excluded from analysis of data 
for the descending aorta. Distensibility measurements are shown in Table 3 and 
Figure 2. Aortic distensibility correlated negatively with systolic and diastolic 
blood pressure at levels 3 and 4 (level 3: Systolic blood pressure r = −0.67, 
p < 0.001, Diastolic blood pressure r = −0.39, p < 0.05; level 4: Systolic blood 
pressure r = −0.60, p < 0.001, Diastolic blood pressure r = −0.35, p < 0.05). Aft er 
correction for systolic and diastolic blood pressure patients still tended to have 
smaller distensibility at level 3 (p = 0.07). Analysis on GH subgroups showed 
aortic distensibility corrected for blood pressure in group A to be smaller at 
level 4, with a tendency for smaller distensibility at levels 1 (p = 0.05), and 
3 (p= 0.07) compared to controls. Distensibility did not show a signifi cant 
correlation with time duration since stop of GH-treatment at any of the levels 
of measurement.
Discussion
The present study shows that patients with the TS have larger aortic diameters 
(mm/m²) at all thoracic levels of measurement and a larger ascending/descending 
aorta diameter-ratio compared to controls. Lower aortic distensibility was 
found at levels 1 and 3 before correction for blood pressure, and a tendency 
(p = 0.07) at level 3 aft er this correction in patients compared to controls. 
Therefore, we conclude the aorta in the TS shows abnormal dimensions and 
signs of impaired wall function. Furthermore we assessed the infl uence of 
received GH dose on aortic distensibility. We will discuss results corrected for 
blood pressure. Distensibility increased with increasing GH dose (Figure 2), 
which resulted in a signifi cantly smaller distensibility in patients who received 
the lowest GH-dose compared to patients who received the highest dose at 
aortic level 4. Moreover we found group A to have lower aortic distensibility 
compared to controls at level 4 and a tendency towards lower distensibility 
at levels 1 (p = 0.05) and 3 (p = 0.07). No diff erences with controls were found 
in both other subgroups. Our results point towards normalization of aortic 
distensibility with increasing GH dose and suggest GH to have a benefi cial 
infl uence on aortic wall properties in the TS.
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Figure 2. Aortic distensibility per level of measurement
Level 2: Descending AortaLevel 1: Ascending Aorta
Level 3: Diaphragm Level 4: Abdominal  Aorta
12
10
8
6
4
2
2
4
6
8
10
12
0
2
4
6
8
10
12
14
D
is
te
ns
ib
ili
ty
 (1
0¯
³*
m
m
 H
g¯
¹) 
 
12
*
†
‡
*
*
†
§
14
10
8
6
4
2
0
GH groups:  Con = controls,  A = 0.045 mg/kg/d
 B = 0.067 mg/kg/d, C = 0.09 mg/kg/d
* Statistically signifi cant diff erence compared to controls 
† Statistically signifi cant diff erence compared to group A 
‡ Statistically signifi cant diff erence compared to controls with correction for diastolic and 
systolic blood pressures
§ Statistically signifi cant diff erence compared to group A with correction for diastolic and 
systolic blood pressures
Aortic Distensibility and Dimensions in Turner Syndrome
153
Previous studies have shown mean aortic root diameter is larger in the TS 
compared to controls.1,3,10 Dilation of the ascending aorta was found in 18 − 
33% of patients.1,10 Dilation and dissection most frequently (50 − 70% of cases), 
but not exclusively, occur in the ascending aorta.(2,11) We found ascending 
aorta diameter to be dilated in 11(30%) patients (> mean plus 2 SD in controls) 
and even in 18(49%) when diameter was indexed for BSA. In accordance with 
previous fi ndings the ascending aorta/descending aorta diameter ratio was 
> 1.5 (a commonly used criterion for ascending aorta dilation) in 13(35%) of 
our patients.1,4,12 In the TS the ascending/descending aorta diameter-ratio 
should be interpreted with some caution because of the frequently encountered 
abnormalities at the classical coarctation site that may infl uence this ratio.1,6 
Furthermore concurrent dilatation of ascending and descending aorta, like we 
found in TS, may result in false normal outcome of this ratio. We conclude that 
mean ascending aorta diameter is dilated in 30 to 50% of patients with the TS 
formerly treated with GH. Furthermore, we found dilation of the aorta is not 
limited to the aortic root and/or ascending aorta but is present throughout 
the entire thoracic aorta. Abnormalities were most prominent in patients that 
previously had received the lowest GH-dose. 
The number of reports on aortic dissection in the TS, especially during 
pregnancy, is increasing.2,6 Post-mortal fi ndings similar to arterial cystic media 
degeneration seen in Marfan syndrome have been described in the TS.2,13 
Increased incidence of complications aft er surgery for coarctation has been 
reported in the TS as a result of apparent friability of the aortic wall.2 A recent 
study showed increased carotid-femoral pulse wave velocity, increased carotid 
intima-media thickness, and a higher carotid augmentation index in TS.10 These 
reports support the hypothesis that connective tissue abnormalities might play 
a role in Turner syndrome. Our fi ndings, especially those in subgroup A, bear 
similarity with results found in Marfan syndrome on aortic wall distensibility 
and support the theory that connective tissue abnormalities play a role in 
aortic disease in the TS.14,15 MRI-determined aortic distensibility has been 
shown to be decreased in a variety of cardiovascular diseases.7 Our fi ndings 
support the use of MRI-determined measurements for (early) detection of 
aortic wall dysfunction and quantifi cation of intervention related eff ects on 
wall function.7
Aortic distensibility in normal subjects is negatively correlated with age, 
progression of atherosclerosis, an abnormal lipid profi le and post-menopausal 
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state in women.16,17,18 With increasing age plasma levels of anabolic hormones, 
such as GH and Insuline-like growth factor I, decline. GH replacement can 
reverse age related catabolic changes.16 In women post-menopausal estrogen 
replacement therapy has been shown to reduce age associated increases in 
arterial stiff ness.17,18 Patients with GH defi ciency show wall thickening of large 
arteries and a tendency towards decreased arterial wall compliance.19,20 In 
response to GH treatment in GH defi ciency arterial wall thickness decreased 
and compliance increased.19,20 Our patient subgroups did not diff er in 1) 
age, 2) plasma levels of cholesterol, triglycerides, Apolipoprotein A1 and 
Apolipoprotein B, or 3) estrogen treatment protocol. As all our patients were 
treated with GH we cannot quantify the sole eff ect of estrogen replacement 
therapy on aortic wall distensibility in the TS.
Elastic properties of the aorta depend on the presence, proportion and 
interaction of smooth muscles, collagen, and elastin proteins. This mixture of 
elements with diff erent elastic properties results in a non-linear arterial pressure-
volume relation. In rats, GH was found to infl uence collagen metabolism and 
change the mixture of fi brous elements in the aortic wall.21 In young rats GH 
increased aortic extensibility.21 In accordance with these fi ndings our results 
in the TS indicate a positive eff ect of GH on aortic wall distensibility. Like 
others we found distensibility to negatively correlate with systolic blood 
pressure and diastolic blood pressure.22 We therefore present distensibility 
results corrected for blood pressure. The aortic pressure-diameter curve has 
a linear, elastin-determined and an exponential, collagen-determined part. An 
increase in blood pressure within the exponential part results in a decrease of 
aortic distensibility.23 With aging the curve shift s downward and to the right 
(age related aortic dilation), through what pressure-changes may occur in the 
exponential part.23 In young subjects, like our patients, pressure changes are 
expected to occur in the linear part. However the degenerative aortic wall 
alterations described in the TS may change the age specifi c behavior. There 
is only litt le data on degenerative alterations in TS, no quantitative data on 
progression of such alterations over time, and no data on possible changes in 
wall composition in TS in relation to GH treatment. 
Based on our data we think GH-treatment to have a (direct or indirect) 
benefi cial eff ect on the biophysical properties of the aortic wall in TS. Further 
evaluation of the role of GH, arterial blood pressure, and their interaction 
on aortic distensibility in TS is required. Limitations of this study are that it 
Aortic Distensibility and Dimensions in Turner Syndrome
155
provides a cross-sectional evaluation in a population with a small age range, 
thus limiting analysis of age/time eff ects. This study was not designed to 
determine the optimal GH-dose leading to normal aortic function, or to 
determine the exact mechanism in which GH eff ects the aortic wall. 
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Abstract
Objectives: In Turner’s syndrome (TS) growth hormone (GH) therapy is well 
established, but data on cardiac status following discontinuation of treatment 
are lacking. This study aimed to assess biventricular size and function in TS 
mid-term aft er discontinuation of GH-therapy.
Methods: TS patients (mean (SD) 5(2) years aft er GH discontinuation) 
and healthy women prospectively underwent cardiac magnetic resonance 
imaging (CMR). Ventricular 2D tomographic cine data was acquired to obtain 
biventricular volume, mass and ejection fraction. Mitral and tricuspid valve 
fl ow measurements were performed using a standard 2D fl ow-sensitized 
sequence. Flow velocity curves were calculated and indices of biventricular 
diastolic fi lling were derived.
Results: Thirty-three patients (mean (SD) age 20(2) years, BSA 1.75(0.15) m²) 
and 23 controls (age 21(2) years, BSA 1.80(0.13) m²) were included. Compared 
to controls patients had smaller mean end-diastolic volumes (RV, 84(11) 
ml/m² versus 79(11), p =  0.04; LV, 81(10) versus 72(10), p = 0.002), end-systolic 
volumes (RV, 38(7) ml/m² versus 36(6), p = 0.09; LV, 34(5) versus 28(6), p < 0.001) 
and stroke volumes (46(6) ml/m² versus 43(6), p = 0.06; LV, 47(7) versus 43(7), 
p = 0.07). Patients had a higher mean heart rate (79(13) beats/min versus 71(10), 
p < 0.05) and LVEF (61(5)% versus 58(4), p = 0.02). Biventricular mass, cardiac 
output and diastolic fi lling patt ern were comparable. 
Conclusion: Mid-term aft er discontinuation of GH therapy TS patients showed 
no myocardial hypertrophy and well-preserved biventricular function. 
Mean ventricular volumes in TS were smaller compared to controls, while 
comparable cardiac output was achieved at a higher resting heart rate, which 
may negatively impact long-term survival in TS.
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Introduction
Turner’s syndrome (TS) is characterized by a constellation of visible 
(dysmorphic) and non-visible physical fi ndings caused by total or partial X-
monosomy.1 Common clinical fi ndings is short stature. In northwestern Europe 
mean adult height in untreated TS is 142 to 147 cm, approximately 20 cm below 
normal average height in women.2 Supra-physiological dosed growth hormone 
(GH) accelerates growth. In TS GH-treatment has been shown to normalize 
adult height in most patients and nowadays it is a well-established therapy.2,3 
In healthy controls supra-physiological dosed GH rapidly induces changes in 
left  ventricular function (increased cardiac index) and size (hypertrophy and 
concentric remodeling).4 Chronic GH excess in acromegaly is associated with 
increased cardiovascular morbidity and mortality.5 Untreated acromegaly is 
associated with dynamic changes in cardiac structure and function that on the 
long-term may cause “acromegalic” cardiomyopathy and heart failure.5,6 The 
GH dose normally used for treatment of short stature in TS is relatively high 
(1.4 mg/m² body surface area (BSA) /day in TS compared to 0.7 mg/m² BSA 
/day in GH defi ciency). This raises concerns on possible cardiovascular side 
eff ects. We and others addressed these concerns in girls with TS during GH 
treatment and reported normal LV volumes without hypertrophy compared to 
controls.7,8 However cardiac data mid- and long-term aft er discontinuation of 
GH treatment are lacking. Furthermore most previous studies focussed on LV 
size and function only. We hypothesize that myocardial eff ects of systemic GH 
treatment if present are biventricular. Cardiac magnetic resonance imaging 
(CMR) is the gold standard for determination of biventricular volumes, function 
and wall mass. The aim of his study was to prospectively assess biventricular 
size and function in TS mid-term aft er discontinuation of GH-therapy and 
compare results to healthy controls.
Methods
Thirty-three young women with TS, all former participants of our GH dose-
response study, prospectively underwent CMR evaluation. The Medical Ethics 
Committ ee approved the study. Writt en informed consent was obtained 
from all participants. During the previous GH-trial, biosynthetic human 
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GH (Norditropin; Novo Nordisk A/S, Bagsvaerd, Denmark) was given. 
Patients were randomly assigned to 1 of 3 groups, treated with diff erent GH-
dosages: group I received 1.3, group II 2.0 and group III 2.7 mg/m² BSA /day 
as previously described by van Pareren et al.3 To induce puberty, micronized 
17β-estradiol was given orally from the age of 12 years, aft er at least 4 years 
of GH-treatment. At start of GH-therapy, there were no diff erences between 
groups in age, height or BSA. Diastolic blood pressure was signifi cantly lower 
in group C compared to both other subgroups, resulting in a lower mean blood 
pressure in group C compared to group A. GH-therapy was continued until 
fi nal height. At inclusion for CMR evaluation GH-treatment in all patients 
had been discontinued for at least 6 months. At our institution age-matched 
untreated TS patients are not available. Therefore 23 healthy age, gender and 
BSA matched controls were included. Height, weight, diastolic blood pressure 
and systolic blood pressure were measured. BSA, BMI and mean blood pressure 
were calculated. Besides the generally accepted contra-indications for MRI no 
exclusion criteria were used.
CMR protocol
Imaging was performed on a GE 1.5-T Signa CV/i scanner using soft ware 
releases V8.4 and V9.1 (GE healthcare, Milwaukee, Wisconsin, USA) with a 
4-channel phased-array coil. All images were acquired during breath-holds at 
end-expiration. A standardized multi-phase, multi-slice volumetric ventricular 
data set in short axis direction was acquired. Imaging was performed using a 
2D fast imaging employing steady-state free precession acquisition sequence 
(FIESTA) with the following imaging parameters: fl ip angle = 45º, TE set at 
min full, TR = 3.4 − 3.6 ms, 8 − 9 mm slice thickness, 0 − 1 mm inter-slice gap, 
12 views/segment, readout bandwidth = 111Khz, a square FOV (30 − 34 cm), 
and a scanning matrix of 160 * 128. Twenty-four phases per cardiac cycle were 
reconstructed retrospectively.
Mitral valve and tricuspid valve fl ow measurements were performed 
perpendicular to fl ow using a standard 2D fl ow-sensitized (phase velocity 
encoded) scan. Flow sensitivity of the sequence (VENC) was set at 120 cm/
s. The VENC was increased with phase aliasing. Scans were retrospectively 
gated. Temporal resolution was approximately 35 − 50 ms per cardiac phase. 
Thirty phases were reconstructed retrospectively. Imaging parameters were: 
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2D FSPGR, TR = 6 − 7 ms, TE = 3 ms, fl ip angle = 20o, readout bandwidth = 90 
Khz, 6 mm slice thickness, 6 views/segment, a rectangular FOV (75% in phase 
encoding direction), scanning matrix of 256 *128. Heart rate (beats/min) was 
assessed during each fl ow measurement.
CMR image analysis
CMR studies were analyzed on a commercially available Advanced Windows 
workstation (GE Healthcare, Milwaukee, Wisconson, USA). Volumetric data 
was quantitatively analyzed using the Mass analysis soft ware package V3.1 
(Medis Medical Imaging Systems, Leiden, The Netherlands). End-diastolic 
and end-systolic time frames from every slice were used for the assessment of 
biventricular end-diastolic and end-systolic volumes. Stroke volumes, ejection 
fractions and cardiac mass were assessed according to common analysis 
techniques.9
Flow images were quantitatively analyzed using the Flow analysis soft ware 
package V2.0 (Medis Medical Imaging Systems, Leiden, The Netherlands). 
This package allows calculation of fl ow velocity curves by multiplying valve 
area (drawn on each of the 30 time frames) and spatial average fl ow velocities 
per time frame. From the resulting fl ow-velocity curves the following indices 
of biventricular diastolic fi lling were derived (Figure 1); 1) peak early fi lling 
rate (PeFR) (ml/s), 2) time to peak early fi lling rate (tt PeFR) (ms) measured 
from end-systole, 3) early fi lling fraction (FF) defi ned as volume increase 
(ml) during the fi rst one-third of diastole normalized for ventricular stroke 
volume, 4) deceleration time (Dt) (ms), measuring the time from PeFR to the 
extrapolation point of deceleration of fl ow to the baseline, 5) peak atrial fi lling 
rate (PaFR) (ml/s), 6) time to peak atrial fi lling rate (tt PaFR) (ms) defi ned as 
time from end-systole to maximal increase in ventricular volume aft er atrial 
contraction, 7) atrial fi lling fraction (AFF) defi ned as the increase in ventricular 
volume aft er atrial contraction normalized for ventricular stroke volume, and 
8) the ratio of peak early fi lling rate over peak atrial fi lling rate (PeFR/PaFR 
ratio).
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Figure 1. Phase velocity encoded AV-valve valve fi lling patt ern: a typical example 
of the mitral valve 
AFF = atria fi lling fraction (% of total diastolic fi lling during atrial contraction), 
Dt = deceleration time, FF = early fi lling fraction (% of total fi lling during fi rst ⅓ diastole), 
PaFR = peak atrial fi lling rate, PeFR = peak early fi lling rate
Statistical analysis
SPSS-PC statistical soft ware package version 11.5 was used for analysis (SPSS, 
Inc., Chicago, Illinois, USA). A p-value < 0.05 was considered to indicate 
statistical signifi cance. Results are expressed as mean (SD). Characteristics and 
absolute CMR parameter values were compared between patients and controls 
using the two-sample T-test or Mann-Whitney U test. To deal with multiple 
comparisons according to Bonferroni’s method a p-value ≤ 0.017 (i.e. 0.05/3) 
was considered to indicate signifi cance when an individual GH-dosage group 
was compared to the controls. Bivariate correlation coeffi  cients were calculated 
using Spearman’s method (rs). 
Analysis of covariance with correction for BSA or weight and height was 
used to compare biventricular short axis data between patients and controls. 
Analysis of covariance with correction for HR was used to compare biventricular 
indices of diastolic fi lling between patients and controls. GH subgroups were 
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compared using analysis of variance. To deal with multiple group comparisons 
the Bonferroni method was used. RVEDV, RV-mass, LVSV and LV-mass were 
log10-transformed before analysis of (co)variance was applied. 
Results 
Characteristics of patients, patient GH subgroups and controls are shown in 
Table 1. In all but 1 patient the Doppler-derived aortic valve pressure gradient 
was less then 35 mmHg. One patient (in group B) had severe aortic valve stenosis 
(Doppler peak velocity 5 − 6 m/s). Three other patients underwent surgical 
repair for aortic coarctation, with a residual but stable Doppler gradient of 15 
− 20 mmHg in one. 
Compared to controls patients were shorter (mean adult height, p < 0.001 
and height SD score, p < 0.001), had a higher mean heart rate (p = 0.006) and 
higher diastolic blood pressure (p = 0.05). Heart rate positively correlated with 
mean blood pressure (rs = 0.53, p < 0.001).
Signifi cant positive correlations were found for GH dose with adult 
height rs = 0.44, p = 0.01), and height SD-score (rs  = 0.45, p = 0.01). Negative 
associations of GH dose were found with systolic blood pressure (rs = −0.39, 
p = 0.02, diastolic blood pressure (rs= −0.40, = < 0.02) and mean blood pressure 
(rs = −0.43, p = 0.01).
Aortic anatomy
In 4 patients an anatomical aortic coarctation was diagnosed on MRI. Of these 
patients 2 had had a previous surgical coarctectomy. A pressure gradient of 
importance was found in 2 (27 mmHg).
Biventricular size and ejection fractions
The biventricular CMR measures normalized or BSA of patients and controls 
are shown in Table 2. Compared to controls biventricular end-diastolic volume 
(RVEDV, p = 0.04 and LVEDV, p = 0.001), LV end-systolic volume (p < 0.001) 
and LV stroke volume (p = 0.02) were signifi cantly smaller in patients. Patients 
had a higher LV ejection-fraction (EF) compared to controls (p = 0.02). Heart 
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rate (beats/min) negatively correlated with LVEDV (ml/m²) (rs = −0.47, p = 
0.001) and RVEDV (ml/m²) (rs = −0.38, p = 0.003). At analysis of covariance with 
correction for height and weight the diff erence found for RVEDV no longer 
was present. For the LV a smaller end-diastolic volume (p= 0.03), a smaller 
end-systolic volume (p = 0.002) and a larger LVEF (p= 0.01) were found in TS 
patients compared to controls. There were no diff erences between GH dose 
subgroups, both without and with adjustment for BSA or weight and height.
Table 1. Patient characteristics
Parameter Controls
(n = 23)
Patients
(n = 33)
Group I
(n = 11)
Group II
(n = 12)
Group III
(n = 10)
Age (years)  21 (2) 20 (2) 21 (2) 20 (2) 19 (2)
Height (cm) 172 (8) 163 (7)* 159 (7) 164 (6) 166 (6)‡
Height SDS§ 0.2 (1.2) −1.1 (1.1)* −1.8 (1.0) −0.9 (1.0) −0.6 (0.3)‡
Weight (kg) 68 (9) 71 (13) 69 (10) 75 (16) 65 (11)
BSA (m²) 1.80 (0.13) 1.75 (0.15) 1.71 (0.14) 1.82 (0.15) 1.72 (0.15)
Duration GH-Rx (years) ----- 8.6 (1.9) 8.3 (1.3) 8.1 (2.3) 9.4 (1.9)
Stop since GH-Rx (years) ----- 4.9 (2.0) 5.1 (1.4) 5.3 (2.2) 4.0 (2.0)
Duration E-Rx (years) ----- 7.2 (2.1) 7.7 (2.1) 7.2 (2.0) 6.6 (0.8)
Systolic Blood Pressure 
(mmHg)
115 (10) 118 (15) 128 (18) 116 (8) 112 (12)‡
Diastolic Blood Pressure 
(mmHg)
64 (9) 70 (12) 77 (14)† 69 (8) 63 (10)‡
Mean Blood Pressure 
(mmHg)
81 (9) 86 (12) 94 (14)† 85 (7) 80 (10)‡
Heart rate (beats/min) 71 (10) 79 (13) * 83 (14)† 78 (14) 75 (11)
Data are mean (SD), Group I received 1.3, group II 2.0 and group III 2.7 mg/m² BSA /day
* Signifi cant diff erence (p < 0.05) between patients and controls (student T-test)
† Signifi cant diff erence (p < 0.017) between patient subgroup and controls (student T-test)
‡ Signifi cant correlation according to Spearman’s method (p < 0.05) with GH dose
§ Height for age: references healthy Dutch girls10
BSA = body surface area, E-Rx = estrogen substitution therapy, GH-Rx = GH-therapy
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Table 2. CMR short axis measurements: Patients versus controls.
Right Ventricle Left  Ventricle
Controls Patients P-value Controls Patients P-value
EDV (ml/m²) 84 (11) 79 (11) 0.04 81 (10) 72 (10) 0.002
ESV (ml/m²) 38 (7) 36 (6) 0.09 34 (5) 28 (6) 0.001
SV (ml/m²) 46 (6) 43 (6) 0.06 47 (7) 43 (7) 0.07
EF (%) 54 (4) 55 (4) 0.92 58 (4) 61 (5) 0.02
Mass (g/m²) 14 (3) 13 (2) 0.17 45 (6) 45 (6 ) 0.97
CO (L/min/m²) 3.4 (0.6) 3.4 (0.6) 0.87 3.5 (0.5) 3.5 (0.6) 0.71
Data are mean (SD) values for CMR values normalized for BSA
P-values are from analysis of covariance on original data with statistical adjustment for 
BSA; CO = cardiac output, EDV = end-diastolic volume, EF = ejection fraction, ESV = end-
systolic volume, SV = stroke volume, Mass = wall mass.
Table 3. Biventricular diastolic fi lling characteristics: patients versus controls.
Tricuspid Valve Mitral Valve
Patient (n = 19) Controls (n = 15) Patient (n = 29) Controls (n = 18)
TtPeFR (ms) 108 (19) 112 (16)  97 (37)  90 (22)
PeFR (ml/s) 337 (58) 317 (66) 396 (75)* 453 (83)
FF (%)  52 (14)  52 (9)  57 (14)*  64 (6)
Deceleration time 
(ms)
174 (43) 185 (48) 135 (32) 134 (26)
TtPaFR (ms) 361 (119) 427 (132) 361 (97) 398 (103) 
PaFR (ml/s) 178 (69) 166 (48) 181 (38) 176 (36)
AFF (%)  23 (11)  23 (7)  24 (5)  22 (3)
E/A-ratio 2.2 (1.1) 2.1 (0.8) 2.3 (0.6)* 2.6 (0.4)
Heart rate (/min)  81 (13)*  71 (10)  80 (11)*  71 (10)
Data are mean (SD) values
* Signifi cant diff erence (p< 0.05) between patients and controls (student T-test)
AFF = atrial fi lling fraction, E/A-ratio = PeFR/PaFR, FF = fi lling fraction fi rst ⅓ diastole, 
PaFR = peak atrial fi lling rate, PeFR = peak early fi lling rate, TtPaFR = time to PaFR, 
TtPeFR = time to PeFR.
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Atrioventricular (AV)-valve infl ow
Results of the quantitative analysis of AV-infl ow are shown in Table 3. For 
logistic reasons tricuspid valve measurements could no be completed in all 
patients. Mitral valve infl ow in patients showed a smaller early peak fi lling 
rate (p = 0.02), a smaller early FF (p = 0.03), a smaller E/A-ratio (p = 0.002) and a 
larger AFF (p = 0.07). Aft er correction for heart rate these diff erences no longer 
were present. Time to PaFR was longer in patients aft er adjustment for heart 
rate (adjusted diff erence 35 ms, standard error 12 ms). 
No diff erences in indices of the tricuspid valve infl ow patt ern were present 
between TS patients and controls. Aft er adjustment for heart rate FF was 
larger in patients (adjusted diff erence 8%, standard error 3%). No signifi cant 
diff erences in tricuspid or mitral valve infl ow indices were present between 
GH dose subgroups (neither with nor without adjustment for heart rate).
Discussion
In this study we prospectively assessed cardiac status in young adult women 
with TS, 5 (±2) years aft er discontinuation of GH therapy and compared 
results to those of a matched reference population. In contrast to previous 
studies analysis was not restricted to the LV. The most striking fi ndings of 
this study were the smaller biventricular volumes in TS compared to controls. 
Patients showed no myocardial hypertrophy or systolic dysfunction and 
minor diastolic function changes compared to controls. Despite smaller stroke 
volumes patients showed comparable cardiac output to controls, by means of 
higher resting heart rate.
All our patients were former participants of a GH dose response study 
during which patients received supra-physiological dosed GH treatment.3,7 
During that trial GH dose ranged from 1 to 2 times the regularly used dose in TS 
and was given for a relatively long period of time (9 (±2) years). No diff erences 
were found for any of the CMR measures between GH dose subgroups.
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GH and ventricular remodeling 
The ability of GH to stimulate growth of cardiomyocytes has extensively 
been documented.6 Eff ects of GH excess on cardiac size are staged.6,11 Initially 
cardiomyocytes increase in cross-sectional area, resulting in concentric 
ventricular remodeling.6 Myocardial hypertrophy induced by short term GH 
is has been shown reversible within 3 months in healthy controls.4 In animal 
models of myocardial ischemia short-term GH excess reduced cell necrosis and 
apoptosis.6 In heart failure models it induced myocardial hypertrophy without 
disproportional fi brosis and restored myocardial capillary density to normal 
levels.6 As such, short-term GH induces the physiological type of myocardial 
hypertrophy. Myocardial hypertrophy in heart failure is characterized by 
cardiomyocyte lengthening, eccentric remodeling, decreased myocyte density 
and increased fi brosis.5,6 This pathological type of hypertrophy is also seen in 
acromegalic cardiomyopathy and is a cause of concern in all (high dosed) GH 
treated patients.5,6,11
Data on cardiac status in relation to GH treatment during childhood is 
limited. All previous studies used echocardiography. During GH treatment 
no LV hypertrophy was found in TS,7,8 Noonan syndrome,12,13 GH defi ciency14 
and idiopathic short stature,15,16 During treatment Radett i et al. found patients 
with TS had smaller LV end-systolic volumes (ml/m²), but normal end-diastolic 
volumes compared to controls.8 At the start of GH treatment in TS Sas et al. 
documented normal SD-scores for LV dimensions, that signifi cantly decreased 
to values < 0 aft er 7 years of treatment.7 In Noonan’s Syndrome, Noordam 
et al. also found negative SD-score changes for LV dimensions during GH 
treatment.12 
Data on cardiac status aft er discontinuation of high dosed GH treatment are 
even scarcer. Adults with childhood onset GH defi ciency formerly treated with 
GH showed smaller LV dimensions, LV stroke volume and LV mass compared 
to controls.17 However, in that study volumetric data were not normalized for 
body size while patients remained smaller than controls. We found wall mass in 
TS was comparable to controls, but biventricular volumes and stroke volumes 
were smaller. This strongly suggests that cardiac growth in our TS patients 
during childhood was disproportionally less than somatic growth. Studies 
among healthy children showed weight and height are important determinants 
of LV growth (indicated by LV mass) and found an important degree of 
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tracking for LV mass during childhood.18,19 Analysis with correction for height 
and weight still resulted in smaller LV volumes in our patients compared to 
controls. We do not know of clinical studies that focussed on cardiac growth 
in relation to somatic growth during GH treatment. In experimental models 
of GH- and IGF1- defi ciency disproportionate and diff erential eff ects on 
specifi c organ growth have been reported, but these studies do not explain our 
observations.20,21 
GH and ventricular function
Initially GH excess is associated with normal to increased ventricular 
function.4,6,11 Over time patients with acromegaly develop LV diastolic 
dysfunction.22,23 In acromegaly diastolic dysfunction relates to disease activity 
and can be detected before evident systolic dysfunction or hypertrophy.4,22 
Compared to controls our TS patients showed normal RV diastolic fi lling and 
some shift ing towards late diastolic LV fi lling. Previously Radett i et al. reported 
a higher A-peak, a smaller E/A-ratio and shortened deceleration time for LV 
fi lling in TS patients during GH treatment compared to controls.8 Diastolic 
fi lling is known to be HR dependent.24,25 In our patients correction for heart 
rate resulted in comparable biventricular diastolic fi lling patt ern to controls. 
Like Radett i previously suggested, the changes seen LV diastolic fi lling in TS 
may result from adaptation to higher heart rates, rather than represent early 
signs of LV dysfunction as they do not entirely fi t abnormalities of relaxation 
or compliance.
Aft er discontinuation of GH for at least 6 months our TS patients showed a 
higher mean heart rate and increased LV ejection fraction compared to controls. 
During GH treatment Radett i et al. found signs of increased ventricular systolic 
performance in TS which was explained by decreased systemic vascular 
resistance and end-systolic meridional stress compared to controls.8 We did not 
assess ventricular contractility in our patients. Compared to healthy controls 
our TS patients had higher mean blood pressure and comparable cardiac 
output. Therefore, aft erload in our patients appeared not to be decreased. 
According to the formula of ejection fraction (EF = SV/EDV*100), a comparable 
stroke volume generated by a smaller ventricle automatically results in 
a higher ejection fraction. The higher LVEF in our TS patients compared to 
controls may be explained by this mathematical drawback of EF and does not 
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necessarily imply increased systolic LV performance. Overall our results lead 
to conclude that young adults with TS formerly treated with GH show normal 
biventricular function.
Clinical importance
So far data on cardiac status in TS aft er discontinuation of GH-therapy 
were lacking. Therefore, concerns on possible long-term cardiovascular side 
eff ects as seen in other situations with GH excess remained. To address these 
concerns we determined cardiac status mid-term aft er GH discontinuation in 
TS. With regard to the well-known complications of GH excess we found the 
following reassuring results: 1) absence of myocardial hypertrophy, 2) absence 
of diastolic dysfunction, generally considered an early sign of ventricular 
dysfunction, and 3) normal global biventricular systolic function. However, 
we did fi nd our TS patients had smaller biventricular volumes and stroke 
volumes, especially for the LV, compared to controls and a higher mean resting 
heart rate. Evidence is increasing on the detrimental eff ect of higher resting 
heart rate on (cardiovascular) mortality.26,27 Increased heart has repeatedly 
been found in TS.28 A recent study described dysregulation of the sympathetic 
nervous system, leading to tachycardia, high blood pressure, increased resting 
norepinephrine levels, and a blunted cathecholinergic response to exercise 
in TS.28 There is also evidence that resting heart rate negatively correlates 
with LV chamber size, which was what we found in our population.29 The 
underlying mechanism for the increased resting heart rate in TS may well be 
multi-factorial. Considering the potential long-term (cardiovascular) mortality 
risk associated with this fi nding further research in TS is required, including 
research focussed on the disproportion between cardiac and somatic growth 
as described in this study.
Limitations
Our study is limited by its cross-sectional study design. Nevertheless we 
think our current data supplement the data previous published by Sas et al. 
on LV mass and volume during GH treatment and results point in the same 
direction.7 
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The absence of an untreated patient group precluded to distinguish between 
eff ects inherent to TS and eff ects related to GH treatment on our results. 
However we feel it’s unethical to withhold GH treatment to TS patients.
One patient with severe aortic stenosis and 2 with residual aortic coarctation 
were included. If this would have infl uenced results, it would have been 
towards concentric LV hypertrophy, which was absent.
Conclusions
Mid-term aft er discontinuation of GH therapy TS patients show no myocardial 
hypertrophy and well preserved biventricular function. Ventricular volumes 
at adult age are smaller compared to controls. Comparable cardiac output to 
controls is achieved at a higher resting heart rate, which may have a negative 
impact on long-term survival.
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In the following section the most relevant fi ndings and their practical 
implications are discussed. When applicable suggestions for future research 
are provided.
General consideration on the Fallot population studied
Because of a lack of studies on long-term follow-up in Fallot patients corrected 
according to contemporary surgical strategies, the common goal of chapters 2 
to 5 was: to evaluate the diff erent aspects of functional cardiovascular condition 
aft er optimal correction in the current surgical era using valid, quantitative 
diagnostic tools. Optimal surgical correction was defi ned as: a post-operative 
status without a residual VSD or clinically important RV outfl ow tract gradient. 
This resulted in the inclusion of a homogeneous population subjected to 
isolated pulmonary regurgitation (PR). Therefore, and in contrast to most 
previous studies, results were not confounded by a mixture of residual lesions, 
diff erent types of cardiac overload, or diff erent surgical approaches.
The population described represents an important part of daily clinical 
practice as residual PR is considered the most important hemodynamic lesion 
associated with both malignant ventricular arrhythmia and sudden cardiac 
death in corrected tetralogy of Fallot (TOF).1 Although the number of patients 
remains relatively small, our population represents one of the largest series 
corrected by the transatrial transpulmonary approach described so far.2-6
Clinical condition aft er optimal surgical correction of TOF in the current 
surgical era
At mid to long-term follow-up the most important fi nding in our patients with 
TOF is that of well preserved clinical condition. This deduction is based on the 
following clinically relevant observations made in this thesis:
all patients were asymptomatic (86% in NYHA class I) or minimally 
symptomatic (14% in NYHA class II) (chapter 2)
all patients were without clinically important ventricular arrhythmia 
(chapter 2)
all patients had preserved biventricular contractile reserve (chapter 4)
1)
2)
3)
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mean oxygen consumption was not diff erent from that in a reference 
population (mean (SD) 97 (17)% of predicted). In ¾ of patients a value > 85% 
was found (chapter 2)
neurohormonal activation was absent in the majority of patients (chapter 
4)
These results support a conservative att itude towards treatment of chronic 
PR in corrected TOF during childhood. Nevertheless, we confi rmed RV dilation 
(85% of patients) and global systolic dysfunction (49% of patients) are common 
in Fallot patients with residual PR, even in those patients corrected according to 
transatrial transpulmonary approaches (chapter 2). Furthermore deterioration 
of RV function and exercise capacity correlate with a longer interval since 
repair (chapter 2). The moderate associations found with time could however 
not be used to predict pace of decline in the individual patient.
Determinants of clinical condition 
Despite the overall well preserved clinical condition in our patients we were 
able to identify risk factors associated with poorer clinical condition. Abnormal 
wall motion of RV outfl ow tract predicted a poorer RV ejection fraction. A 
higher PR-percentage predicted more severe RV dilation. As such chapter 2 
leads to conclude further improvement of long-term clinical condition in the 
current surgical era may be obtained by improved preservation of RV outfl ow 
tract function, both in terms of normal wall motion and normal function of the 
pulmonary valve.
Following the above, the question how to improve RV outfl ow tract 
function arises. Previous studies stressed the negative impact of transannular 
patch repair on severity of PR, RV dilation, RV dysfunction and exercise 
capacity.7-9 We found transannular patch repair was an independent predictor 
of a higher PR-percentage, but not of the other parameters of clinical condition. 
Furthermore transannular patch repair clearly related to abnormal RV outfl ow 
tract wall motion (chapter 2). As in TOF corrected by a transventricular 
approach, abnormal wall motion in the RV outfl ow tract contributed to global 
RV systolic dysfunction.10 Therefore, the avoidance of a transannular patch 
may be expected to contribute to bett er preserved RV outfl ow tract function. 
4)
5)
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However, the use of a transannular patch may not be avoidable in all 
patients. Therefore alternative approaches were developed. Rao et al. reported a 
strategy aimed at the preservation of the native pulmonary valve, with excellent 
short term results regarding both residual PR and residual RV outfl ow tract 
gradients.11 Nevertheless, the necessity to apply transannular patch repairs 
remained in patients with insuffi  cient diameters of the pulmonary valve 
annulus.11 An alternative may be a combined approach of annular enlargement 
combined with valve repair at the time of surgical correction. For this purpose 
several papers reported the use of so-called “cusped patches” to enlarge the 
RV outfl ow tract.12-15 Despite good short-term results reported by some, the 
long-term functional gain with regard to residual PR was disappointing, 
or is still subject of ongoing investigation.12-15 In our patients none of these 
strategies were applied. Still one could try and minimize the extent of the 
infundibular incision made and the size of the patch introduced. We found 
magnitude of right ventricular stress reserve was not eff ected by the presence 
of a transannular patch, or in other words the presence of a non-contractile 
wall section (chapter 4). This indicates patches in our patients generally had 
limited functional impact, which may refer to the use of relatively limited sized 
patches.
In contrast to our results, the incidence of abnormal wall motion in 
transventricular corrected TOF was comparable between patients with and 
without a transannular patch.10 This may indicate transatrial transpulmonary 
approaches, by avoidance of a (large) ventriculotomy, result in less wall motion 
abnormalities. Both our and previous results show abnormal wall motion is 
not restricted to patients with a transannular patch, which implies other (non-) 
surgical factors, such as age at repair and extensiveness of the infundibulectomy, 
play a role in the development of wall motion abnormalities in the RV outfl ow 
tract. Severity of residual PR also seems to be aff ected by factors besides the 
use of a transannular patch, as a higher preoperative RV peak pressure in 
our series, independent of the presence of a transannular patch, predicted a 
higher PR-percentage at follow-up. This may be interpreted to indicate more 
extensive surgery needed to correct for more severe stenosis, results in worse 
RV outfl ow tract function at follow-up. In line with this hypothesis freedom 
of adverse eff ects aft er correction of pulmonary valve stenosis was bett er with 
isolated commisurotomy of the pulmonary valve compared to more extensive 
surgery.16 
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The debate on optimal age at repair is still ongoing. As all our patients 
were corrected aft er the age of 2 months we can only speculate on possible 
further improvement of clinical condition if patients were to be repaired in the 
neonatal period. We at least did not fi nd important eff ects of age at repair on 
outcome in patients corrected between 2 and 24 months of age as is reported 
in chapter 2. 
Restrictive RV physiology in TOF
Several types of diastolic dysfunction have been reported in TOF among 
which restrictive RV fi lling.17-21 Reports were equivocal on how restrictive RV 
fi lling, indicated by end-diastolic forward fl ow (EDFF) in the main pulmonary 
artery, aff ects long-term clinical condition.17-21 Therefore, chapter 3 focused on 
diff erences between patients with and without EDFF. We concluded EDFF was 
associated with worse clinical condition at follow-up in corrected TOF.
Predominant or isolated diastolic dysfunction can cause the clinical 
syndrome of heart failure, including exercise intolerance.22,23 To explain for 
the observed diff erence in clinical condition between our subgroups based on 
the presence of EDFF, we did not fi nd signifi cant diff erences in degree of RV 
dilation or global RV systolic function. Surprisingly, data on RV diastolic fi lling 
at rest appeared to contradict with our fi ndings on exercise capacity, as most 
abnormal fi ndings were found in patients without EDFF. Changes in the patt ern 
of RV fi lling with stress so far had not been assessed in TOF. We hypothesized 
analysis during stress might reveal additional abnormalities, and therefore 
give additional information on RV function with chronic PR. Dobutamine 
stress imaging “unmasked” relaxation related diastolic dysfunction in patients 
with EDFF, while patients without EDFF showed no change in the RV fi lling 
patt ern. Considering healthy subjects respond to dobutamine stress with 
improved ventricular relaxation, the observations made in patients with EDFF 
are highly abnormal.24,25
The observed fairly normal patt ern of RV fi lling found at rest in patients 
with EDFF may be explained by so-called pseudo-normalization. Pseudo-
normalization may mask diastolic dysfunction in patients that have both 
impaired and/or delayed ventricular relaxation and reduced eff ective 
chamber compliance.23,26 With both types of diastolic dysfunction present, 
the characteristics of both ventricular fi lling patt ern may be cancelled out 
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by accumulation, to result in an intermediate patt ern that resembles normal 
ventricular fi lling (Figure 1). Results in chapter 3 showed Fallot patients 
as a group are characterized by impaired RV relaxation. EDFF in the main 
pulmonary artery, generally accepted to indicate restrictive ventricular fi lling 
or decreased RV compliance, was present in about ⅔ of patients. Our results 
at rest show that as with other cardiac conditions, relaxation related diastolic 
dysfunction may become masked in the presence of a less compliant ventricle. 
Instead of absent diastolic dysfunction at rest in patients with EDFF, it is more 
likely that these patients had both restrictive and relaxation related diastolic 
dysfunction, which may be graded to be a more severe form of diastolic 
dysfunction.23
Right ventricular diastolic filling paern:
Tricuspid
Flow
Velocity
Filling characteristics:
E
A
Dt
1. Relaxation
2. Compliance
Descriptives:
1. Functional 
    Type
2. Severity of 
    dysfunction
Normal
Normal
Normal 
(Young)
None
Impaired
Normal
Impaired
Relaxation
Mild
Impaired
Midly Decreased
Pseudo 
Normal
Moderate
Impaired
Severly Decreased
Restrictive
Physiology
Severe
  
Figure 1. Diastolic ventricular fi lling in the normal heart and with cardiovascular 
disease.
A = peak atrial fi lling, DT = deceleration time, E = peak early fi lling
In summary chapter 3 showed stress imaging may unmask severe diastolic 
dysfunction not appreciated at rest in patient with restrictive RV physiology. 
Diastolic stress imaging proved useful, as it contributed to our understanding 
of decreased functional capacity in Fallot patients with EDFF compared to 
those without EDFF. Restrictive RV diastolic fi lling has been thought to act 
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benefi cially in adults with TOF.21 Our results show this is not the case in 
children and young adults corrected according to current surgical strategies 
and as such confi rm earlier observations made in children.17
Recent insights on heart failure applied to TOF
Both a blunted response to beta-adrenergic stimulation27-32 and elevated levels 
of neurohormonal are considered early signs of heart failure.33-37 According to 
these recent insights neurohormonal activation and blunted ventricular stress 
response should be looked for during management of patients at risk for heart 
failure.38,39 Moreover, ventricular stress reserve and level of neurohormonal 
activation have been used as prognosticators in heart failure.31-37,40 The 
evaluation of contractile reserve appeared promising for optimisation of 
timing of surgery for mitral regurgitation,30,41 and aortic regurgitation.31 Trials 
with ACE-inhibitors and beta-blockers showed improved long-term outcome 
in heart failure patients.40 Only litt le information is available in children and 
patients with congenital heart disease. Nevertheless, in these groups elevated 
levels of neurohormones related to worse NYHA class, decreased ventricular 
function and worse exercise capacity.42-46
Fallot patients subjected to chronic PR generally are considered to be at 
risk for the development of heart failure. Nevertheless, surprisingly few data 
is available on RV remodelling as a result of chronic PR and the associated 
level of neurohormonal activation or decline in functional reserve. The 
population presented in this thesis off ered a unique opportunity to evaluate 
the above, which was done in chapter 4. In contrast with previous studies that 
analysed the type of ventricular response to stress in corrected TOF, chapter 4 
described a normal biventricular response to stress, characterized by increased 
ventricular performance.47-49 Moreover, patients uniformly showed a positive 
biventricular contractile reserve, irrespective of severity of PR, ventricular 
size or duration of follow-up since repair. Furthermore, the overall levels of 
neurohormonal markers in our series were normal (chapter 4). No signifi cant 
relations were found for any of the neurohormonal markers with degree 
of RV dilation, biventricular systolic function at rest or exercise capacity. A 
weak positive correlation was found between NT pro-BNP and PR-percentage 
and risk levels of NT pro-BNP, found in 22 (44%) patients, related to smaller 
biventricular stress reserve. 
Chapter 8
182
In summary chapter 4 shows recent but generally accepted early indicators 
of heart failure are absent in our patients, which fi ts their asymptomatic to 
minimal symptomatic status. Nevertheless, the limited changes in biomarker 
levels found, especially those of NT pro-BNP, related to relevant RV loading and 
decreased ventricular stress reserve. This may be interpreted as a confi rmation 
of the diagnostic potential of cardiac biomarkers as early signs of activated 
compensatory mechanisms with abnormal ventricular loading. The prognostic 
potential of ventricular stress reserve and level of neurohormonal activation 
on outcome measures such as mortality and freedom of reoperation, will have 
to be studied among patients with TOF and chronic residual PR. 
Validity of criteria for timing of intervention for residual pulmonary 
regurgitation
This thesis did not aim to optimise timing of interventions for residual PR in 
corrected TOF. Nevertheless, results found may contribute to the discussion 
on validity of currently used criteria for timing of interventions. Most 
published series on pulmonary valve replacement for PR use occurrence of 
clinical symptoms as a primary indication for intervention.50 Results from 
chapter 2 indicate TOF patients, like others patients with congenital heart 
disease, may not be aware of changes in clinical condition even in the presence 
of substantial ventricular remodelling and dysfunction.9,51-53 This legitimates 
the fear in corrected TOF that by the time symptoms or exercise limitations 
become distinct irreversible ventricular damage may have occurred.9,32,54-57 As 
such our results question the validity of occurrence of symptoms as a criterion 
for timing of intervention for PR in TOF.
Another frequently used criterion for pulmonary valve replacement, 
especially in recent studies using MRI techniques, is presence of RV 
dilation.54,55,58-60 MRI derived criteria for RV size from recent studies applied 
to our population indeed identifi ed patients with worse clinical condition 
(chapter 2). However, the prognostic value of volumetric criteria on long-
term morbidity and mortality still has to be proven in prospective studies. As 
suggested earlier, ventricular stress reserve and the level of neurohormonal 
activation may be expected to bear prognostic value in patient subjected to 
chronic ventricular overload. These measures therefore may also proof useful 
in the process of decision making during the follow-up of Fallot patients with 
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chronic PR. In our series RV size and PR-percentage at best showed poor 
correlations with impaired exercise capacity, biventricular stress reserve and 
level of neurohumoral activation (chapters 2 and 4). Therefore our results not 
only show compensatory neurohormonal pathways associated with heart 
failure are not yet activated in our patients with considerable PR and RV 
dilation, but they may also indicate that TOF patients should not undergo 
pulmonary valve replacement solely based on RV volumetric or PR criteria. 
Future research on prognosticators for timing of pulmonary valve replacement 
should include neurohormonal cardiac biomarkers and ventricular functional 
stress reserve. 
Role of bicycle ergometry
Sudden cardiac death, a major cause of late mortality in corrected TOF, 
oft en is att ributed to the occurrence of ventricular arrhythmia.1 Residual PR 
is the most important hemodynamic lesion associated with both ventricular 
arrhythmia and sudden cardiac death.1 With several congenital heart diseases 
exercise is considered a provocative factor for ventricular arrhythmia.61 So far 
all electrocardiographic arrhythmia risk predictors in TOF were established at 
rest and almost no data was available on ECG changes with physical stress.1,62-65 
Therefore, an extensive analysis of ECG changes with physical exercise was 
made in chapter 5.
The main fi nding was a signifi cant increase of electrical inhomogeneity 
during repolarization with physical exercise. An additional observation of 
clinical interest was that more severe PR and RV dilation, related to larger 
electrocardiographic abnormalities with physical exercise. Inhomogeneity of 
repolarization is known to predispose for ventricular arrhythmia66,67 and sudden 
cardiac death.68 In line with this, Fallot patients with sustained ventricular 
tachycardia were shown to have larger QT and/or JT dispersions compared 
to other Fallot patients at rest.63,69 Together with our data this may indicate 
patients with corrected TOF, especially those with severe PR, show increased 
susceptibility to arrhythmia with physical exercise. As such results presented 
in chapter 5 could be interpreted as to be in support of exercise restrictions 
in TOF patients with severe PR.61,70 However, as none of our patients showed 
clinically important ventricular arrhythmia at any point during physical 
exercise, we can not prove this hypothesis based on the current data. 
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The role of QRS duration in the management of TOF
In corrected TOF QRS-duration (> 180 ms in adults and > 170 ms in children) 
is regarded the main predictor of malignant ventricular arrhythmia.1,62-65 
QRS-duration within the population described in this thesis did not exceed 
170 ms. Moreover none of the patients showed clinically important ventricular 
arrhythmia on 24 hours Holter monitoring. Findings may refl ect the positive 
infl uence of the surgical techniques used. In support of this assumption less 
QRS-prolongation and life threatening arrhythmia have been reported with 
transatrial transpulmonary repair for TOF compared to transventricular 
repair.5,66 However, we should realize the critical values indicative of arrhythmia 
risk were mainly identifi ed in patients corrected by a transventricular approach 
at a relatively old age. Secondly it should be noted that many comparisons 
on surgical approaches in Fallot literature are characterized by limited 
comparability between patient populations studied.3,4,6,71-73
Previously RV dilation has been associated with QRS prolongation.62,74,75 
Chapter 2 showed QRS prolongation in Fallot patients corrected according 
to contemporary surgical techniques predominantly related to worse 
functional condition. This predictive eff ect was present in a QRS range 
below the critical values reported to predispose for malignant ventricular 
arrhythmia. Pulmonary valve replacement has been shown to reduce QRS-
duration proportional to the degree of RV volume reduction.76,77 Therefore, a 
combined approach of pulmonary valve replacement with cryoablation was 
suggested for arrhythmia management in TOF.78 Success rates of pulmonary 
valve replacement to improve RVEF on the other hand are inconsistent.55,58,78,79 
Cardiac resynchronization therapy in heart failure patients with prolonged 
QRS-duration has been shown benefi cial for ventricular contractile function, 
symptomatic status, and mortality.80,81 The relations found for QRS-duration 
with RVEF and exercise capacity in chapter 2 suggest functional gain may be 
achieved by cardiac resynchronization therapy in selective groups of patients 
with corrected TOF.
Final comments and future research perspectives in TOF
The generally well-preserved clinical condition in our series, combined with 
the cross-sectional study design, prevented determination of predictors of 
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important outcome measures such as mortality, ventricular arrhythmia or need 
for re-operation. Assessment of predictors of these “classic” outcome measures, 
requires longitudinal follow-up. The associations found with longer interval 
since repair in chapter 2 indicate clinical deterioration may still develop in our 
population. The diagnostic techniques applied throughout this thesis allowed 
us to acquire a quantitative assessment of the diff erent aspects of functional 
cardiovascular condition. Although such quantitative tools are relatively 
expensive and time-consuming they are well suited for serial assessments of 
clinical condition. 
The data from chapter 5 indicate electrocardiographic diff erences during 
repolarization between patients at variable risk for ventricular arrhythmia 
according to degree of hemodynamic overload (severity of PR) become distinct 
during physical exercise. Changes seen during repolarization, especially in 
patients with severe PR, may indicate increased susceptibility to arrhythmia. 
Longitudinal data is necessary to evaluate the suggested prognostic value of 
this observation. When proven valid, this knowledge is important considering 
the potential role in early detection of patients at risk for sustained ventricular 
arrhythmia. 
Aortic disease in Turner’s syndrome
In recent MRI studies aortic dilation was reported in up to 50% of patients 
with Turner’s syndrome, which was far more than previously assumed from 
echocardiographic reports.82-85 Aortic dilation may be complicated by dissection 
and rupture. In Turner’s syndrome the number of reports on aortic dissections 
is increasing,85,86 with the ascending aorta considered to be the location of 
preference.85,87 Etiology of aortic disease in Turner’s syndrome is unknown, 
but abnormal aortic wall composition may play a role. This “connective tissue 
hypothesis” gains support in literature on Turner’s syndrome.88,89
Non-invasive measures of aortic wall stiff ness indirectly refl ect aortic 
wall composition.90 These measures were shown to be abnormal in patients 
with connective tissue disease.91,92 Although data on aortic wall stiff ness may 
also contribute to our understanding of aortic disease in Turner’s syndrome, 
they so far are missing. Therefore, we aimed to evaluate aortic diameters and 
regional distensibility in Turner’s syndrome in chapter 6. We concluded that 
the aorta in Turner’s syndrome shows abnormal dimensions and signs of 
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impaired wall function and abnormalities that stretch beyond the ascending 
aorta. Furthermore results showed normalization of aortic abnormalities with 
increasing growth hormone dose, which suggests a benefi cial eff ect of growth 
hormone on aortic abnormalities in Turner’s syndrome. Findings, especially 
those in the subgroup that received the lowest dose of growth hormone, bear 
similarity to results found in Marfan’s syndrome and as such support the 
connective tissue hypothesis.
Abnormal aortic wall stiff ness in Turner’s syndrome
Aortic wall stiff ness depends on the presence, proportion and interaction of 
smooth muscle cells, collagen, and elastin proteins, or in short wall composition. 
An explanation for the observed abnormal aortic wall stiff ness in Turner’s 
syndrome may be found in changed wall composition. Arterial cystic media 
degeneration similar to that in Marfan’s syndrome has been observed in Turner’s 
syndrome.85,89 These changes do not essentially diff er from the degenerative 
changes seen in the human aortic wall with aging.93-95 In the theoretical model 
of aging, “wear and tear” of the aortic wall result in progressive fragmentation 
of the medial elastin network to be repaired by collagen, which results in 
changed relative concentrations of fi brillar material.96,97 The breakdown of 
elastic fi bers leads to aortic dilation with age and increased aortic stiff ness.97 
The increase in aortic stiff ness with aging is explained by a shift  of the elastin 
determined part of the aortic pressure-diameter relation to the lower pressures 
range.98 In the presence of degenerative like changes, the same mechanism 
may be assumed to play a role in Turner’s syndrome. 
Growth hormone and wall stiff ness
An explanation for the observed benefi cial eff ect of growth hormone on aortic 
wall stiff ness may be that growth hormone eff ects aortic wall composition.99 It 
is well established that aortic wall stiff ness increases with age in both humans 
and animals,96,100 while growth hormone secretion and serum IGF-I decline.101 
The increase in aortic stiff ness is accompanied by increased cross-linking 
of collagen and elastin, gradual increased collagen content and decreased 
elastin content. Growth hormone administration to rats has been shown to 
change collagen content and composition of the aorta, and result in a decrease 
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of arterial wall stiff ness especially in younger rats.99,101 Moreover untreated 
patients with growth hormone defi ciency have increased arterial wall thickness 
and increased arterial wall stiff ness.102,103 In such patients growth hormone 
replacement therapy reduces arterial wall thickness and stiff ness.102,103 
An alternative explanation for the observed benefi cial eff ect of growth 
hormone on aortic wall stiff ness may be a dose dependent eff ect of growth 
hormone on blood pressure. We found blood pressure to decrease with 
higher dose of growth hormone (chapter 6, table 1). According to the aortic 
pressure-diameter relation a decrease in blood pressure results in a decrease 
of aortic wall stiff ness if changes occur in the exponential (non-elastin) part of 
the curve. Assuming degenerative changes are present in Turner’s syndrome, 
pressure changes may now occur in the exponential part of the curve and 
result in changes of aortic wall stiff ness. The eff ect of growth hormone on 
aortic distensibility may however also be the sum of multiple smaller eff ects, 
which requires further research to be revealed.
Long-term cardiac eff ects of growth hormone in Turner’s syndrome 
Growth hormone treatment nowadays is a well-established in Turner’s 
syndrome.104 Especially when started at young age and at supra-physiological 
doses excellent results on fi nal height are reported.105 However, based on 
knowledge of the cardiovascular eff ects of growth hormone excess in other 
situations, such as acromegaly, concerns have risen on the possible long-
term cardiovascular side eff ects associated with high dosed growth hormone 
treatment.106,107 So far data on cardiovascular condition aft er discontinuation 
of growth hormone therapy in Turner’s syndrome are lacking. 
We hypothesized side eff ects, if present, would be biventricular. Therefore, 
and in contrast to most previous studies we assessed biventricular size and 
function in young adult Turner patients formerly treated with growth hormone 
in chapter 7. Mid-term aft er discontinuation of growth hormone treatment we 
can conclude the feared deleterious type of cardiac remodelling associated 
with growth hormone excess (myocardial hypertrophy plus ventricular 
dysfunction) is absent in patients with Turner’s syndrome. Furthermore, 
considering treatment had been discontinued for at least 6 months, this type of 
ventricular remodelling is not likely to develop in the future.
Chapter 8
188
Chapter 7 showed Turner patients had smaller biventricular volumes 
compared to healthy controls. The previously studied Dutch Turner 
population from which our participants represent a non-selective subset, 
showed signifi cant decreases of SD-scores for LV dimensions during active 
growth hormone treatment in childhood.108 Together with our current results 
this strongly suggests disproportionate cardiac growth in Turner’s syndrome, 
which can not be explained by observations from previous studies on organ 
specifi c eff ects of deregulation of the growth hormone / IGF-I axis.109,110 
As in previous studies, chapter 7 showed a higher mean resting heart rate 
in Turner patients compared to healthy controls.111 Evidence is increasing 
on the detrimental eff ect of a chronic higher heart rate at rest on long-term 
(cardiovascular) mortality.112,113 Heart rate has been shown to inversely relate 
to LV volume. The etiology of the increased resting heart rate found in Turner’s 
syndrome may be multifactorial.111 
Final comments and future research perspectives in Turner’s syndrome
In summary, results on cardiovascular condition aft er discontinuation of high 
dosed growth hormone treatment in Turner’s syndrome indicate this type of 
treatment is safe. Moreover, according to our results growth hormone acts 
benefi cially on aortic abnormalities with increasing dose. 
As described in this thesis aortic dilation is common among young adults 
with Turner’s syndrome. The risk for aortic dissection is known to increase 
with larger aortic diameters, though dissection may also occur in the non-
dilated aorta.114 Besides aortic dilation, decreased aortic distensibility has 
been shown to predict progressive aortic disease in Marfan’s syndrome.114 We 
described signs of abnormal aortic wall function similar to those in Marfan’s 
syndrome. The prognostic value of aortic diameter and decreased wall stiff ness 
on progression of aortic dilation and occurrence of complications in Turner’s 
syndrome should be evaluated. With regard to the observed benefi cial eff ect 
of growth hormone on aortic distensibility our study design did not allow to 
determine the optimal dose needed to normalize wall function, nor to assess 
longevity of the observed benefi cial eff ect aft er discontinuation of treatment. To 
answer these research questions dedicated longitudinal studies are required. 
No untreated Turner patients were included in our study. Therefore 
a possible growth hormone related eff ect on ventricular growth and the 
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volumetric abnormalities observed in our study can not be excluded. The 
absence of diff erences between our growth hormone dose subgroups argues 
against this possibility. Nevertheless, further research is necessary to reach 
defi nitive conclusions. Serial follow-up of patients using the newer quantitative 
imaging tools, such as the MRI techniques applied in this thesis, should be 
able to satisfactorily address this problem. Quantitative diagnostic (imaging) 
tools in general would be helpful in the assessment of organ specifi c growth 
in response to growth hormone to evaluate the possibility of disproportionate 
cardiac growth in Turner’s syndrome. The importance of such analysis lays in 
the possible association of smaller ventricular volumes with a higher resting 
heart rate. Considering the potential long-term mortality risks associated with 
the repeatedly reported higher resting heart rate in Turner’s syndrome future 
research should focus on underlying etiology. 
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Adequate and serial functional cardiovascular assessment is important in 
patients with congenital heart disease because many show disruption of 
normal myocardial geometry, which may or may not be accompanied with 
hemodynamic overload. We now know, that even aft er so-called “corrective 
surgery”, total cure is only seldomly achieved. The presence of residual 
cardiac abnormalities may lead to malignant myocardial remodeling, which 
eventually may result in heart failure. 
Surgical correction of tetralogy of Fallot (TOF), the most common cyanotic 
congenital heart lesion, has been performed since 1955. Literature on clinical 
condition following corrective surgery is extensive. Nevertheless, studies 
acquired with appropriate diagnostic tools, long-term aft er correction according 
to contemporary surgical strategies are lacking. The need for studies based on 
quantitative diagnostic tools for (repeated) documentation of clinical condition 
has been recognized, however such studies are expensive, time-consuming and 
therefore limited in number. Previous (MRI) studies oft en included a mixture 
of patients with regard to diagnosis at repair, age at repair, surgical techniques 
used for repair, and post-operative status, which complicates interpretation of 
results.
Therefore, the common purpose of the studies described in chapters 2 to 
5 was to evaluate diff erent aspects of functional cardiovascular condition at 
mid- to long-term follow-up aft er optimal surgical correction of TOF in the 
current surgical era. Using a cross-sectional study design patients with the 
following characteristics were studied between September 2002 and November 
2004: 1) total surgical correction performed before the age of 2 years, 2) interval 
since correction of at least 5 years, 3) total surgical correction performed by a 
transatrial transpulmonary approach, and 4) optimal correction of the initial 
lesions of TOF, defi ned as a post-operative status without residual VSD or 
residual outfl ow tract Doppler gradient > 30 mmHg
 Based on cardiovascular side-eff ects of growth hormone excess in 
diseases such as acromegaly, concerns have risen on the possible long-term 
cardiovascular risks associated with high dosed growth hormone treatment. 
Turner syndrome is one of the currently well-established indications for growth 
hormone treatment during childhood. Data on cardiovascular condition 
aft er discontinuation of growth hormone therapy in Turner’s syndrome are 
lacking. 
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Therefore the common purpose of chapters 6 and 7 was to assess the 
diff erent aspects of functional cardiovascular condition in young adult women 
with Turner’s syndrome formerly treated with growth hormone. Participants 
represents a non-selective part of the Turner population from a previous 
Dutch growth hormone dose response study, based on voluntary participation 
in the described MRI-evaluation study. Patient data was compared to fi ndings 
in healthy age, gender and body surface area (m²) matched controls. MRI 
examinations were performed between May 2003 and June 2004.
Chapter 1 provides an introduction to 1) the general problems seen during 
the follow-up of congenital heart diseases, 2) the specifi c problems seen with 
corrected TOF, and with Turner’s syndrome, and 3) diagnostic tools used 
throughout this thesis. At the end of the chapter (chapter 1.5) the specifi c study 
aims are presented.
 
The specifi c study aims in tetralogy of Fallot were:
to assess clinical condition, including the assessment of biventricular 
volumes and function by cardiac MRI 
to identify factors associated with RV dilation, RV dysfunction and decreased 
exercise tolerance 
to assess RV diastolic function, in terms of RV fi lling patt ern, at rest and 
during pharmacological stress
to evaluate the eff ect of restrictive RV physiology, indicated by end-diastolic 
forward fl ow in the main pulmonary artery, on clinical condition 
to assess the level of 1) neurohormonal activity, 2) biventricular contractile 
reserve, and 3) maximal exercise capacity, in relation to the amount of 
residual PR and RV volume
to assess pro-arrhythmogenic electrocardiographic changes in the surface 
ECG during maximal physical exercise
to explore possible relations between electrocardiographic changes during 
physical exercise with other determinants of clinical condition 
The specifi c study aims in Turner’s syndrome were:
to assess aortic dimensions and distensibility in young adults with Turner’s 
syndrome formerly treated with growth hormone 
−
−
−
−
−
−
−
−
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to assess the eff ect of growth hormone dose on aortic dimensions and 
distensibility 
to assess biventricular size and function in young adults with Turner’s 
syndrome formerly treated with growth hormone 
to evaluate the eff ect of growth hormone dose on biventricular size and 
function 
In chapter 2 clinical condition was assessed in 59 patients with corrected 
TOF, and risk factors associated with RV dilation, RV systolic dysfunction and 
decreased exercise tolerance were identifi ed. Despite the common fi ndings of 
RV dilation (85% of patients) and RV systolic dysfunction (49% of patients), 
chapter 2 demonstrated symptomatic status, exercise performance and rhythm 
status were relatively normal at mid- to long-term follow-up since correction. 
Severity of residual PR independently predicted the degree of RV dilation, 
but not of RV systolic dysfunction. Worse RVEF was independently predicted 
by abnormal wall motion of the RV outfl ow tract. Severity of both RV dilation 
and RV systolic dysfunction related to longer interval since repair, however 
the moderate associations found with interval since repair could not be used 
to predict the pace of decline in the individual patient. The most important 
predictor of worse exercise capacity was worse RVEF. Prolongation of QRS-
duration, which was expected to predict larger RV volumes, also independently 
predicted worse RVEF and worse exercise capacity, or in short functional 
decline.
We suggest that further improvement of clinical condition may be obtained 
by improved preservation of RV outfl ow tract function (both in terms of 
preserved valvular function and in terms of preserved wall motion), and by a 
reduction of myocardial electrical inhomogeneity. 
In chapter 3 RV diastolic fi lling patt ern at rest and during dobutamine stress 
were assessed in a non-selective subset of 36 patients. From previous studies 
the impact of restrictive RV physiology on clinical condition in corrected TOF 
remains unclear. End-diastolic forward fl ow (EDFF) in the main pulmonary 
artery, a generally accepted sign of restrictive RV fi lling, was shown to relate to 
worse exercise capacity at mid- to long-term follow-up. Furthermore patients 
with EDFF had a higher mean PR-percentage and tended to have a larger 
RV compared to patients without EDFF. These data are in contrast with the 
−
−
−
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previous concept that restrictive RV physiology acts protective against the 
detrimental eff ects of PR. 
RVEF was comparable between patients with and without EDFF and 
could not be used to explain the observed diff erence in exercise capacity. 
Surprisingly, analyses of RV diastolic fi lling showed the RV fi lling patt ern was 
most abnormal in patients without EDFF. We hypothesized stress imaging 
might provide additional information. Repeated measurements of RV diastolic 
infl ow during low dose dobutamine stress showed no change in the RV fi lling 
patt ern of patients without EDFF, while highly abnormal changes indicative 
of relaxation related dysfunction emerged in the RV fi lling patt ern of patients 
with EDFF. 
We concluded dobutamine stress MRI may be used to “unmask” 
abnormalities in RV diastolic fi lling not appreciated by rest imaging alone. 
Furthermore it was speculated that the highly abnormal RV fi lling patt ern 
observed during stress in patients with EDFF contributed to our understanding 
of the observed diff erence in exercise limitation between subgroups. 
The most recent guidelines for LV heart failure management are partly 
based on the neurohormonal concept. Surprisingly few data are available on 
RV remodeling as a result of chronic PR in relation to neurohormonal activation 
and/or functional ventricular stress reserve. Chapter 4 describes studies in 
which 1) level of neurohormonal activation, 2) biventricular contractile reserve, 
and c) exercise performance were assessed in patients with TOF. In patients 
corrected at young age according to contemporary surgical strategies, overall 
levels of neurohormonal markers were normal and biventricular contractile 
reserve was preserved, irrespective of the amount of residual PR or the 
subsequent degree of RV dilation.
 Only a weak signifi cant positive relation was found between the level of NT 
pro-BNP and PR-percentage. Risk levels of NT-proBNP were found in 22 (44%) 
patients. These patients showed smaller biventricular ΔESV with stress and 
smaller RV-CR compared to other patients. Furthermore patients with hsCRP 
levels above the median tended to have worse exercise capacity compared to 
the others. These results can be interpreted as a confi rmation of the diagnostic 
potential of cardiac biomarkers as early signs of activated compensatory 
mechanisms in case of abnormal ventricular loading conditions.
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According to chapter 4, RV size and PR-percentage at best show poor 
correlations with impaired exercise capacity, biventricular stress response 
or neurohormonal activation, in a population operated according to current 
surgical strategies. We therefore question the validity of PR or RV volume 
criteria for pulmonary valve replacement in this group and suggest patients 
should probably not undergo pulmonary valve replacement solely based on 
RV volume or PR fraction criteria. 
Previous studies successfully identifi ed indicators of electrical inhomo-
geneity in the resting ECG of patients with TOF to predict ventricular 
arrhythmia. In congenital heart disease exercise is considered a predisposing 
factor for the development of ventricular arrhythmia. Exercise testing may be a 
useful diagnostic tool to detect such arrhythmia. An extensive analysis of ECG 
changes with exercise was not yet performed in corrected TOF. Chapter 5 was 
used to assess pro-arrhythmogenic changes in the surface ECG of TOF patients 
and healthy controls during maximal physical exercise.
TOF patients showed signifi cant lengthening of mean QTc duration during 
exercise, while in controls QTc remained unchanged. Furthermore both QTc 
and JTc dispersion increased in patients, while controls showed no change. At 
peak exercise mean JTc dispersion was signifi cantly larger in patients compared 
to healthy controls and mean QTc dispersion tended to be larger. In addition a 
larger increase in QTc duration was found to correlate with a larger RV volume 
and with worse RV systolic function. Finally, a larger increase in JTc dispersion 
correlated with more severe PR. 
Although TOF patient showed no arrhythmia it may be speculated that the 
increase in inhomogeneity of repolarization indicates increased susceptibility 
to arrhythmia associated with physical exercise, especially in patients with 
severe residual PR. As such the data support exercise limiting advices given to 
TOF patients with severe residual PR. 
Using MRI aortic dimensions and distensibility at four predefi ned locations 
in young adult women with Turner’s syndrome formerly treated with growth 
hormone were studied in chapter 6. During childhood the patients studied 
randomly received 1, 1.5 or 2 times the regularly used growth hormone dose 
in Turner’s syndrome. In line with previous fi ndings the ascending aortic 
diameter was enlarged in 30 − 50% of patients. In addition to previous data 
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Turner patients were shown to have larger mean aortic diameters at all sites 
of measurement along the thoracic aorta. Compared to healthy controls aortic 
distensibility in Turner patients was smaller at 2 out of 4 levels of measurement. 
From this it was concluded that Turner patients, besides aortic dilation, showed 
signs of impaired wall distensibility. Our fi ndings in Turner’s syndrome show 
similarity with results in Marfan’s syndrome and as such are in support of 
the hypothesis that connective tissue abnormalities may play a role in aortic 
disease in Turner’s syndrome. 
Compared to healthy controls mean aortic diameters were larger at all 
thoracic levels of measurement in the subgroup of Turner patients that received 
the smallest dose of growth hormone. The other two subgroups only had a 
larger ascending aorta diameter compared to healthy controls. Compared to 
controls aortic distensibility was smaller at 3 out of 4 levels of measurement 
in the subgroup that received the smallest dose of growth hormone, while no 
diff erences were found for the other two subgroups. As such results suggest 
severity of aortic abnormalities in young adulthood relate to growth hormone 
dose received during childhood, with a benefi cial eff ect of a larger dose on 
aortic abnormalities. 
Chapter 7 of this thesis showed young adult women with Turner’s syndrome 
formerly treated with growth hormone do not have myocardial hypertrophy, 
and show well preserved biventricular function. As such fi ndings contradict 
the fear for pathologic myocardial remodeling with supra-physiologically 
dosed growth hormone treatment during childhood in Turner’s syndrome. 
Mean ventricular volumes, especially that of the left  ventricle, were found 
to be smaller in patients compared to controls. Participants to the present study 
are a non-selective subgroup of a larger population that participated in a Dutch 
growth hormone dose-response study. Together with the cardiac fi ndings from 
this larger cohort, the current data suggests disproportional cardiac growth 
in Turner’s syndrome during childhood. No diff erences were found between 
growth hormone subgroups for indices of cardiac size or function.
Turner patients achieved comparable cardiac output to healthy controls, 
however at a higher mean resting heart rate. In Turner’s syndrome a higher 
mean resting heart rate has repeatedly been found. Left  ventricular size may 
play a role in the underlying aetiology of a higher resting heart. From previous 
fi ndings in Turner’s syndrome, aetiology may be expected to be multi-factorial. 
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Considering the potential long-term (cardiovascular) mortality risk associated 
with a higher resting heart rate, we suggest future research in Turner’s 
syndrome to specifi cally address this topic.
Finally in chapter 8 the main fi ndings of this thesis are discussed. When 
applicable suggestions for future research are made. 
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Adequate en seriële bepalingen van de functionele cardiovasculaire conditie 
van patiënten met een aangeboren hartafwĳ king zĳ n van belang aangezien veel 
patiënten een abnormale geometrie van het hart en grote bloedvaten hebben, 
die al dan niet gepaard gaat met hemodynamische overbelasting. We weten 
nu dat zelfs na zogenaamde “correctieve hartchirurgie” slechts zelden een 
totaal normale situatie wordt bereikt. De aanwezigheid van cardiovasculaire 
restafwĳ kingen kan de aanleiding zĳ n van pathologische remodellering van 
hartspierweefsel, wat uiteindelĳ k kan resulteren in hartfalen.
Chirurgische correctie van tetralogie van Fallot, de meest voorkomende 
aangeboren cyanotische hartafwĳ king, is mogelĳ k sinds 1955. Er is veel 
literatuur verschenen met betrekking tot klinische conditie na chirurgische 
correctie. Desondanks is er een gebrek aan studies gebaseerd op adequate 
diagnostiek waarin lange termĳ n resultaten worden beschreven bĳ  patiënten 
gecorrigeerd volgens de huidige chirurgische norm. De behoeft e aan studies 
gebaseerd op kwantitatieve diagnostiek voor de (herhaaldelĳ ke) bepaling 
van de klinische conditie van patiënten wordt onderkend. Dit type studies 
blĳ ft  echter beperkt in aantal omdat ze kostbaar en tĳ drovend zĳ n. In eerdere 
studies werd vaak een niet homogene patiëntenpopulatie geïncludeerd wat 
betreft  diagnose, leeft ĳ d op moment van chirurgische correctie, de gebruikte 
chirurgische technieken en de postoperatieve conditie. Daardoor wordt de 
interpretatie van de resultaten uit deze studies bemoeilĳ kt. 
Het gemeenschappelĳ k doel van de studies beschreven in de hoofdstukken 
2 tot 5 van dit proefschrift  is daarom, de verschillende aspecten van functionele 
cardiovasculaire conditie te onderzoeken op midden tot lange termĳ n na 
optimale chirurgische correctie van tetralogie van Fallot volgens de huidige 
chirurgische norm. Gebruik makend van een crossectionele studieopzet werden 
tussen september 2002 en november 2004 Fallot patiënten met de volgende 
eigenschappen onderzocht: 1) totale chirurgische correctie voor de leeft ĳ d van 2 
jaar, 2) interval na correctie van minstens 5 jaar, 3) totale chirurgische correctie 
gebruik makend van een transatriaal transpulmonale benaderingswĳ ze, en 4) 
optimale correctie van de initiële cardiale afwĳ kingen passend bĳ  tetralogie van 
Fallot. Dit laatste werd gedefi nieerd als een postoperatieve status zonder rest 
VSD en zonder rest gradiënt in de rechter ventrikel uitstroombaan > 30 mmHg. 
Gedocumenteerde cardiovasculaire bĳ werkingen in geval van een 
groeihormoon overschot, zoals in patiënten met acromegalie, zĳ n de aanleiding 
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geweest voor zorgen omtrent mogelĳ ke cardiovasculaire risico’s verbonden 
aan hooggedoseerde groeihormoonbehandeling. Het syndroom van Turner 
is op dit moment één van de indicaties voor groeihormoonbehandeling bĳ 
kinderen. Er is momenteel echter geen data voorhanden met betrekking tot 
cardiovasculaire conditie van patiënten met het syndroom van Turner na het 
stoppen van groeihormoonbehandeling. 
Het gemeenschappelĳ k doel van de studies beschreven in de hoofdstukken 
6 en 7 van dit proefschrift  is daarom om de verschillende aspecten van 
functionele cardiovasculaire conditie te onderzoeken bĳ  jong volwassen 
vrouwen met het syndroom van Turner, die gedurende de kinderjaren werden 
behandeld met groeihormoon. De deelneemsters vormen een niet-selectieve 
afspiegeling van een grotere populatie die eerder deelnam aan een Nederlandse 
groeihormoon dose-response studie op basis van vrĳ willige deelname aan de 
beschreven MRI studie. De bevindingen bĳ  patiënten werden vergeleken met 
bevindingen bĳ  gezonde vrouwelĳ ke controles, met een vergelĳ kbare leeft ĳ d 
en een vergelĳ kbaar lichaamsoppervlak (m²). De MRI onderzoeken werden 
uitgevoerd tussen mei 2003 en juni 2004.
Hoofdstuk 1 bevat een inleiding betreff ende 1) de algemene problematiek 
gezien tĳ dens het vervolgen van patiënten met een aangeboren hartafwĳ king, 
2) de specifi eke problematiek gezien bĳ  patiënten na chirurgische correctie 
van tetralogie van Fallot en bĳ  patiënten met het syndroom van Turner, en 3) 
de diagnostische middelen gebruikt in dit proefschrift . Aan het eind van dit 
hoofdstuk komen de specifi eke studiedoelen van dit proefschrift  aan de orde.
De specifi eke studiedoelen in tetralogie van Fallot waren:
het bepalen van de klinische conditie, inclusief de bepaling van het volume 
en de functie van beide ventrikels, gebruik makend van MRI
de identifi catie van risicofactoren voor het optreden van rechterventrikel 
dilatatie, rechterventrikel disfunctie en verminderde inspanningscapaciteit
het bepalen van rechterventrikel diastolische functie op basis van 
vullingpatronen in rust en tĳ dens farmacologische stress 
de evaluatie van het eff ect van restrictieve rechterkamer fysiologie, 
aangeduid door einddiastolische voorwaartse fl ow in de arteria pulmonalis 
communis, op de klinische conditie van de patiënt
−
−
−
−
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het bepalen van de graad van 1) neurohormonale activiteit, 2) biventriculaire 
functionele contractiele reserve en 3) maximale inspanningscapaciteit, in 
relatie tot de mate van rest pulmonaalklep insuffi  ciëntie (PI) en de ernst van 
rechterkamer dilatatie
de bepaling van pro-arritmogene electrocardiografi sche veranderingen 
tĳ dens maximale fysieke inspanning in het oppervlakte ECG 
nagaan van de mogelĳ ks aanwezige relaties tussen electrocardiografi sche 
veranderingen in patiënten tĳ dens fysieke inspanning en andere 
determinanten van klinische conditie 
De specifi eke studiedoelen in het syndroom van Turner waren:
het bepalen van de dimensies en de distensibiliteit van de aorta in 
jongvolwassen patiënten die tĳ dens de kinderjaren werden behandeld met 
groeihormoon 
het eff ect nagaan van groeihormoon op de dimensies en de distensibiliteit 
van de aorta
het bepalen van de afmetingen en de functie van beide ventrikels in 
jongvolwassenen patiënten die tĳ dens de kinderjaren werden behandeld 
met groeihormoon 
het eff ect nagaan van groeihormoon op de afmetingen en functie van beide 
ventrikels
In hoofdstuk 2 werd in 59 patiënten na chirurgische correctie van tetralogie 
van Fallot de klinische conditie bepaald en werden risico factoren geassocieerd 
met rechterkamer dilatatie, rechterkamer systolische disfunctie en verminderde 
inspanningscapaciteit geïdentifi ceerd. Ondanks dat er frequent rechterkamer 
dilatatie (85% van de patiënten) en rechterkamer systolische disfunctie werd 
vastgesteld onder deze patiënten laat hoofdstuk 2 zien dat allen asymptomatisch 
tot minimaal symptomatisch zĳ n, een relatief normale inspanningscapaciteit 
hebben, zonder klinisch belangrĳ ke ventriculaire ritmestoornissen. 
De ernst van rest PI bleek een onafh ankelĳ ke voorspeller van rechterkamer 
dilatatie, maar niet van rechterkamer disfunctie. Abnormale wandbeweging 
in de rechterventrikel uitstroombaan bleek een onafh ankelĳ ke voorspeller van 
verminderde rechterkamer ejectiefractie. Ernst van zowel rechterkamer dilatatie 
als disfunctie waren geassocieerd met een langer interval sinds correctie. 
−
−
−
−
−
−
−
Samenvatt ing
211
Deze associaties konden echter niet worden gebruikt om achteruitgang in de 
individuele patiënt te voorspellen. De belangrĳ kste voorspeller van verminderde 
inspanningscapaciteit was een verminderde rechterkamer ejectiefractie. Zoals 
verwacht uit eerder onderzoek was een verlengd QRS-interval geassocieerd 
met een groter rechterkamer volume. Daarnaast vonden wĳ  echter dat QRS 
verlenging ook een onafh ankelĳ ke voorspeller was van een verminderde 
rechterkamer ejectiefractie en verminderde inspanningscapaciteit, of in het 
kort van functionele achteruitgang. 
Op basis van deze gegevens stellen wĳ  dat verdere verbetering van de 
klinische conditie in patiënten met tetralogie van Fallot kan worden bereikt 
door te streven naar een verbeterde rest functie van de RV uitstroombaan na 
chirurgische correctie (zowel wat betreft  minder rest PI als minder afwĳ kingen 
in wandbeweging), en door het reduceren van de elektrische inhomogeniteit 
in het hartspierweefsel. 
 
In een niet-selectieve subgroep van 36 patiënten werd in hoofdstuk 3 de 
diastolische functie van de rechterkamer in rust en tĳ dens dobutamine stress 
bepaald door middel van vullingpatronen. Op basis van eerder onderzoek 
was het eff ect van restrictieve vulling van de rechterkamer op klinische 
conditie onduidelĳ k. In hoofdstuk 3 werd aangetoond dat einddiastolische 
voorwaartse fl ow in de arteria pulmonalis communis (EDFF), een algemeen 
aanvaard teken van restrictieve rechterkamer vulling, gerelateerd is aan 
verminderde inspanningscapaciteit op midden tot lange termĳ n na correctie. 
Bovendien hadden patiënten met EDFF gemiddeld een hoger PI-percentage 
en neigden zĳ  naar een gemiddeld grotere rechterkamergroott e in vergelĳ king 
tot patiënten zonder EDFF. Aldus zĳ n onze data in tegenspraak met de eerdere 
veronderstelling dat restrictieve rechterkamer fysiologie patiënten zou 
beschermen tegen de schadelĳ ke eff ecten van pulmonaalklep insuffi  ciëntie.
Er werd geen signifi cant verschil gevonden in rechterventrikel ejectiefractie 
tussen patiënten met en zonder EDFF ter verklaring van het vastgestelde verschil 
in inspanningscapaciteit. Bovendien, en tot onze verrassing liet analyse van de 
rechterkamer vulling het meest abnormale patroon zien in patiënten zonder 
EDFF. Wĳ  stelden de hypothese dat stress imaging aanvullende informatie 
zou kunnen verschaff en. Een herhaling van de meting van het rechterventrikel 
vullingpatroon tĳ dens dobutamine stress liet geen verandering zien in 
patiënten zonder EDFF, terwĳ l zeer abnormale veranderingen, wĳ zend op 
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relaxatie gebonden disfunctie, zichtbaar werden in het vullingpatroon van 
patiënten met EDFF. 
We concludeerden dat dobutamine stress MRI gebruikt kan worden om 
afwĳ kingen in het diastolische vullingpatroon van de rechterkamer aan het 
licht te brengen die gemaskeerd worden in rust. Daarnaast stelden wĳ  dat het 
vastgestelde abnormale patroon van rechterventrikel vulling in patiënten met 
EDFF tĳ dens stress bĳ droeg aan ons begrip van het vastgestelde verschil in 
inspanningscapaciteit tussen patiënten met en zonder EDFF.
De meeste recente richtlĳ nen betreff ende de behandeling van patiënten 
met linkerventrikel falen zĳ n gedeeltelĳ k gebaseerd op het zogenaamde 
“neurohormonale concept” (zie hoofdstuk 1.4.1). Er is verrassend weinig 
informatie beschikbaar over rechterkamer remodellering ten gevolge van 
chronische pulmonaalklep insuffi  ciëntie in relatie tot neurohormonale 
activiteit en/of ventriculaire functionele stress reserve. In hoofdstuk 4 werden 
de volgende zaken daarom bepaald in patiënten met tetralogie van Fallot: 1) 
de neurohormonale activiteit, 2) de contractiele reserve van beide ventrikels, 
en c) de inspanningscapaciteit. In patiënten gecorrigeerd op jonge leeft ĳ d 
volgens de huidige chirurgische norm werden normale waarden gevonden 
voor neurohormonale markers van hartfalen en bleek de contractiele reserve 
van beide ventrikels behouden, onafh ankelĳ k van de ernst van insuffi  ciëntie 
van de pulmonaalklep en de graad van rechter ventrikel dilatatie.
Er werd alleen een zwakke, positieve relatie gevonden tussen NT-proBNP 
en het PI-percentage. NT-proBNP waarden geassocieerd met een verhoogd 
risico op hartfalen werden vastgesteld in 22 (44%) patiënten. Tĳ dens 
dobutamine stress lieten deze patiënten een kleinere verandering in het eind-
systolische volume van beide ventrikels zien, evenals een kleinere toename 
van de rechterkamer ejectiefractie. Tenslott e neigden patiënten met een hsCRP 
waarde boven de mediaan naar een gemiddeld lagere inspanningscapaciteit 
ten opzichte van de overige patiënten. Deze resultaten kunnen worden gezien 
als een bevestiging van het diagnostisch potentieel van cardiale biomarkers 
voor vroegtĳ dige onderkenning van activatie van compensatoire mechanismen 
bĳ  abnormale ventriculaire belasting.
Volgens de bevindingen in hoofdstuk 4 correleren rechterventrikel groott e 
en PI-percentage matig met inspanningscapaciteit, functionele ventrikel reserve 
en mate van neurohormonale activatie in een populatie gecorrigeerd volgens 
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de huidige chirurgische norm. Daarom stellen wĳ  de waarde van richtlĳ nen 
voor pulmonaalklepvervanging gebaseerd PI-percentage en rechterventrikel 
groott e in deze patiënten populatie ter discussie en opperen we dat de indicatie 
voor pulmonaalklepvervanging waarschĳ nlĳ k niet louter gesteld dient te 
worden op basis van PI-percentage en rechterkamer groott e. 
 
Eerdere studies hebben met succes indicatoren gevonden van elektrische 
inhomogeniteit in het elektrocardiogram van Fallot patiënten tĳ dens rust, die 
ventriculaire ritmestoornissen kunnen voorspellen. In meerdere aangeboren 
hartafwĳ kingen wordt fysieke inspanning gezien als een uitlokkende factor 
voor het ontwikkelen van ritmestoornissen. Inspanningstesten kunnen nutt ig 
zĳ n om dergelĳ ke ritmestoornissen te documenteren bĳ  risicopatiënten. 
Tot op heden werd geen uitgebreide analyse verricht van veranderingen in 
het elektrocardiogram van Fallot patiënten tĳ dens fysieke inspanning. In 
hoofdstuk 5 werden pro-arritmogene veranderingen in het elektrocardiogram 
van Fallot patiënten en gezonde controles bepaald tĳ dens maximale fysieke 
inspanning.
Patiënten met TOF toonden een signifi cante verlenging van de gemiddelde 
QTc-duur tĳ dens inspanning, terwĳ l er geen verandering werd gezien in 
gezonde controles. Bovendien was er sprake van een toename van de QTc 
en JTc dispersies tĳ dens inspanning in patiënten, terwĳ l geen veranderingen 
werden gezien in gezonde controles. Hierdoor was op het moment van 
maximale inspanning de gemiddelde JTc dispersie signifi cant groter in 
patiënten. Bovendien correleerde een grotere toename in QTc duur met 
een groter rechterkamer volume en met een slechtere rechterkamer functie. 
Tenslott e werd vastgesteld dat een grotere toename in JTc dispersie correleert 
met meer PI. 
Ondanks dat onze patiënten geen ritmestoornissen lieten zien, kan op 
basis van onze gegevens worden gespeculeerd dat de toename in elektrische 
inhomogeniteit tĳ dens ventrikel repolarisatie verwĳ st naar een verhoogde 
ontvankelĳ kheid voor het ontwikkelen van ritmestoornissen tĳ dens inspanning. 
Een verschĳ nsel dat in de grootste mate aanwezig lĳ kt in de subgroep 
patiënten met ernstige rest PI. Aldus steunen onze resultaten het gebruik van 
inspanningsbeperkende adviezen bĳ  patiënten met een ernstige rest PI. 
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Gebruik makend van MRI technieken werd in hoofdstuk 6 op vier vooraf 
vastgestelde meetpunten de dimensie en distensibiliteit van de aorta bepaald 
in jongvolwassen vrouwen met het syndroom van Turner. Gedurende de 
kinderjaren waren deze patiënten behandeld met groeihormoon, waarbĳ 
ad random 1, 1.5 of 2 maal de normaal gebruikte dosis werd gegeven. 
Overeenkomstig met eerdere resultaten werd in 30 − 50% van de patiënten 
een vergrote diameter van de aorta ascendens gevonden. In aanvulling op 
eerdere resultaten werd bĳ  Turner patiënten een gemiddeld grotere diameter 
van de aorta gevonden ten opzichte van gezonde controles ter hoogte van alle 
meetpunten in de thoracale aorta. Ten opzichte van gezonde controles was de 
distensibiliteit van de aorta kleiner op 2 van de 4 meetpunten in patiënten. Op 
basis van deze gegevens werd geconcludeerd dat patiënten met het syndroom 
van Turner naast dilatatie ook tekenen van abnormale distensibiliteit van de 
aorta vertonen. Onze bevindingen vertonen overeenkomsten met bevindingen 
in patiënten met het syndroom van Marfan en steunen de hypothese dat aorta 
afwĳ kingen in het syndroom van Turner mogelĳ ks gerelateerd zĳ n aan een 
afwĳ kende samenstelling van de aortawand. 
Ten opzichte van gezonde controles waren de gemiddelde diameters van 
de aorta in de subgroep patiënten die de laagste dosis groeihormoon kreeg 
tĳ dens de kinderjaren groter ter hoogte van alle thoracale meetpunten. De 
andere twee subgroepen hadden alleen een grotere diameter ter hoogte van 
de aorta ascendens. Ten opzichte van gezonde controles was de gemiddelde 
distensibiliteit van de aorta kleiner op 3 van de 4 meetpunten in de subgroep 
die de laagste dosis groeihormoon kreeg tĳ dens de kinderjaren, terwĳ l er 
geen verschillen werden gevonden ten opzichte van controles in de andere 
2 subgroepen. Aldus wekken deze resultaten de indruk dat de ernst van 
aorta afwĳ kingen bĳ  jongvolwassen patiënten met het syndroom van Turner 
gerelateerd zĳ n aan de dosis groeihormoon ontvangen in de kinderjaren, 
waarbĳ  er een heilzaam eff ect op de mate van afwĳ kingen lĳ kt uit te gaan van 
een hogere dosis groeihormoon. 
Hoofdstuk 7 van dit proefschrift  laat zien dat jongvolwassen vrouwen met 
het syndroom van Turner die eerder werden behandeld met groeihormoon, 
geen tekenen van myocard hypertrofi e hebben en een goed bewaarde functie 
van beide ventrikels. Deze bevindingen weerleggen de angst voor pathologische 
remodellering van het myocard ten gevolge van supra-fysiologisch gedoseerde 
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groeihormoon behandeling tĳ dens de kinderjaren bĳ  het syndroom van 
Turner.
De gemiddelde ventrikel volumes, en vooral die van de linker ventrikel, 
bleken kleiner in patiënten ten opzichte van gezonde controles. Deelneemsters 
aan deze studie zĳ n een niet-selectieve afspiegeling van een grotere populatie 
die eerder deelnam aan een Nederlandse groeihormoon dose-response studie. 
Samen met de cardiale gegevens afk omstig uit dit groter cohort, wekken 
de data beschreven in hoofdstuk 7 de indruk dat er disproportionele groei 
plaatsvindt van het hart tĳ dens de kinderjaren in patiënten met het syndroom 
van Turner. Er werden geen verschillen gevonden voor ventrikel groott e en 
functie tussen de verschillende groeihormoon subgroepen. 
In rust hadden onze Turner patiënten een vergelĳ kbare cardiac output ten 
opzichte van gezonde controles, maar bereikten deze output aan een gemiddeld 
hogere hartfrequentie. Een hogere hartfrequentie in rust werd herhaaldelĳ k 
beschreven in het syndroom van Turner. Linker ventrikel afmetingen kunnen 
een rol spelen in de onderliggende etiologie van een toegenomen hartfrequentie. 
Echter gezien eerdere bevindingen in het syndroom van Turner kan worden 
verondersteld dat de etiologie multifactorieel bepaald is. Het potentieel lange 
termĳ n risico op toegenomen mortaliteit in ogenschouw nemend, stellen wĳ 
voor toekomstig onderzoek specifi ek toe te spitsen op dit fenomeen.
Tenslott e worden de belangrĳ kste bevindingen van dit proefschrift  in 
hoofdstuk 8 besproken en worden suggesties gedaan voor toekomstig 
onderzoek.
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Dankwoord
Het mag dan eindelĳ k gebeuren, het schrĳ ven van mĳ n dankwoord. In de 
afgelopen 5 jaar zĳ n er heel wat mensen in meer of mindere mate betrokken 
geweest bĳ  het tot stand komen van dit proefschrift . Daarvoor wil ik allen 
hartelĳ k danken. Hiermee mĳ n proefschrift  af sluiten zou echter geen recht 
doen aan de inspanningen geleverd door een aantal mensen die ik hieronder 
persoonslĳ k wil noemen. 
Om te beginnen mĳ n promotoren. Prof. W.A. Helbing, beste Wim, tĳ dens 
ons eerste sollicitatiegesprek stelde je voor eerst ervaring op te doen in de 
kliniek. Er was immers nog heel wat voorwerk te doen. Gelukkig waren er 
ook daarna nog genoeg hordes te nemen, zodat dit onderzoeksproject al snel 
aanvoelde als mĳ n project. Hierbĳ  speelde de ruimte die ik kreeg om zelfstandig 
te werken een belangrĳ ke rol. Gelukkig kon ik wel altĳ d bĳ  je aankloppen voor 
overleg en advies. Vĳ f jaar later, en wĳ zer, weet ik dat dit soort begeleiding 
niet vanzelfsprekend is. Je enthousiasme en doorzett ingsvermogen werkten 
aanstekelĳ k en hebben in belangrĳ k mate bĳ gedragen tot het eindresultaat dat 
nu voor je ligt. 
Prof. P.M.T. Patt ynama, beste Peter, ik wil je bedanken voor de mogelĳ kheden 
die je realiseerde binnen de afdeling radiologie. Dank voor je kritische, maar 
altĳ d opbouwende commentaar tĳ dens het bespreken van de diverse artikelen. 
Dat mĳ n keuze uiteindelĳ k niet op de radiologie is gevallen neemt niet weg 
dat ik me er met veel plezier in heb verdiept. 
Prof. A.J.J.C. Bogers, beste Ad, ik wil je hier niet alleen bedanken omdat je 
plaats wilde nemen in de kleine commissie, maar zeker ook voor de voorbĳ e 
jaren waarin ik altĳ d snel kon rekenen op feedback. Prof. A. de Roos en Prof. 
A.J. van der Heĳ den, wil ik bedanken voor het plaatsnemen in de kleine 
commissie en het beoordelen van mĳ n proefschrift . 
Prof B.J.M. Mulder en Prof J.L.L. Kimpen wil ik bedanken voor de toezegging 
plaats te willen nemen in de grote commissie. Dr. F.J. Meĳ boom, beste Folkert, 
na de vele leerzame discussies in de afgelopen jaren ben ik blĳ  dat je als 
deskundige op het gebied van de congenitale cardiologie plaats wilt nemen in 
de grote commissie. Dr. S.M.P.F. de Muinck Keizer-Schrama, beste Sabine, ik 
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heb met veel plezier meegewerkt aan het Turnerproject en ik ben blĳ  dat je als 
deskundige op dit gebied plaats wilt nemen in de grote commissie. 
Mĳ n onderzoeksperiode bevatt e veel pionierswerk achter de MRI console. 
Daarbĳ  heb ik veel geleerd van een aantal personen. Ondermeer van onze 
MRI fysicus, Piotr Wielopolski. Beste Piotr, we hebben heel wat technische 
frustraties gedeeld en overwonnen. Bedankt voor al je inspanningen gericht 
op het optimaliseren van mĳ n resultaten en het zo min mogelĳ k belasten van 
de deelnemende kinderen. Geen hart blĳ kt hetzelfde waardoor het scannen in 
de praktĳ k een uitdaging blĳ ft . De praktĳ k heb ik voor een groot deel geleerd 
van Robert-Jan van Geuns, waarvoor ik hem wil bedanken. See one, do one, 
teach one. Timo Baks, ik denk dat we uiteindelĳ k veel van elkaar hebben 
geleerd, bedankt voor de levendige discussies over het werk, maar ook over 
de belangrĳ ke dingen er omheen. 
Ik wil iedereen van de afdeling kindercardiologie bedanken voor hun 
bĳ dragen aan dit proefschrift , maar ook voor de gezellige jaren in Rott erdam. 
Wilma Willemse, bedankt voor je hulp in de afgelopen jaren, niet te vergeten 
je ondersteuning bĳ  de laatste loodjes. Je onophoudelĳ k geloof in een 
opleidingsplaats kindergeneeskunde was een steun in de rug. Arno van Vliet 
en Marco Kruit, zoals vaak bĳ  onderzoek waarbĳ  veel techniek komt kĳ ken 
ging er regelmatig iets mis. Jullie bĳ stand in raad en daad over alles wat 
maar met computers te maken had heb ik erg gewaardeerd. De dames van de 
polikliniek wil ik bedanken en in het bĳ zonder Martha, Irma en Emel, die vele 
uren hebben doorgebracht bĳ  de scanner en naast de fi ets. Bedankt voor de 
fi jne samenwerking.
Een deel van mĳ n proefschrift  is tot stand gekomen in goede samenwerking 
met de afdeling kinderendocrinologie en in het bĳ zonder dr. Sabine M.P.F. 
de Muinck Keizer-Schrama en Ellen M.N. Bannink. Beste Ellen, ik heb met 
veel plezier met je samengewerkt, bedankt voor al je hulp, je ideeën en de 
gezelligheid. 
Dr. Wim C.J. Hop wil ik bedanken voor zĳ n hulp bĳ  de data analyse en 
interpretatie, en voor zĳ n bĳ drage in het overzichtelĳ k op papier brengen van 
de resultaten.
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Dr. Jan L.M. Strengers, kindercardioloog in het Wilhelmina Kinderziekenhuis 
te Utrecht, wil ik bedanken voor zĳ n hulp bĳ  de inclusie van patiënten in toch 
al erg drukke tĳ den.
Dr. Frans Boomsma en dr. Yolanda B. de Rĳ ke wil ik bedanken voor hun 
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